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ABSTRACT

Congenital Heart Diseases (CHD) are abnormalities present in the heart and great
vessels at birth. It is one of the most frequently diagnosed congenital disorders, affecting
approximately 40,000 live birth each year in the United States. The incidence of new CHD
patients and the relative distribution of defects have not changed over time and remain a
birth rate function. Out of the new patients found to have CHD each year, an estimated
2,500 patients have a defect that requires a substitute, non-native valve, or conduit artery
to replace structures that are congenitally absent or hypoplastic. Materials in current use
for conduit and valve replacement involve varying degrees of stiffness and flexibility,
durability, calcification, susceptibility to infection, thrombosis, and a lack of growth
potential for the replacement.
Biomaterials developed using tissue engineering principles could overcome the
limitations encountered with current strategies. This research aims to develop potentially
superior valves and conduits using acellular xenograft tissues that are physically crosslinked to protect the Extracellular Matrix (ECM) from rapid degradation. The hypothesis
is that such a replacement graft would allow cellular ingrowth of host cells and potentially
enable regenerative growth and remodeling of the graft. A decellularization protocol was
developed, and the most effective crosslinker protecting the extracellular matrix structure
was identified. The decellularized scaffolds crosslinked with Penta galloyl glucose (PGG)
were analyzed in-vitro for stability and mechanical properties, in subcutaneous rat and in
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valve replacement in sheep-models to determine the biocompatibility and functionality of
the developed scaffolds.
Tissue-engineered scaffolds prepared from decellularized PGG treated tissues were
found to have mechanical properties comparable to that of native tissues, while being more
resistant to enzymatic degradation. Subcutaneous implantation of scaffolds demonstrated
their biocompatibility and superior resistance to calcification compared to currently
available glutaraldehyde fixed tissues. The tissue-engineered conduits and valves
implanted in large animal models also demonstrated adequate implant functionality,
cellular infiltration, implant remodeling, and growth of the implants. PGG treated
decellularized xenografts could be an effective replacement option for pediatric patients,
reducing the need for reoperations required with current devices.
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CHAPTER ONE
INTRODUCTION

Congenital Heart Diseases (CHD) are one of the most prevalent defects present at
birth, affecting approximately 0.8% to 1.2% of live births worldwide (1). Risk factors for
incidence of CHD are largely unknown, but some factors like chromosomal aneuploidies,
genetic defects, and conditions of diabetic mellitus, phenyl-ketonuria, rubella, alcohol use,
maternal obesity, exposure to thalidomide, retinoic acid, and organic solvents attribute to
~15% of known CHD cases. The incidence and distribution of CHD worldwide has
remained stable from 1990 – 2017, indicating little improvement in its prevention over the
years (2).
Defects in the heart and blood vessels present at birth range from minor defects to
critical conditions lead to impaired blood flow within the body. The typical human
cardiovascular system is a closed system consisting of systemic and pulmonary
circulations, with unidirectional flow of blood maintained by the heart valves and blood
vessels. (3). Deformities in CHD, occurring as septal defects, stenotic or regurgitant aortic
or pulmonary valves, valve atresia, dextro-transposition of the great arteries, or a Tetralogy
of Fallot, disrupts this normal flow of blood within the body (4). These deformed structures
need to be treated to restore normal blood flow.
Treatment strategies for CHD deformities utilize catheterization techniques or
open-heart surgeries. Cardiac catheterization is a minimally invasive technique that can be
used to repair minor deformities within the heart. Critical conditions, however, require

1

surgical interventions. Surgical strategies like the Ross-Konno procedure, Rastelli
procedure, and Fontan procedure require the use of non-native conduit arteries, valves, and
patches to repair and replace deformed structures (5). The gold standard for these
replacements is homograft form donors; however, the insufficient number of heart donors
in combination with donor-recipient heterogeneity and the wide range of deformities
present in CHD makes the treatment more challenging. This leads to high mortality rates
among infants and financial burden on the healthcare system (6).
Early intervention is required in congenital defects for normal physical and
cognitive development of the patients (7). However, most of the currently available
artificial replacements cannot keep up with the rapid changes in the size and structure of
the heart from neonatal stages to childhood and adulthood. Synthetic conduit replacements
made from polytetrafluoroethylene (PTFE) or Dacron tubes display various degrees of
stiffness, kinking, stenosis, and calcification. Bioprosthetic conduits, commonly developed
from glutaraldehyde treated bovine jugular veins, display severe calcification and stenosis
upon implantation (8, 9). Mechanical valve replacements require the use of blood
coagulants throughout the patient’s life, whereas bioprosthetic heart valves generally
display high levels of degradation upon implantation (10). Moreover, none of the currently
available conduit or valve replacement strategies allow for growth with the patients,
leading to failure of implants usually after 10-12 years of implantation (11).
To reduce multiple surgical interventions, and overcome the limitations of currently
available biomaterials, tissue engineering techniques for preparation of these scaffolds
seem to be the most promising. Tissue engineered scaffolds are ‘patient specific’ and can

2

adapt to the alterations in the recipient’s body. The desired replacement conduit or valve
should be biodegradable, biocompatible, flexible, durable, with an absence of
immunogenicity, thrombosis, and calcification (12). The scaffolds should be composed of
materials with specific morphological, functional, and mechanical properties to support
cell attachment and proliferation at the implantation site. Additionally, they should allow
neovascularization, allowing for oxygenation for the implanted tissue. The tissue
engineered scaffolds should also resist rapid degradation upon implantation to prevent
implant failure.
Decellularization of native tissues have been shown to reduce the incidence of
calcification by removing the principal sites of calcification (13). To prevent rapid
degradation of the decellularized scaffolds, the extracellular matrix components within the
scaffolds need to be stabilized (14). Penta galloyl glucose (PGG), a derivative of tannic
acid, has been shown to effectively stabilize elastin and collagen within extracellular
matrices owing to its hydrophobic core and various hydroxy groups (15). PGG has also
been shown to be non-toxic to human smooth muscle cells, as well as possess various
therapeutic properties like anti-inflammatory, anti-oxidative, and anti-microbial, which
might be beneficial in its use in cardiovascular applications (16-18).
In this research, we initially established the efficiency of the decellularization
procedure in different tissues and determined the best stabilizing agent capable of
protecting elastin and collagen from rapid degradation. Subsequently, decellularized and
PGG treated conduits and valves were developed from native tissues and characterized in
vitro. The PGG treated scaffolds were found to be biocompatible and resist calcification in
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subcutaneous rat models. Sheep pulmonary conduit replacement with PGG treated valved
conduits showed the regeneration and growth potential of the scaffolds. PGG treated
porcine aortic and pulmonary valves were however found to be unsuitable in the pulmonary
position.
Additionally, the PGG treated decellularized bovine pericardium scaffolds were
evaluated as intra-muscular implants in diabetic conditions. Diabetes is a chronic condition
resulting in delayed wound healing due to elevated pro-inflammatory phase and reduction
in anti-inflammatory cells and cytokines. PGG as a therapeutic agent possesses antioxidant properties as well as anti-bacterial properties. The effects of these therapeutic
properties of PGG treatment of scaffolds in diabetic conditions were analyzed. Overall, the
goal of this research was to develop tissue-engineered scaffolds from decellularized, PGG
treated scaffolds and determine the biocompatibility, growth, and regeneration potential of
these developed scaffolds.

The dissertation is arranged into the following chapters:
•

Chapter II presents a comprehensive overview of the Cardiovascular
system, anatomy of the heart and great vessels, extracellular matrix in the
cardiovascular system, congenital heart diseases, current treatment
strategies for congenital defects, tissue engineering strategies, animal
models for assessment of biocompatibility and functionality of tissue
engineered scaffolds, diabetic wound healing, scaffolds used in diabetic
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wound healing conditions, and animal models for the development of Type
II diabetes.
•

Chapter III presents the specific aims of this research and the approaches
employed to achieve those aims.

•

Chapter IV assesses the consistency of the decellularization procedure for
different tissue types, and the effectiveness of different polyphenols and
retinoic acid at crosslinking the extracellular matrix components within the
decellularized scaffolds.

•

Chapter V presents the development and characterization of conduit
replacements from decellularized and PGG treated bovine jugular vein
valved conduits, as well as biocompatibility and functionality assessment
of these conduits in animal models.

•

Chapter VI describes the development and characterization of valve
replacements from decellularized PGG treated porcine aortic valves and
porcine pulmonary valves and the assessment of these valves as pulmonary
valve repair units in sheep.

•

Chapter VII evaluates PGG treated decellularized bovine pericardium
scaffolds as intra-muscular implants in healthy and diabetic rats.

•

Chapter VIII presents the conclusions of this research and discusses future
recommendations for the discussed research.
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CHAPTER TWO
LITERATURE REVIEW

2.1 The Cardiovascular System
The cardiovascular system, also known as the circulatory system, is one of the most
important organ systems, facilitating blood circulation and mass transportation (19). It is a
closed tubular system within which a muscular heart propels blood into the blood vessels.
There are primarily two circuits of blood vessels, the pulmonary and systemic circulations,
composed of arterial, capillary, and venous components (Figure 1) (20).

Figure 1: Schematic representation of the systemic and pulmonary circulatory system
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The cardiovascular system performs the major function of transport of nutrients,
gases, and waste products within the body. It plays a vital role in maintaining homeostasis
by continuously regulating the blood flowing throughout the system, transporting nutrients,
electrolytes, gases, and other essential cytokines to the different body tissues and organs
(3). Protection against foreign microbes and toxins is carried out by white blood cells,
antibodies, and complement proteins circulating through the blood. Clotting factors present
within the blood prevent blood loss after injuries (21).
Anatomy of the heart and great vessels
The heart is a muscular organ, somewhat conical in shape, and enclosed within an
outer fibrous pericardium, and a thinner delicate layer of serous pericardium. The layers of
the serous pericardium form a pericardial cavity, enclosing some fluids that facilitate the
movement of the heart within the pericardial cavity (20). The muscles of the heart are
composed of three layers of outer epicardium, middle myocardium, and inner endocardium
(22).

Figure 2: Anatomy of the heart and heart valves
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The heart is composed of four chambers, left and right atria, and left and right
ventricles. Blood from the right ventricles pass through the pulmonary artery, into the
lungs, and back into the left atria through the pulmonary veins, completing the pulmonary
cycle. From the left atria, blood flows into the left ventricle, from where it is pumped into
the rest of the body (except the lungs) through the aorta (Figure 2). The aorta branches out
into numerous smaller arteries, arterioles, and finally thin-walled capillaries, which are
permeable to vital cellular nutrients and waste products that are received and redistributed.
Blood within the capillaries is collected in veins through venules and returned to the right
atria via the superior and inferior vena cava.
All blood vessels (arteries and veins) are composed of three primary layers: the
intima, media, and adventitia (Figure 3). The innermost intima layer, lined with endothelial
cells, are in direct contact with blood. The internal elastic lamina forms a barrier between
the intima and medial layers in arteries. The media layer is composed of elastic fibers
arranged in circular sheets and consists of numerous layers of smooth muscle cells which
control the diameter of the vessel by contracting and relaxing to neural or chemical signals.
The outer most layer of adventitia is composed mostly of fibrous tissue whose collagen
fibers impart tensile strength and prevent excessive vasodilation (23). The cells within the
arteries and veins require nourishment and produce waste. However, owing to the fast flow
of blood through the great vessels, as well as the thickness of the vessels, diffusion of
nutrients and waste is not possible through the walls. Larger arteries and veins, therefore,
contain smaller vessels within their walls called vasa vasorum, to provide them with this
critical exchange. In addition, since large veins are often under low pressure, they are
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equipped with valves to maintain the unidirectional flow of blood. The walls of the veins
immediately proximal to the valves, often show a slight bulge, called the venous sinus (24).

Figure 3: Structure of blood vessels (a) arteries and (b) veins have the same general
features, but arteries have thicker walls to resist higher pressure of blood flow. (c) a
micrograph showing relative difference in thickness between arterial and venous structures
(25)
Blood within the heart flows through valvular openings, which permit the flow of
blood only from the atria to ventricle, but not in the reverse direction. In the adult heart,
the atrial and ventricular cavities are completely separated from each other via the
impervious inter-atrial and inter-ventricular septum respectively. In fetal heart however,
blood can flow within the atria through the foramen ovule, and for a short time between
the ventricles through the interventricular foramen (26).
The human heart consists of four valves. The tricuspid and the mitral
atrioventricular valves (AV) separate the atria and ventricles, while the pulmonary and the
aortic semilunar valves (SL) separate the ventricles from the great arteries (27). All the
valves are tricuspid (3 cusps or leaflets), except the mitral valve, which has only two cusps.
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AV valves have a specialized support structure, while SL valves have a unique selfcontained support structure within the arterial roots (28, 29). The SL valves are composed
of different sized cusps and do not have symmetrical geometries.
Additionally, they are tethered to the inner walls of the ventricles by chordae
tendinea, which prevents valve collapse during systole. AV valves, on the other hand, have
similar-sized leaflets, attached to the basal wall at the basal attachment, and the free leaflets
coapting to direct blood flow. Neighboring leaflets of the AV valves meet at the highest
point to form a commissure. The aortic valve also has coronary artery ostioles behind two
of the leaflets, leading to the nomenclature of non-coronary, left and right coronary leaflets
(30).

Figure 4: Histology of (a) Mitral valve, (b) Tricuspid valve, (c) Aortic valve, and (d)
Pulmonary valve. SL valves have fibrosa, spongiosa, and atrialis layers, while AV valves
have fibrosa, spongiosa, and ventricularis layers (31)
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SL heart valves have a tri-layer tissue structure composed of fibrosa, spongiosa,
and ventricularis layers (Figure 4). The fibrosa is composed primarily of Type I collagen
fibers and is the main load bearing layer. The ventricularis layer, composed of dense
network of elastin and collagen fibers assist in reducing radial strains during maximum
forward flow. The middle spongiosa layer is composed of Glycose aminoglycans (GAGs)
and Proteoglycans (PGs) that act as a lubricant for the other two layers as they shear and
deform. Fibrosa and ventricularis layers consist primarily of endothelial cells, while the
spongiosa is composed of interstitial cells like smooth muscle cells (SMC), fibroblasts and
myofibroblasts (25).

Extracellular matrix in the cardiovascular system
As mentioned in previous sections, the extracellular matrix in the great vessels and
heart valves are composed primarily of elastin, collagen, and glycosaminoglycans. This
ECM composition is tissue-specific and varies with conditions and stages of development,
homeostasis, and disease (32).
In media and adventitia layers of blood vessels, collagen type-I and type-III are the
most predominant. Type-V collagens have been found to be concentrated in the media and
basement membranes (33). In addition to type I, III, and V fibrillar collagen, type-VI
collagen associated with fibrillin-1 in blood vessels and serve to connect elastic lamellae
to the basement membrane of SMCs or SMCs to other ECM structures (34). Similarly, in
valves, collagen types I, III, and V are the most predominant, imparting stiffness and
integrity to the valve leaflets (35).
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Collagen formation in the body starts with procollagen chains synthesized in the
endoplasmic reticulum (ER) (Figure 5). The pro-collagen chains are brought together by
interactions between the C-pro-peptides, and they fold to form rod-like triple-helical
domain flanked by globular N- and C-pro-peptides. Post-translational modifications occur
in pro-collagen within the ER. Procollagen molecules are then transported across Golgi
stacks, the N- and C-propeptides are removed, and it results in collagen molecules
assembled into fibrils. Triple helical collagen molecules are covalently crosslinked into
fibrils (36).

Figure 5: Overview of collagen fibril formation process from procollagen in fibroblasts
(36)
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In addition to being the primary source of tensile strength within the tissues,
collagen also interacts with vascular cells and plays an essential role in pathobiology and
cell biology (33, 37). Mutations, deficiencies, or different compositions in the collagen
within vasculatures lead to diseased conditions like Osteogenesis imperfecta (Collagen-I
mutation), Ethers Danlos Syndrome (EDS) (Collagen III procollagen mutation), Bethlem
myopathy and Ulrich’s disease (mutation of collagen-VI) (38-41).
The other major ECM component found in heart valves and blood vessels is elastin.
Elastin is the main structural component of elastic fibers and is a largely unstructured
protein compared to collagen. This unstructured nature accounts for the ability of elastin
to stretch and recoil. Elastin is composed of two primary components: a core comprising
90% of the fiber, and a scaffold of microfibrils, composed of fibrillin-1 and -2 (42). The

Figure 6: Elastogenesis: Synthesis of elastic fibers from tropoelastin
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primary structure of elastin, tropoelastin, is expressed within elastogenic cells (including
SMCs, endothelial cells, fibroblasts, and chondroblasts), after which it is trafficked to the

Figure 7: Crosslinking of elastin and mechanism of elastic stretch and recoil (52)
extracellular regions for cross-linking and assembly. This transport is mediated by elastin
binding proteins (EBPs), which prevent intracellular aggregation and proteolysis of the
tropoelastin (Figure 6). Tropoelastin molecules cluster by forming self-aggregated
spherules, and they are crosslinked by lysyl oxidase into the networks of elastic fibers by
depositing the spherules onto microfibrils and forming intramolecular and intermolecular
crosslinks (42-45).
Most of the elastin synthesis in humans occurs at a young age. With the increase in
age, elastin expression is reduced, resulting in decreased elastin production and difficulties
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in elastin repair (46). Elastin is the major component in arterial walls, comprising ~50% of
the dry weight (43). It is found throughout the medial layer of blood vessels, present as
fenestrated elastic laminae. The microfibrils embedded within the amorphous core of
elastin allow its elastic recoil (Figure 7). Elastic laminae in the blood vessels render tissue
integrity as well as elastic recoil (33). Within valves, elastin is present in the ventricularis,
aligned mostly in the radial direction, limiting radial stress during leaflet openings (47-50).

Figure 8: Schematic representation of stress-strain relationship in heart valves during
motion (51)
The structure and arrangement of collagen along with elastin determine the
mechanical properties of blood vessels and valves. Within valves, as demonstrated Figure
8, biomechanical cooperation exists between the collagen and elastin layers. During valve
opening, elastin is extended at minimal load, while collagen uncrimps and corrugates. Near
full closure, this load-bearing capability is shifted from elastin to collagen; while the stress
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rises steadily, coaptation is maintained. Finally, during systole, the contracted
configuration of the cusps is restored by elastin (51).
In addition to resistance to tensile forces, cardiovascular extracellular matrix also
possesses resistance to compressive forces. This is rendered by Glycosaminoglycans
(GAGs) and proteoglycans (PGs) within the ECM. GAGs, which are long chains of
repeating disaccharides, retain large amounts of water to resist compression. GAGs are
further classified into proteoglycans and hyaluronidases, depending on the arrangement of
the GAG molecules (52). The presence of GAGs within cardiovascular ECM ensures
smooth movement of the various structures.

2.2 Congenital Heart Diseases (CHD)
Congenital heart diseases (CHD) are deformities present in the heart and blood
vessels at birth. These deformities might change the normal flow of blood through the heart
(53). CHDs are the most common forms of birth defects and can range from mild
deformities (like a hole in the heart) to severe defects (such as missing or poorly formed
parts of the heart) (54).
Approximately 0.8% - 1.2% of live births worldwide are affected by congenital
heart defects (1, 55, 56). In the United States (US), CHD affects approximately 40,000
newborns each year. The total number of patients living with CHD is now estimated to be
approaching 2 million patients (57). Statistical studies have determined that from 1990 to
2017, the incidence of CHD has remained constant in both males and females, indicating
there has been little or no improvement in its prevention over the years (Figure 9) (1, 58).
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Figure 9: Total CHD Birth prevalence over time (55)

Only ~15% of the cases of CHD can be attributed to a known cause (59).
Chromosomal aneuploidies like Down’s syndrome, Turner syndrome, DiGeorge
syndrome, trisomy 13, and trisomy 18 might lead to deformations in the heart structures.
Conditions with defects in single genes like Alagille syndrome, Holt–Orem syndrome, and
Noonan syndrome contribute to 3% - 5% of CHD cases. Known environmental risk factors
leading to defects include maternal diabetes mellitus, phenylketonuria, obesity, alcohol
use, febrile illnesses, rubella infection, use of thalidomide and retinoic acid, as well as
exposure to organic solvents (60, 61).
More than 80% deaths in CHD patients happen before five years of age, thereby
emphasizing the importance of early screening and correction of the deformities (1).
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Types of CHD
Congenital defects in the heart occur in various forms that might be present
individually or in combination. Some of the more common CHD conditions are as follows
(2, 62-68):

Septal Defects:
Atrial Septal Defect (ASD): A defect in the septum between the left and right atria,
leading to leaking of oxygenated blood into the right atria.
Ventricular Septal Defect (VSD): A defect in the septum between the ventricles
leading to leakage of oxygenated blood into the right ventricle, which might in turn cause
higher pressure in the lungs or less oxygenated blood circulation throughout the body.
Atrioventricular Septal Defect (AVSD): A large defect in the heart affecting blood
flow in all the four chambers (left and right atria and left and right ventricles). In a complete
AVSD conditions, both the mitral valve and the tricuspid valves are malformed, whereas
in a partial defect, only one of the valves might be deformed.
A

B
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Figure 10: Septal defects in CHD: (A) Atrial Septal Defect (ASD), (B) Ventricular Septal
Defect (VSD); (C) Atrioventricular Septal Defect (AVSD)

Valve Defects:
Atresia: Valve atresia refers to a valve that is malformed or not formed at all,
resulting in no opening for the flow of blood. In CHD, usually, atresia occurs in the
pulmonary or tricuspid position.
Ebstein’s anomaly: Defect in the tricuspid valve that prevents its proper closing.
This leads to leakage of blood in the opposite direction, and it usually exists with ASD
conditions.
Valve stenosis: Stenosis of the aortic or pulmonary valve where the respective
valves are narrower than usual, leading to pressure build-up in the heart, and over time,
hypertrophy in the heart muscles.
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Figure 11: Valve defects in CHD: (A) Pulmonary Valve Atresia; (B) Tricuspid Valve
Atresia; (C) Ebstein’s Anomaly (D) Aortic Valve Stenosis; (E) Pulmonary Valve Stenosis
(62)
Combined Defects:
Total (or partial) Anomalous Pulmonary Venous Connection (TAPVC): This
condition refers to abnormalities in the connection of the pulmonary veins to the heart. In
TAPVC, the pulmonary veins are connected to the right atria instead of the left, leading to
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oxygenated blood delivery to the right side of the heart (Figure 12). Usually, the condition
coexists with ASD to enable blood leakage to the left atria and its circulation throughout
the body.

Figure 12: Total Anomalous Partial Venous Connection (TAPVC) representing pulmonary
valve attachment to the right atria along with ASD

Tetralogy of Fallot: Tetralogy of Fallot is a combination of four different heart
defects present at birth. The defects include a defect in the ventricular septum (VSD),
stenotic pulmonary valve with narrowed pulmonary artery, a malformed aortic valve that
is present right above the ventricular defect, along with right ventricular hypertrophy
(Figure 13). The combination of these conditions creates a critical defect that might lead to
reduced circulation of oxygen throughout the body resulting in bluish skin, heart
arrythmias, higher risk of endocarditis, along with delayed growth and development.
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Figure 13: Tetralogy of Fallot condition demonstrating pulmonary stenosis, ventricular
hypertrophy and VSD (62)

Dextro-transposition of the great arteries (d-TGA): The main arteries from the
heart, the pulmonary artery and the aorta are swapped in their connection to the heart in
this condition (Figure 14). This results in low oxygenated blood being circulated through
the body via the right atria and the aorta attached to the right ventricle.

Figure 14: Dextro-transposition of the great arteries with swapping of the connections of
the main arteries
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Patent ductus arteriosus (PDA): This condition refers to a hole in the aorta. In fetal
condition, the blood is oxygenated through the umbilical cord even after skipping the
pulmonary circulation (Figure 15.A). However, after birth, the hole within the aorta should
close to enable oxygenated blood flow throughout the body.

Truncus arteriosus: The condition refers to the presence of a single large artery
instead of two to carry blood throughout the body. Instead of separate pulmonary and aortic
valves, only a single truncus valve is present which might be narrowed and leaky, allowing
back-flow of blood through the valve (Figure 15.B). This leads to accumulation of more
blood in the lungs and less oxygenated blood through the body. The deprivation of
oxygenated blood in the body might lead to higher pressure on the heart muscles leading
to hypertrophy.
B

A

Figure 15: (A) Patent ductus arteriosus representing defect in aorta; (B) truncus arteriosus
with merged blood vessels (62)
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2.3 Treatment for CHD
Minor defects in the heart, like holes within the septum or small holes in the aortas
usually close without any interference. Critical congenital defects, however, require
surgical intervention or catheterization to repair the defects.

Cardiac Catheterization
Cardiac catheterization is a procedure in which a small, flexible, hollow tube (a
catheter) is inserted through a patient’s arm, neck, or groin into the blood vessels and
guided into the aorta and the heart with the help of X-ray images (63). Once the catheter is
in place, it can be used for the repair of minor defects. Usually, a catheterization procedure
is used for the treatment of atrial septal defects and patent ductus arteriosus. It can also be
used for reopening stenotic valves or narrowed arteries (62, 69). The earliest use of
catheterization for the treatment of congenital defects dates to 1976, when the first catheter
device was developed for the repair of atrial septal defects (70). Subsequently, there has
been significant development in catheterization repair of heart defects (Figure 16).
Catheterization is a minimally invasive technology; however, in most cases of
congenital heart diseases, the deformities might be too complex to repair via
catheterization. In such cases, open-heart surgeries are required to repair or replace
deformed structures. Out of the new patients diagnosed with CHD each year, an estimated
2,500 patients require the use of non-native conduits and valves to repair structures
congenitally absent or hypoplastic.
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Figure 16: Gore cardioform atrial septal defect occluder deployment using Mullin's sheath
(A) Left atrial disc deployment (B) As delivery system is withdrawn, the sheath maintains
disc orientation (C) Right atrial disc deployment (D) on either side of septum (71)

Surgical Interventions
Septal defects including ASD, VSD, AVSD, and TAPVC are repaired using
pericardium or synthetic patches to prevent leakage of blood through the atria or ventricle
walls. Repair patches are also used for conditions of the interrupted aortic arch and double
inlet left ventricle. Valve defects like absent pulmonary valve, aortic or pulmonary stenotic
valves are usually replaced using homograft, mechanical or bioprosthetic valves.
Pulmonary and tricuspid atresia conditions are repaired using valved conduits (72).
CHD conditions of pulmonary atresia with the intact ventricular wall, tricuspid
atresia, double inlet ventricle, and hypoplastic left heart syndrome are corrected using the
Fontan surgery (Figure 17.A). The procedure aims at directing the systemic flow of venous
blood through the lungs without passing through any ventricles (73). Recent modifications
in the Fontan operation connect each vena cava to the pulmonary artery using valved
conduits, thereby completely bypassing the right atria and ventricle (74, 75).
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Rastelli procedure is the standard surgical treatment for correction of ventricular
septal defect, dextro-transposition of the arteries, and pulmonary stenosis (Figure 17.B)
(76). An intracardiac tunnel is used to connect the left ventricle to the aorta, and the right
ventricle is connected to the pulmonary artery using an extracardiac valved conduit (77,
78).
B
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Figure 17: (A) Fontan procedure using an extracardiac conduit to bypass the ventricles (B)
Rastelli procedure for correction of d-TGA using 1-an intracardiac tunnel, 2-an
extracardiac conduit (C) Ross-Konno procedure for replacement of aortic valve with
pulmonary valve, and repair of the pulmonary valve using a valved conduit

Damaged or malformed aortic valves are usually replaced using the Ross
procedure. In this procedure, the patient’s damaged aortic valve is replaced using their own
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pulmonary valve. A donor conduit or valve is then implanted in the place of the pulmonary
valve (79, 80). As a modified Ross-Konno procedure, the left ventricular outflow tract is
also enlarged to enhance blood flow (Figure 17.C) (81).
Complex Tetralogy of Fallot condition is surgically corrected using an intracardiac
repair. The VSD defect is closed using a patch, and the narrowed pulmonary valve is
repaired or replaced to increase blood flow to the lungs (Figure 18) (82).

Figure 18: Corrective surgery for Tetralogy of Fallot (83)

27

2.4 Tissue engineering Strategies
Tissue engineering is an interdisciplinary field that applies the principles of life
sciences and engineering towards developing biological substitutes that help restore,
maintain, or improve tissue functions or whole organs (84, 85). As described by Langer
and Vacanti in 1993, tissue engineering principles utilize the body’s natural growth and
regeneration processes for the repair and replacement of damaged or non-functional tissues
with healthy, native tissues. Tissue engineering approaches include utilization of
biodegradable polymeric scaffolds, decellularized extracellular matrix, as well as stem
cells, and cells harvested from patients.
As discussed previously, repair and replacement of cardiovascular deformities for
patients with congenital heart disorders, as well as with acquired cardiovascular defects,
requires the use of substitute tissues or grafts. To fabricate tissue replacements, three main
approaches are employed for cardiovascular tissue engineering: (1) Direct transplantation
of cells; (2) Decellularized or Acellular scaffolds; and (3) Tissue substitutes with cells
seeded on scaffolds (9).
For direct transplantation of cells, isolated cells are injected directly into the body,
and the differentiation and proliferation of these injected cells help restore the function of
the damaged tissue. Several studies have shown the ability of injected cardiomyocytes as
well as autologous skeletal myofibroblasts in restoring myocardial contractility and
function (86-88). However, with autologous cell injection, several problems exist with cell
survival, integration, and differentiation.
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The second approach for tissue engineering involves the use of decellularized or
acellular scaffolds. Decellularized scaffolds have widely been used in developing valve
and conduit replacements for cardiovascular diseases. The advantage of utilizing
decellularized scaffolds is the absence of cellular isolation and expansion in vitro. This
reduces the chances of contamination that might occur from in-vitro cell culture. The
approach relies on the infiltration of cells from the patient after implantation (89, 90).
Although studies with decellularized scaffold implantations have shown cellular
repopulation, the complete repopulation of decellularized scaffolds with cells is a challenge
(90, 91). Moreover, decellularized scaffolds by themselves, do not have significant
resistance to enzymatic degradation, and therefore need to be crosslinked (92). The effect
of the crosslinking reagent also needs to be considered for in vivo implantation of these
scaffolds (93).
The third approach in tissue engineering is the use of tissue constructs with live
cells. Autologous cells are isolated from the patient and expanded in-vitro. The cells are
then seeded on the prepared scaffold allowing cellular growth, differentiation, and
formation of a new extracellular matrix. Suitable biochemical and mechanical cues are
provided within a bioreactor. The constructs are then implanted back into the patient to
improve the functioning of the diseased tissue or organ. The use of cell-seeded tissue
constructs has three requirements: cells, scaffolds, and bioreactor. Cells seeded onto
scaffolds should be non-immunogenic, therefore autologous cells (94). For cardiovascular
tissue, usually smooth muscle cells, myofibroblasts, and endothelial cells from arteries and
veins are used (95, 96). When cardiomyocytes have limited growth capability, embryonic
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and adult stem cells capable of differentiating into multiple cardiovascular cell types are
used (97, 98). Biomaterials or scaffolds are obtained from natural or synthetic sources.
Scaffold materials have been discussed in later chapters. Lastly, bioreactors used for tissue
engineering applications are aimed at replicating environmental factors seen in human
biological systems and to provide mechanical and biochemical stimulation for cell growth
and ECM remodeling. (99, 100) Rotating-wall vessel bioreactors, perfusion bioreactors,
and pulsatile flow bioreactors have generally been used for cardiovascular applications
(101-103). While progress in bioreactor technology is still being made, problems of
bioreactor control, sterility, and tailoring device-specific variability still need to be
addressed (103).

Biomaterials for Tissue Engineering Scaffolds
Tissue engineering techniques require the use of porous scaffolds serving as a threedimensional structure for cellular attachment and subsequent remodeling and tissue
generation. An ideal tissue-engineered scaffold should be able to resist enzymatic
degradation and provide mechanical support to withstand mechanical stresses at

Figure 19: Load bearing properties vs time for tissue engineered scaffolds

30

implantation. Over time, to restore normal functioning of the tissues, scaffolds should
degrade and allow cellular infiltration and remodeling of the implants (Figure 19). Several
biomaterials, including synthetic and natural materials, have been utilized for the
development of scaffolds for tissue engineering.

Synthetic Scaffolds:
Synthetic scaffolds used for tissue engineering applications can be biodegradable
or non-biodegradable. Non-degradable materials like polytetrafluorethylene (PTFE) and
Dacron have extensively been used as vascular graft replacements. Owing to the nonbiodegradability of these materials, there might be physical barriers to the long term
adaptation of these grafts. Additionally, despite their excellent mechanical strength, nonbiodegradable scaffolds have been associated with graft kinking, scarring, inflammatory
response, and increased risk of infection (104).
Biodegradable synthetic materials like poly(lactic) acid (PLA), poly(glycolic) acid
(PGA), and poly (lactic-co-glycolic) acid (PLGA) are approved by the Food and Drug
Administration (FDA) for human use (105). The degradation rate of these polymers can be
controlled by adjusting the molecular weight, crystallinity, and the ratio of the combining
units for these copolymers (106). PLA and PGA polymers have been investigated as
biomaterials for heart valves, vascular grafts, and cardiac patches (107-109). Additionally,
poly(ɛ-caprolactone) (PCL), polyurethanes (PU), and Polyglycerol sebacate (PGS) have
also been used as bioresorbable scaffolds for tissue engineering (108, 110-118).
Polyhydroxyalkanoates (PHAs) and poly-4-hydroxybutyrate (P4HB) fabricated scaffolds
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tested as heart valve materials have not shown favorable results after 17 weeks of the
implant (119). Recently, polycaprolactone-based UPy (supramolecular 2-ureido-4[1H]pyrimidone) composed scaffolds, have shown promising results as conduit and valve
replacement materials (120).
Synthetic scaffolds for tissue engineering might have the advantage of providing
adequate mechanical properties, as well as the ability to modulate the polymer properties
like degradation time, microstructure, and mechanical properties. However, they might not
be an ideal attachment site for cells due to their surface characteristics. Moreover, toxicity
and inflammatory responses from the degradation products of biodegradable polymers
continue to be of concern (121).

Natural Scaffolds:
An alternative to synthetic scaffolds is the use of naturally derived materials.
Chitosan, collagen, alginates, gelatin, Matrigel, and decellularized extracellular matrices
have been extensively used for cardiovascular tissue engineering applications.
The first complete tissue-engineered blood vessel conduit, composed of collagen
gel, was developed by Weinberg in 1986 (122). Although the scaffold promoted cellular
attachment, it had mechanical limitations even after being reinforced with Dacron. Cyclical
mechanical conditioning of collagen gel scaffolds resulting in cell-mediated ECM
reorganization has significantly improved the strength of collagen scaffolds in later years
(123, 124).
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Similarly, gelatin scaffolds demonstrate poor mechanical resistance and are often
used in combination with synthetic polymers (125-128). Alginates have evolved as
attractive hydrogel matrices for cardiovascular tissue engineering. When used in
combination with chitosan and alginates generate polyelectrolyte complexes with highly
porous structures demonstrating reduced fibrosis, increased vascularization, and
integration with host tissue (129-131). However, concerns remain over the long-term
stability of alginate hydrogels and their ability to induce homeostasis. Chitosan has similar
structures to GAGs in the extracellular matrix and also exhibits antimicrobial properties.
However, there might be uncontrolled dissolution with chitosan scaffolds (125, 126, 132).
Decellularization of organs and tissues is another attractive approach to developing
scaffolds for cardiovascular tissue engineering. The extracellular matrix is obtained from
native tissues (allogenic or xenogeneic sources) by decellularization procedures involving
minimal loss and disruption of the matrix and maximum removal of native cells. Due to
the removal of native cells, the remaining ECM matrix is resistant to inflammatory
responses. Additionally, it has been observed that the spatial orientation of the extracellular
fibers affects the ability of cells to self-organize into tissue mimics (121). Since derived
from natural functioning tissues, decellularized scaffolds provide the structural and
biochemical cues required for cellular organization and proliferation. For cardiovascular
approaches, porcine sub intestinal mucosa (SIS), bovine jugular veins, porcine aortic and
pulmonary valves, as well as bovine pericardium decellularized scaffolds have been
extensively used. However, the decellularization process needs to be standardized and
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quality assessment investigated for effective use of decellularized scaffolds for tissue
engineering applications (121).

2.5 Conduit Replacement Strategies
As discussed in the surgical treatments of CHD, valved conduits are required for
the repair and replacement of deformed structures. The replacement conduits can be
obtained from homograft tissues, synthetic or bioprosthetic sources. Homograft pulmonary
conduits remain the preferred replacement of pulmonary arteries and veins; however, they
might not always be readily available. Currently available synthetic and bioprosthetic
conduit replacements come with their own limitations. Table 1 below lists some of the
currently available conduit replacement strategies with the outcomes of their clinical trials.
Type

Material

Year

Clinical

Intro-

Trials

Outcomes

duced
Synthetic or

Handmade ePTFE

2001

Pediatric

Implantation in 1776 patients

Composite

conduits with bulging

for RVOT reconstruction; 0.5%

sinuses and fan-

conduit related unknown death,

shaped ePTFE valve

15.9% reintervention, 10.7%
required explantation caused by
relative stenosis, 0.5% infection

(133)
Woven/knit Dacron

1957

Pediatric

tubes

Kinking,, rigid, cannot revive
lost biomechanical function

34

Gelatin/Collagen

2002

Pediatric

impregnated Dacron

High incidence of stenosis,
fibrotic neointima (8)

grafts
Hancock conduit:

1975

Dacron conduit with

Pediatric,

Implantation in adults showed

Adults

favorable results, however, not

porcine aortic valve

recommended in children
because of high profile valve;
shows calcification and stenosis
after long-term implantation;
persistent post-operative
inflammation might be an
indication of graft failure in
later stages (134-137)

Xeltis pulmonary

2020

Pediatric

No calcification or stenosis

valved conduit:

observed after implantation in

Conduit wall

patients, significant pulmonary

composed of poly-

regurgitation in a substantial

caprolactone-based

number of patients (138)

UPy (supramolecular

Modified design of the conduit

2-ureido-4[1H]-

resulted in reduced onset of

pyrimidone), valve

early regurgitation (120)

leaflets made of
polycarbonate based
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UPy; produced by
electrospinning
Bioprosthetic

Labcor Conduit:

1996

Pediatric

Implantation of Labcor conduits

stentless porcine

in patients resulted in high

tricomposite valve

incidence of post-operative

assembled in bovine

fever. (140) Furthermore, early,

pericardium tube,

and late mortality rate was 5%,

crimped to achieve

peripheral conduit narrowing

tubular configuration,

due to inflammatory infiltration

glutaraldehyde

and pseudo-intimal reaction

treated (139)

(141-143)

Glutaraldehyde

1997

treated porcine aortic

Animal

5-month implant in sheep did

studies

not show any pathological

valves and main

changes, thrombosis, reduced

pulmonary artery

calcification

sutured together,
coupled with 0.1%
partially degraded
heparin (144)
Contegra: Bovine

2001

Animal

Sheep implants of contegra

jugular vein conduits

studies,

conduits have showed spots of

fixed with

Pediatric,

calcification in jugular vein

glutaraldehyde

Adults

walls. (145) Implantation of

36

conduits in patients have shown
development of circumferential
stenotic membrane requiring
reintervention, as well as a high
incidence of development of
endocarditis (146-148)
Shelhigh No-react:

2001

Pediatric

Implanted conduits resist

Glutaraldehyde

calcification; however, foreign-

treated porcine

body-type reactions result in

conduit detoxified

pseudo-intimal peel formation

using heparin process

and early conduit stenosis

(149)

(150)

Bovine pericardial

2001

Pediatric

Calcification after implantation

conduit containing di-

in patients (83.7% and 58.8%

epoxy treated porcine

after 4 and 6 years of implant),

aortic root (151)

explant obstruction (152)

Di-epoxy treated

2001

Pediatric

Explant obstruction,

bovine pericardial

calcification after implantation

valved conduit

(152)

Matrix P plus:

2007

Pediatric

38% reoperation due to

decellularized

obstructed grafts, stenosis

porcine pulmonary

formation observed due to

valve surrounded by

inflammatory infiltration and

37

three glutaraldehyde

severe fibrogenic pseudo

fixed equine

intimal reaction (153)

pericardial patches
Decellularized and

2008

photo-oxidatively

Animal

Implants in dogs showed host

studies

cell repopulation of leaflets,

crosslinked bovine

little calcification, some

jugular vein (154)

endothelialization after 6
months (155)

Decellularized

2016

extracellular matrix

Animal

Pulmonary conduit replacement

studies

in sheep resulted in 50%

made from porcine

morbidity along with leaflet

small intestinal

thickening, pulmonary stenosis,

submucosa (SIS)

and valve regurgitation (156)

(CorMatrix®)
Glutaraldehyde

Pediatric

Calcification observed after 6

treated bovine

years of implant, conduit

pericardial valved

thrombosis, endocarditis (152)

conduit
Wharton’s Jelly

2021

(gelatinous inner

Animal

Cellularized conduit implanted

studies

in 2 Landrace pigs; 6-month

portion of umbilical

follow up showed patent

cord) mesenchymal

conduits with no rupture,

stem cell (MSC)

stenosis, deformation,

38

seeded decellularized

thrombosis, calcification; re-

porcine SIS

endothelialization observed

(157)
Table 1: Currently available conduit replacement strategies
Synthetic replacements for valved conduits are often faced with the limitation of
rigidity of the tubes, which makes them an unsuitable option for neonates (137).
Bioprosthetic conduits, on the other hand, have been found to have the advantage of easy
handling (158). However, most bioprosthetic conduits are crosslinked with Glutaraldehyde
to protect extracellular matrix degradation. Implantation of Glutaraldehyde treated
bioprosthetic conduits have resulted in stenosis, calcification, and ultimately conduit
failure (Figure 20).

Figure 20: CT at follow-up showing calcification in (A) 16 mm bovine jugular vein treated
with glutaraldehyde treated eight years after truncus arteriosus repair; (B) 19 mm bovine
pericardial valved conduit treated with glutaraldehyde treated six years after Ross-Konno
procedure (159)
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A few synthetic and bioprosthetic conduits, like Xeltis (electrospun synthetic
conduit) and Wharton’s jelly MSC seeded decellularized scaffolds, have shown significant
improvements over traditionally available replacements; however, the long-term
functioning and patency of these conduits are yet to be assessed (120, 157).

2.6 Valve Replacement Strategies
Valve replacements are required for the treatment of critical congenital conditions
like pulmonary stenosis or narrowing of the right ventricle. Valve repair or replacement
might also be necessary for conditions of pulmonary atresia or Tetralogy of Fallot
conditions

(160). Commercially available valve replacements are either mechanical

valves, synthetic valves, or bioprosthetic valves.

Mechanical heart valves
Mechanical heart valves have been in use since the 1950s (161). They are primarily
composed of silicone rubber, stelite alloys, Teflon, titanium, or pyrolytic carbon (162176); materials that are highly durable and do not degrade. Figure 21 shows some of the
commercially available mechanical heart valve devices.
Mechanical valves, however, have several drawbacks. Risk of valve thrombosis
and subsequent systemic embolism in patients with mechanical valve prosthesis requires
life-long treatment with anti-coagulant therapies (177, 178). Obstruction in mechanical
valves is also relatively frequent and is associated with thrombus and pannus formation
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(179, 180). Mechanical erosion due to cavitation has also been observed in several
mechanical valves (181).

A

B

C

D

E

F

Figure 21: Mechanical heart valves; (A) Starr-Edwards prosthesis, (B) AorTech Ultracor
mechanical valve, (C) Bjork-Shiley monostrut valve (D) Edwards bileaflet valve (E) OnX aortic valve (F) Edwards Mira valve (161)
Donor Valves
Donor heart valves or homografts are a more favorable replacement option
compared to mechanical valves. Unlike mechanical heart valves, donor heart valves have
a lower risk of infection, blood clots, do not require the administration of blood thinners,
and demonstrate improved blood flow (182, 183).
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With homograft valves, there, however, arises the concern of storage of the valves
and the immunogenicity from donor valves. The cellular components in homograft valves
have been observed to rapidly decrease along with loss of normal tissue architecture during
the first year of implantation (184). Additionally, they suffer from limited durability,
resulting in reoperations in young patients (183). Moreover, homograft valve replacement
units might not always be easily available or be available in pediatric sizes.

Bioprosthetic heart valves (BHV)
Bioprosthetic or tissue valves are obtained from animal or human tissue sources.
Like donor valves, bioprosthetic valves do not require life-long anti-coagulation therapy;
however, they are also prone to degradation requiring reoperations and valve replacement
(185, 186).
Tissue-engineered valves developed from autologous tissue are often decellularized
to remove any donor cell immunogenicity. Efforts have been made to recellularize acellular
allograft matrices with primary human endothelial cells (HEC) (187). Allograft valve
tissues, however, face the same problem of availability as with homograft vessels.
Another allograft valve reconstruction method was pioneered by Dr. Ozaki. In this
model, tissues are harvested from the patient’s pericardium, cut into the appropriate sizes,
treated with glutaraldehyde at room temperature for a few minutes, and sutured in place of
the defective valve (Figure 22) (188). This procedure has shown optimum short-term
results in young patients; however, long-term results remain to be seen (189-191).
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Additionally, since the tissues are glutaraldehyde fixed, surgical annular enlargement is
required at a later time for pediatric patients as the patient grows (192).

Figure 22: Autologous pericardial tissue valve reconstruction using Ozaki procedure (193)
Xenograft bioprosthetic valves are derived primarily from bovine pericardium or
porcine aortic valves. Pericardium valves are developed by mimicking the native heart
valve as much as possible by designing crosslinked animal-derived tissue into a tri-leaflet
structure around a polymeric or metallic stent (194). The advantages of pericardium are its
ease of handling and the ease of pericardium sheets to be cut into desired sizes. However,
pericardium tissue lacks the intrinsic tri-layer structure found in heart valves. Moreover,
glutaraldehyde is the most commonly used approved crosslinker, and glutaraldehyde
treated tissues prevent cellular infiltration and growth, and remodeling of the valves (195).
Porcine aortic valves much closely resemble the native tri-layer structure of valves.
Porcine valves, however, have a muscle shelf supporting the right coronary cusp, and they
also possess less fibrous continuity between the mitral and aortic valves. The presence of
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a shelf within the valve might lead to additional risk of calcification and reduced valve
motion (10, 196-198). To overcome these challenges, optimal leaflets are individually
selected and matched for the appropriate size (194).
Bioprosthetic heart valves can also be stented or non-stented. Stented valves have
a stent made out of artificial materials, either metallic or plastic, which are covered with a
fabric sewing ring to provide a frame for the valves. Early stented valves demonstrated
high failure rates due to tearing at the commissures. Modern approaches to stented valves
utilize flexible polymers, increasing the ease of valve implantation procedures. Stented
valves are also widely used for percutaneous intracatheter delivery strategies (199-205).
Stentless valves, on the other hand, do not have any struts to support the valve leaflets. The
absence of struts allows for a greater effective orifice area (206). The increased size also
allows for a better approximation of the patient’s normal valve. Although stentless valves
rely greatly on surgeons’ expertise, they have been shown to demonstrate better
hemodynamics, lesser obstruction to blood flow, reduced risk of endocarditis, and
increased durability compared to stented valves (207-213).
Several bioprosthetic valves are commercially produced for pulmonary and aortic
valve replacements. One of the first valves to be used in clinical applications was the
SynerGraft valve made of decellularized porcine aortic valve (214, 215). It resulted in rapid
degradation and structural failure after implantation in patients, along with extensive
calcification and inflammatory responses (216). Subsequently, improvements have been
made in the crosslinking of heart valves, and presently, the most commonly used valves
are produced by Medtronic, Edwards Lifesceinces, and St Jude Medical (217). Medtronic
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valves are fabricated from a line of porcine aortic valve leaflets crosslinked with
glutaraldehyde and treated with anti-calcification agent AOATM (alpha-oleic acid) as well
as proprietary physiological fixation (218). St. Jude Medical Inc and Edwards Lifesceinces
utilize bovine pericardium tissues wrapped in proprietary material around proprietary
stents and crosslinked with glutaraldehyde or formaldehyde to mimic native aortic valves
(194, 219, 220). However, as discussed in previous sections, these fixed valves are not
composed of ‘living tissue’ and do not have the capacity to grow with the patients, therefore
making them unsuitable for pediatric valve replacements.

2.7 Decellularization strategies
Various approaches have been employed to decellularize native tissues producing
decellularized scaffolds composed of extracellular matrix components without any native
cells. Although there is no universal consensus for adequate decellularization, the
following three criteria generally apply to decellularization of tissues: (1) < 50 ng DNA/
mg dry weight of decellularized tissue; (2) DNA fragments < 200 base pairs in length; (3)
No visible nuclear material from Hematoxylin and Eosin (H&E) or DAPI staining (221224). Decellularization methods can be broadly classified as physical, enzymatic, and
chemical, as well as a combination of two or more of these.

Physical Decellularization
Physical approaches for decellularization involve the mechanical separation of a
cellular layer from the underlying extracellular matrix (223). Physical characteristics like
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temperature, force, and pressure are modulated to facilitate the removal of cells from the
matrix (225).
Freeze-thaw cycles, sonication, pressure gradients, and pressurization techniques
aim at disrupting the cell membrane and causing cell lysis (226-233). Scraping of cells is
also occasionally used to mechanically remove cells from the ECM (234). All these
approaches, however, have a very high potential of disrupting the ECM structure within
the native tissue. Electroporation has been used to decellularize tissues by the formation of
micropores in cell membranes leading to cell lysis. However, It is more a suitable technique
for small size tissues (235, 236). Moreover, solvents used for electroporation might be
toxic. Perfusion, capable of removing cells as well as debris from the ECM is an effective
technique with less damage; however, it requires the presence of vasculature within the
tissue (233, 237, 238). Tissues without innate vasculature can be decellularized physically
by immersion and agitation into decellularization solution. It provides a more homogenous
exposure to detergents than static decellularization without significantly altering the ECM
structure. However, compared to perfusion, there might be more damage to tissue because
of the limited diffusion of chemicals by agitation (239-241).
Although physical methods of decellularization are an essential step to the removal
of cells and debris, they need to be optimized to produce minimal damage to the native
ECM of the tissues.
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Enzymatic Decellularization
Enzymes specifically target cellular components or ECM structures without
disrupting the whole tissue. Nuclease, trypsin, lipase, dispase, and phospholipase are
commonly used enzymes for the effective removal of cells and unwanted ECM
constituents.
DNase and RNase are routinely used in decellularization procedures to remove any
remaining nuclear material. The treatment is usually done after detergent treatment to allow
infiltration of the enzyme within the tissue. Although nucleases selectively remove nuclear
components, treatment for a very long period might negatively affect tissue matrix
components and mechanical stability (242). Additionally, proper washing of decellularized
tissues after nuclease treatment is required since incomplete washing and remaining
nuclease within the scaffold might invoke immunogenic response as well as inhibit the
recellularization of scaffolds (243).
Another commonly used enzyme in decellularization procedures is trypsin. Trypsin
functions by cleaving peptide bonds on the carboxyl-side of lysine and arginine, leading to
the release of cells from the extracellular matrix (92). Typically, cardiovascular tissues are
treated with 0.1% trypsin for 24-96 hours after nuclease treatments. Decellularization
protocols using trypsin have observed gross maintenance of the ECM components, as well
as limited toxicity from the enzyme (244). Some studies have, however, also found that
trypsin does not effectively remove all resident cells from native tissues (245). Remains of
native cells might cause immunogenic response as well as calcification after implantation.
Therefore, longer incubation times might be required. However, longer incubations might
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also lead to the destruction of elastin and collagen within the tissue matrix. The time and
concentration of trypsin treatment, therefore, needs to be optimized for the
decellularization protocol.

Chemical Decellularization
Detergents, acids, bases, hypertonic, and hypotonic solutions are utilized as
chemical reagents for decellularization.
Ionic detergents like SDS and SDC solubilize cytoplasmic membranes of cells and
nucleus as well as disassociate DNA from proteins. (246-248) Triton X-100/200, a nonionic detergent, is frequently used in decellularization procedures. Triton also solubilizes
cell membranes and dissociates DNA from proteins without disrupting the interaction
between proteins (249). Zwitterionic detergents like CHAPS, SB-10, and SB-16 also
function similarly by solubilizing cell membranes and disrupting DNA-protein, lipidprotein, and lipid-lipid interactions (250-252). All detergent treatments might alter ECM
structures and reduce the GAG and fibronectin/ laminin content within ECM. However, a
mild combination of the detergents within the decellularization solution has been shown to
maintain the ECM structures within decellularized valves (253).
Acids and bases help catalyze the degradation of biomolecules, cellular and nuclear
components. Peracetic acid (PAA), hydrochloric acid, ammonium hydroxide, sodium
hydroxide, and sodium sulfide have been utilized in decellularization procedures (254,
255). Similar to detergents, acids and bases can also lead to ECM alteration and removal
of components of ECM, and therefore need to be used in mild concentrations. Peracetic
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acid at 0.1% concentration has been shown to have minimal effects on ECM structure
(256).
Hypotonic and hypertonic solutions disrupt cell membranes due to differences in
osmotic pressures and cause cell lysis. Protein removal has been observed to be more
effective in hypertonic solutions, while hypotonic solutions effectively remove DNA (257).
Additionally, these solutions are removed by washing and therefore cause very little
toxicity. They also maintain ECM structures relatively well compared to other chemical
treatments. Hypotonic/ hypertonic treatments might however not be very effective by
themselves and are routinely used in combination with other detergents or enzymes (255).

Other Decellularization Approaches
In addition to the more conventional methods of decellularization as mentioned
above as well as a combination of these procedures, some groups have also developed
novel decellularization procedures. Casali et al. has developed a supercritical CO2-based
decellularization procedure in the porcine aorta that maintains the scaffold hydration and
mechanical properties while effectively removing most cellular components (258).
Vacuum-assisted decellularization, achieved by using negative pressure to accelerate the
decellularization procedure has been developed by Wang et al (259, 260). This approach,
while being highly effective in combination with physical, chemical, and enzymatic
treatments, might lead to ECM damage due to prolonged exposure to vacuum. Apoptosis
inducing agents like camptothecin, and rotenone has been pioneered for decellularization
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of nerve and lung tissues (261, 262). However, further research needs to be conducted to
apply these novel decellularization methods extensively.

2.8 Sterilization and crosslinking of decellularized scaffolds
Sterilization
Scaffolds, after decellularization need to be sterilized to remove micro-organisms
from the matrix. However, the sterilization technique should not alter the physical
characteristics of the scaffold or induce toxicity (92).
One of the most commonly used sterilization techniques is irradiation by gamma
rays (263). The process effectively removes micro-organisms but might alter the physical,
chemical, and biocompatibility properties of the ECM (264). Ethylene oxide (EO)
sterilization is another method that alkylates nuclear acids, rendering the macromolecules
inactive (265). EO treatment might lead to the accumulation of toxic residues within the
scaffold (266). Antibiotic treatment of the decellularized scaffold is capable of inhibiting
bacterial growth but does not effectively hinder the growth of virus and spores (267, 268).
Additionally, treatment with Peracetic acid is another method for sterilization of
decellularized scaffolds. The decomposition products from peracetic acid treatment are
non-toxic, but it might alter the physical characteristics of the scaffold (269, 270). This
necessitates combining two or more sterilization techniques in mild concentrations to
develop a balance between effective removal of micro-organisms and maintenance of the
physical and chemical properties of the scaffold.
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Crosslinking or stabilization of scaffolds
Decellularized scaffolds are susceptible to enzymatic degradation (14). To prevent
their rapid degradation on implantation, extracellular components within the scaffolds need
to be either chemically crosslinked or stabilized. Crosslinking also helps in improving or
maintaining the mechanical strength of the scaffolds. Crosslinking strategies of
decellularized scaffolds cab be broadly divided into physical, chemical, and natural
crosslinking.
Glutaraldehyde is the most commonly used crosslinker for scaffolds used in tissueengineering applications. Glutaraldehyde significantly improves the mechanical strength
of scaffolds; however, it has been shown to crosslink only the collagen within the ECM.
Elastic fibers still degrade rapidly after glutaraldehyde crosslinking (Figure 23) (15).

Figure 23: Histology of glutaraldehyde fixed aortic samples (A) before and (B) after
elastase treatment showing loss of elastin. (Adapted from (15))

Additionally, Glutaraldehyde crosslinking has been associated with toxicity and
calcification after scaffold implantation, leading to the final failure of the implant. (271)
Glutaraldehyde crosslinked bioprosthetic heart valves have been severely associated with
calcification. Devitalization and cellular alterations within heart valves result in the
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formation of debris within the cells, which act as nucleation sites for calcification. In
normal cells, low levels of intracellular calcium are maintained. However, after cell death,
high concentrations of calcium can infiltrate cells, react with remaining phosphorous
within tissues, and can ultimately lead to calcification. Anti-calcification strategies have
been developed to detoxify the adverse effects of glutaraldehyde, as well as improve
cellular adhesion and proliferation on these scaffolds. Pre-treatment with citric acid and
amino acid solutions has been shown to improve cell attachment to glutaraldehyde treated
tissues by removing free aldehyde groups (272, 273). Ethanol and its solutions have also
been used to remove phospholipids and cholesterol molecules from scaffolds, which play
a vital role in the induction of calcification (274, 275).
Another

crosslinking

agent

commonly

used

is

1-Ethyl-3-(3-dimethyl

aminopropyl)-carbodiimide or EDC. EDC crosslinking has been shown to protect collagen
from enzymatic degradation; however, it has not been able to inhibit calcification within
scaffolds, rendering them ineffective for cardiovascular uses (276, 277). Biological heart
valves and vascular grafts have also been crosslinked with epoxy compounds, which
interact with amino, carboxyl, and hydroxyl functional groups. This crosslinking approach
creates linear crosslinking, and collagen is not effectively protected from enzymatic
degradation. Moreover, epoxy crosslinking compounds have also been shown to exhibit
toxicity causing immune responses similar to calcification in Glutaraldehyde fixed tissues
(278).
Apart from chemical compounds, some natural substances like genipin,
nordihydrogualeric acid (NDGA), tannic acid and procyanidins have been used as
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crosslinking agents for tissue-engineered cardiovascular scaffolds. Natural crosslinkers are
considered superior to chemical crosslinking owing to their non-cytotoxic and anticalcification properties. Genipin crosslinked ECM scaffolds have been shown to exhibit a
lower inflammatory response compared to glutaraldehyde, and there is no loss of the
crosslinker during the preservation process (279-281). NDGA, a polyphenolic compound,
crosslinks collagen with ECM rendering increased tensile strength to scaffolds. However,
they are cytotoxic above 100 µM concentrations (282).
Polyphenols like tannic acid and it’s derivatives, as well as procyanidins, a
flavonoid have shown the ability to crosslink elastin along with collagen within
extracellular matrices, thereby imparting superior resistance to cardiovascular scaffolds
compared to traditional techniques (16, 283). These scaffolds have also been shown to
resist calcification as well as increased biocompatibility in in vitro and in vivo experiments
(284, 285). Therefore, natural crosslinking agents might be an excellent alternative to
traditionally used chemical crosslinking and help alleviate some of the adverse effects of
these crosslinking approaches.
Penta galloyl glucose (PGG) is a derivative of Tannic Acid that has previously
shown to reduce biodegradation and calcification in Tissue Engineered Vascular Grafts
(TEVG) (286). The structure of PGG is composed of a hydrophobic core with numerous
external phenolic groups (Figure 24). On account of the structure of PGG, it is capable of
binding to hydrophobic regions, as well as forming several hydrogen bonds. PGG shows a
particularly high affinity for proline, which is present in abundance within collagen and
elastin within the extracellular matrix (287, 288).
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Figure 24: Structure of Penta-galloyl Glucose (PGG), a derivative of Tannic Acid

Similar to tannic acid, PGG possesses the ability to establish strong cohesive bonds
between the structural proteins and protect them from enzymatic degradation (289).
Moreover, it has been found to exhibit lower toxicity than Tannic acid at the local and
systemic levels (16). , The addition of PGG to aneurysmal cell cultures, has been shown to
improve the elastogenesis process within the cells. Local and systemic delivery of PGG
has also been shown to reverse abdominal aortic aneurysms in rodents (290, 291).
Additionally, PGG is a potent anti-oxidant, and has been shown to possess anti-cancer,
anti-microbial, and anti-inflammatory activities (292). All of these functionalities make
PGG an ideal crosslinker for cardiovascular tissue engineering applications.
In addition to PGG, polyphenols Quercetin, Hesperidin, D-Salicin, and All-trans
Retinoic Acid have been shown to interact and modulate extracellular matrix components
in cell cultures (Table 2). Some of these properties of polyphenols are similar to those of
PGG, and therefore these other polyphenols might have the potential to interact and
stabilize ECM components in scaffolds.
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Compound
Quercetin

Advantages

Reference

Prevents in-vitro enzymatic
degradation in porcine heart
valves at concentrations of 1,

Wanyin J et al., Acta
Biomaterialia, 2010 (293)

2.5, 5 and 10 mg ml
Jianbo X et al., Molecular
Interacts with bovine γNutrition Food research,
globulin
January 2011 (294)
Stimulates collagen and elastin
expression in human dermal

Edwin D, Cosmetics, 2021

fibroblasts
Sherliane CP et al.,
Decreases activity of MMP-2
Atherosclerosis, 2018
in renovascular hypertension
(295)
Hesperidin

Jianbo X et al., Molecular
Interacts with bovine γNutrition Food research,
globulin
January 2011 (294)
Franziska B et al.,
Antioxidant and collagen
Materials, December 2020
crosslinking
(296)
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Promotes Osteogenesis and

Patricia AM et al., Int

modulated collagen matrix

Journal of Molecular

organization and mineralization
D-Salicin

Science, 2021 (297)
Jianbo X et al., Molecular

Interacts with bovine γNutrition Food research,
globulin
2011 (294)
Influences rheological and film
forming properties of collagen

Katarzyna A et al.,
Molecules, 2021 (298)
Feng G et al., Artificial

Inhibits AGE-induced
degradation of type ii collagen

cells, Nanomedicine, and
Biotechnology, 2019
(299)

Protects retinal endothelial

Yu S. et al., Artificial

cells from IL-1β-induced

cells, Nanomedicine, and

endothelial inflammatory

Biotechnology, 2019

response

(300)
Rosetti D et al.,

Induces dermal elastin
International Journal of
synthesis and elastin fiber
Cosmetic Science, 2010
formation
(301)
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All-trans Retinoic
Acid

Remodels extracellular matrix
and suppresses laminin
Yo-Chen C et al., Exp Eye
enhanced contractility of
Res, 2008 (302)
human retinal pigment
epithelial cells
Regulates TGF-β1-induced
extracellular matrix production
in nasal polyp-derived

Su-Jong K et al., Int forum
allergy rhinol, 2020 (303)

fibroblasts
Regulates proliferation,
migration, differentiation, and
extracellular matrix turnover of
human arterial smooth muscle

Dorothea IA et al.,
Cardiovascular Research,
2001 (304)

cells
Table 2: Properties of Quercetin, Hesperidin, D-Salicin and All-trans Retinoic Acid

2.9 Diabetes and wound healing
Diabetes is a chronic condition that develops due to insufficient production of
insulin by the pancreas or the ineffectiveness of the body to utilize the insulin produced
(305). Insulin is a hormone that regulates the metabolism of carbohydrates, fats, and
proteins within the body by promoting glucose absorption from blood into fat, liver, and
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skeletal muscle cells (306). Elevated levels of glucose, or hyperglycemia, is an effect of
uncontrolled diabetes, resulting in damage to the body’s systems, especially the vascular
and nervous systems (305). Diabetes, in a combination of higher-than-optimal blood
glucose conditions within the cardiovascular disease, chronic kidney conditions, and
tuberculosis, leads to approximately 2.2 million deaths worldwide (307).
Diabetes incidence can be broadly classified into two groups. Type I diabetes, or
childhood-onset diabetes, results from insufficient production of insulin in the pancreas.
There is very little information on the cause and prevention of type I diabetes. Type II
diabetes, on the other hand, also known as adult-onset diabetes, is a result of the ineffective
use of insulin by the body (308). Type II is the most prevalent form of diabetes, accounting
for almost 90-95% of all diabetes cases in the United States (309). Type II diabetes
develops due to several factors, including overweight and obesity, physical inactivity,
insulin resistance, and genetic predisposition (310). In the context of congenital heart
disorders discussed previously in this chapter, it is also important to observe, pregnancies
with type I and type II diabetes are at a higher potential risk of development of CHD
conditions in the babies (311).
Among many complications induced by elevated blood sugar levels, the altered
metabolism in diabetic conditions leads to impaired wound healing (312). The normal
wound healing process progresses through stages of inflammation, proliferation, and
remodeling (313, 314). The stages of normal wound healing along with the predominant
cell types and the cellular events in each stage have been demonstrated in Figure 25 below
(315)
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Figure 25: Stages of normal wound healing; EPCs: Endothelial progenitor cells, (315)
Impaired wound healing in diabetic conditions is manifold. Hyperglycemia leads
to increased protein kinase C (PKC) activity, contributing to vascular complications (316).
It also leads to non-enzymatic glycation of collagen and the formation of advanced
glycosylation end products (AGEs), leading to dysfunctional endothelial cells and
extracellular matrix along with reduced solubility of the extracellular matrix (Figure 26)
(317-320).

Figure 26: Effect of diabetes on wound healing; MMPs: Matrix metalloproteinases (315)
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Chronic inflammation is caused by an increase in M1 macrophages compared to
M2 macrophages (321). Additionally, an increase in pro-inflammatory cytokines like
interlukin-1 (IL-1), interlukin-2 (IL-2), and tumor necrosis factor-alpha (TNF-alpha) leads
to a prolonged inflammatory phase (322). Fibroblasts in diabetic wounds also display
decreased proliferation, decreased migration, and increased apoptosis (323). Decreased
keratinocyte differentiation and migration also leads to slower wound repair (324).
Additionally, there is an increase in the levels of MMPs (matrix metalloproteinase) and a
decrease in TIMPs (Tissue inhibitors of MMPs) (325-328).
Furthermore, the phagocytic and bactericidal activities of polymorphonuclear
leukocytes in diabetic patients have been found to be impaired compared to patients with
normal blood glucose levels (329, 330). These changes in metabolism and cellular
dysfunction along with granulocyte impairment leads to slower wound healing in diabetic
patients along with an increased risk of infection.

Scaffolds for diabetic conditions
As discussed previously, diabetic conditions lead to impaired wound healing due
to imbalance of protease, the presence of reactive oxygen species, degraded essential
growth factors, and impaired angiogenesis. Biomaterial scaffolds providing matrices for
cellular attachment and proliferation are widely used in such conditions to facilitate wound
healing and tissue regeneration. Several tissue-derived, hydrogel-based, and controlled
release biomaterials have been used for wound repair in diabetic conditions.
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Tissue-based scaffolds mimic the extracellular matrix of natural tissues and provide
suitable microenvironments for cells. Allografts from cadavers, placental tissue, and
porcine sub-intestinal mucosa have been used as tissue sources for wound healing scaffolds
(331-334). Living skin substitutes seeded with allogenic fibroblasts or keratinocytes have
been used for chronic skin wound healing (335, 336). Such substitutes are composed of
natural (collagen) or synthetic (polyglactin scaffolds) components (337). Acellular
scaffolds have been composed of porcine sub intestinal mucosa, decellularized human
dermis, crosslinked bovine collagen, composites of collagen and cellulose as well as
calcium alginate fibers (337-339). Additionally, biopolymeric scaffolds derived from Nacetyl glucosamine, hyaluronic acid, and crosslinked dextran and PEG acrylates have been
reported to interact with fibroblast and endothelial cell infiltration stimulating chronic
wound healing (340-342). Hydrogels can be engineered to mimic extracellular matrices of
soft tissue, thereby providing a defined ECM for cellular infiltration, proliferation, and
vascularization (343). L-Glutamine loaded Chitosan hydrogels have been shown to
enhance collagen deposition and angiogenesis in diabetic wounds (344).
In addition to tissue supports, inductive signals like Vascular Endothelial Growth
Factors (VEGF) and basic fibroblast growth factors (bFGF) have been shown to promote
angiogenesis in wounds. Since these molecules degrade very rapidly in diabetic wound
conditions, controlled release mechanisms have been fabricated to provide efficient
concentrations of these molecules at the affected area (345). SDF 1-Alpha activated
collagen scaffolds have been shown to restore pro-angiogenic wound healing in human
diabetic adipose-derived stem cells (346). Nanoparticles, vectors (DNA, plasmid, virus),
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as well as preloaded encapsulation within hydrogels have been used for controlled delivery
of molecules at the wound site (347-349).

Animal models for Type II Diabetes
Type II diabetes is characterized by insulin resistance and increased apoptosis as
well as decreased replication of the beta cells (350, 351). Animal models to study type II
diabetes are therefore aimed towards the development of these physiological conditions to
effectively analyze the effects of the condition. Due to species-specific differences, there
are no perfect animal models for diabetes; however, several approaches have been
investigated.
The development of type II diabetes in animal models has two main approaches:
obesity-induced diabetes and beta-cell inadequacy induced diabetes. Since most cases of
onset of type II diabetes in humans are associated with obesity, related animal models are
widely used in diabetes research (352).
Obesity-induced type II diabetes can again be divided into two main categories:
genetically obese animals and high fat-induced obesity. Depending on the genetic mutation
or stress induction, different animal models mimic different physiological features of
diabetes in humans. Animal models of type II diabetes have been developed in rats, mice,
hamsters, pigs, and some invertebrates to study the pathophysiology and treatment of
diabetes.
Mice and rat models of diabetes are the most common because of the ease of
handling of these animals. Genetically developed diabetic rodent models include the
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AKITA mice, GK Rats, Obese hypersensitive rats (OHS), Zucker diabetic fatty rats, and
diabetic mice with mutations in either the leptin gene (ob/ob) or in the leptin receptor
(db/db). Spontaneous auto-immune rodent models include NOD-mouse, diabetes-prone
BB rats, KDP rat, LETL rat, and LEW-iddm rat. Most of these auto-immune disorder
models more closely represent Type 1 diabetes (353, 354).
Chemically induced diabetic models in rats depend on the induction of diabetes
using Alloxan or Streptozotocin. Alloxan is an analog of glucose that is cytotoxic and
inhibits glucose-incited insulin emission as well as induces the formation of reactive
oxygen species. About 20 -200 mg/kg doses of alloxan are used intravenously in rats for
induction of diabetes. Streptozotocin (STZ) is also a toxic analog of glucose that targets
pancreatic ß-cells. In diabetic models, STZ can be administered in high doses or in multiple
low doses. In high doses, it destructs pancreatic ß-cells, while low doses induce
inflammatory and immune responses similar to autoimmune diabetes (354, 355). Single
doses of STZ produce characteristics similar to Type 1 diabetes, whereas low doses more
closely resemble type 2 diabetes.
For wound healing applications, diabetic models of rats are extensively used. The
High Fat Diet-STZ model for induction of type II diabetes in SD rats serve as an excellent
model for wound healing applications. High-fat diet (HFD) in rats induces insulin
resistance, whereas STZ injections lead to dysfunction in ß-cells. This model, therefore,
mimics the type 2 diabetes development in humans and can be ideal for studying effects
(356, 357)
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CHAPTER THREE
PROJECT RATIONALE AND SPECIFIC AIMS

As discussed previously, patients with congenital heart diseases have congenital or
hypoplastic structures within their heart and great vessels. While many of these defects are
small and can repair without any intervention, critical defects require surgical interventions
to repair or replace the defect and restore normal blood flow. Valve, conduit, and patch
replacements are required for absent pulmonary valves, aortic stenosis, double outlet right
ventricle, extracardiac conduit, and pulmonary valve replacement in Tetralogy of Fallot
conditions of congenital defects (358). Homograft replacements are the most desired but
might not always be easily available. Synthetic or bio-prosthetic replacement options, on
the other hand, have the advantage of being easily produced on a large scale. For conduit
replacement, the more commonly used materials are Dacron, Gore-Tex, or Glutaraldehyde
(Glut) fixed heterograft jugular veins (359) (360). Unfortunately, with most of the available
materials, the conduits become stenotic over time, requiring their replacement. This results
in multiple interventions ranging from catheterization with stents to replacement
operations.
Current valve replacement strategies involve the use of mechanical or bioprosthetic
valves. Mechanical valves are prone to thrombus formation and require the administration
of life-long anticoagulants. Available bioprosthetic valves, on the other hand, eventually
wear out. Valve repair is preferred over valve replacement, whenever possible, because of
the lower incidence of infection, thrombosis, and reoperations with repair. One repair
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procedure pioneered by Dr. Ozaki utilizes autologous pericardium tissue from the patient;
pericardium is harvested from the patient, crosslinked with glutaraldehyde for a few
minutes, cut into suitable size, and the patient’s valve is repaired using sutures. (361) This
procedure has shown acceptable short-term results in young patients with small aortic
annuli. However, surgical annular enlargement might be required as the patients grow.
(362) Moreover, the glutaraldehyde crosslinked pericardium tissue lacks the tri-layer
structure of native valve leaflets and is incapable of growth or repair.
An ideal replacement graft for pediatric replacement should withstand the
mechanical forces at the time of implantation as well as display capacity for remodeling to
be efficient in the long term. Several approaches have been utilized in the past few decades
to develop implants with growth potential, but with few successes. This research aims to
develop superior valves, patches, and conduits by utilizing decellularized xenologous
tissue that is treated to stabilize the elastin and collagen within the extracellular matrix. The
decellularized PGG treated tissues would resist calcification due to the removal of the
principal sites of calcification with the decellularization procedure. (363) Crosslinking with
PGG would also protect the elastin and collagen within the decellularized tissues from
rapid degradation. (364) PGG treated Engineered Tissue Vascular Grafts have been shown
to exhibit good mechanical and biological properties in vivo by subdermal implantation in
rats and were found to be non-thrombogenic in acute implantation studies in rabbits. (365)
PGG treated valve leaflets with the attached potion of the wall would additionally maintain
the native structure and functionality of the valve leaflets. The attached wall would also
allow ease of surgical implantation by ensuring sutures pass through the wall and not the
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valve leaflet, thereby minimizing manipulation of the functional leaflet structure.
Moreover, the acellular grafts would be able to allow cellular infiltration and remodeling
of the grafts with the potential to grow with young patients.
Additionally, the research aims to develop tissue biomaterials capable of resisting
calcification and structural degradation from enzymatic digestion by treating decellularized
tissue scaffolds with PGG. The approach would provide durable, off-the-shelf biomaterial
that is robust, biocompatible, with significant implant life, compared to decellularized
scaffolds and would allow cellular ingrowth of host cells, thereby potentially enabling
regenerative growth and remodeling after implantation. The biocompatibility of the
biomaterials was tested in subcutaneous implants as well as intra-muscular implants.
Furthermore, the functionality and efficiency of the PGG treated valved conduits
and leaflet patches were evaluated in a large animal model circulatory environment. Along
with implant functionality, this will determine the hemocompatibility of the biomaterial,
as well as cellular infiltration, remodeling, and growth potential of the scaffold after
implantation.
Aim 1: Assessment of the efficiency of polyphenols in stabilizing Elastin and
Collagen in scaffolds
Approach: Decellularized scaffolds will be prepared from fresh tissues and will be
treated with polyphenols Penta-Galloyl Glucose (PGG), All-Trans Retinoic Acid (ATRA),
Hesperidin, D-Salicin, and Quercetin to determine the ability of the polyphenols to
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crosslink the scaffolds. The efficiency of the polyphenol treatments to cross-link the elastin
and collagen will be determined by subjecting the scaffolds to degradation by Elastase and
Collagenase enzymes. Primary cultures of Human Aortic Smooth Muscle Cells
(HAoSMCs) will be treated with polyphenols to determine effect of polyphenol treatment
on the production of soluble tropoelastin by the cells as well as the deposition of healthy
cross-linked elastin will be analyzed after 14-day cell-culture.
Aim 2: Development of tissue engineered bovine jugular vein conduits for
pediatric patients
Approach: Tissue-engineered Bovine Jugular vein (BJV) conduits will be prepared
from decellularized tissues crosslinked with PGG. The concentration of PGG for optimal
crosslinking will be determined by the resistance of the scaffolds to resist degradation by
elastase and collagenase enzymes. The potential of the prepared jugular vein conduit
tissues to maintain their properties after long-term storage will be analyzed. The
biocompatibility and functionality of the PGG treated jugular vein conduits will also be
determined by implantation in sheep as pulmonary conduit replacement units.
Aim 3: Development of tissue-engineered valve leaflet patch for pulmonary
valve repair in pediatric patients
Approach: Pulmonary valve repair units will be developed from porcine aortic
valves (PAV) and porcine pulmonary valves (PPV) by decellularization and PGG treatment
of the decellularized scaffolds. The tissue-engineered valves, with attached wall portions,
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will be analyzed histologically for the decellularization efficiency, as well as their ability
to resist degradation by elastase and collagenase enzymes. The mechanical properties of
the native tissues and the decellularized and PGG treated scaffolds will be determined using
biaxial mechanical testing. Suture retention strength of the PGG treated aortic walls will
also be compared to that of Glutaraldehyde treated aortic wall tissues.
PGG treated porcine aortic valve and wall tissues will be implanted subcutaneously
in rats for up to 90-days to determine their biocompatibility, as well as analyze their ability
to resist calcification compared to Glutaraldehyde treated tissues. After subcutaneous
implantation, the explants will be analyzed histologically, as well as using flow-cytometry
to determine cellular infiltration within the subcutaneous implants.
PGG treated porcine aortic valves and porcine pulmonary valves with attached
walls will also be implanted in sheep as pulmonary valve repair units to determine the
functionality of the tissue-engineered scaffolds. The animals will be monitored for valve
functionality during the implantation period. Explants will be analyzed by their gross
histology as well as histologically to determine the infiltration of cells within the implanted
scaffolds.
Aim 4: Evaluation of PGG treated Bovine Pericardium scaffolds as intramuscular implants in diabetic conditions
Approach: Bovine pericardium patches will be prepared by decellularization and
PGG treatment of the native tissues. The tissue-engineered pericardium patches will be
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analyzed for their ability to resist bacterial attachment in Staphylococcus aureus cultures.
Patches will then be implanted in diabetic and non-diabetic rats as full-thickness abdominal
wound healing patches for up to 6 weeks. The efficiency of the patches as intra-muscular
implants in diabetic conditions will be compared to that under non-diabetic conditions
using gross view analysis and histological analysis of the explants.
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CHAPTER FOUR
SPECIFIC AIM 1: ASSESSMENT OF THE EFFICIENCY OF POLYPHENOLS IN
STABILIZING ELASTIN AND COLLAGEN IN SCAFFOLDS

4.1 Introduction
Tissue-engineered scaffolds derived from xenogeneic sources need to be
decellularized to remove the native cellular and nuclear components capable of inducing
immunogenic response upon implantation (366, 367). The decellularization of native
extracellular scaffolds also removes the principal sites for calcification, providing superior
grafts compared to glutaraldehyde-fixed native tissues (368). The efficiency of the
decellularization process itself might be dependent on the structure and arrangement of
ECM components within the tissue (369, 370). To establish the consistency of the
decellularization procedure, different tissues were decellularized using the developed
decellularization protocol, and its effectiveness in removing native nuclear components
was analyzed.
Additionally, despite their resistance to calcification and immunogenic responses,
decellularized scaffolds are susceptible to enzymatic degradation by enzymes (371, 372).
To protect decellularized scaffolds from rapid degradation by elastase and collagenase
enzymes after implantation, the elastin and collagen within the ECM need to be
crosslinked. PGG, the core structure of polyphenol Tannic Acid (TA), has been shown to
stabilize elastin within the extracellular matrix of tissues while being less toxic than TA
(373). Owing to its hydrophobic core and numerous external hydroxy groups, PGG is
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capable of binding specifically to hydrophobic regions of elastin and collagen in addition
to establishing numerous hydrogen bonds (374-376).
PGG has also been shown to promote elastogenesis within healthy and aneurysmal
rat smooth muscle cell cultures(377). Elastogenesis is an elastic fiber assembly process that
is highly upregulated during the late fetal and neonatal stages (378). Mature cells show
poor recruitment, crosslinking, and elastin precursor organization into fibers (379). The
presence of pro-elastogenesis compounds within the implanted scaffolds might therefore
potentially enable elastin formation and remodeling within the scaffolds.
Polyphenols Quercetin, Hesperidin, and D-Salicin, have been shown to interact
with γ-globulins (380). All-trans Retinoic Acid (ATRA) has been shown to influence ECM
synthesis and ECM degradation in Human Arterial Smooth Muscle cell cultures (381). In
this study, the ability of these polyphenols to interact and stabilize ECM components in
decellularized scaffolds was studied. To this effect, the polyphenols were analyzed for their
ability to crosslink collagen and elastin within ECM of decellularized scaffolds and prevent
their rapid degradation. The ability of the polyphenols to deposit elastin and fibrillin within
the extracellular matrix of smooth muscle cells was also determined.

4.2 Materials and methods
Decellularization of Native Tissues:
Fresh bovine pericardium, bovine jugular veins, bovine inferior vena cava, porcine
fascia, and porcine aortic valve tissues were obtained from Animal Technologies, Inc. The
tissues were inspected ante mortem and were found to be free from contagious diseases.
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Blood was removed from the native tissues by washing with PBS, and any muscle within
the tissue was trimmed.
Native Tissues

Sodium Hydroxide
treatment
1 hour at room
temperature

Decellularizing Solution
N=3 for 48 hours each
0.25% SDS
0.5% DOC
0.5% Triton X
0.2% EDTA

DNA Quantification

Histology
Enzyme Challenge

DNase/RNase
Treatment
N=4 days for 24
hours at 37℃
DNase: 360 U/ml
Sterilization
0.1% Peracetic Acid

Polyphenol Treatment

Storage
PBS with 1% Pen/Strep

Figure 27: Decellularization process and Polyphenol Treatment of native tissues
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Native tissues were incubated with 0.05 M sodium hydroxide (NaOH) for one hour
at room temperature, following which, they were treated with a decellularizing solution
composed of 0.25% sodium dodecyl sulfate (SDS) (Fisher BP349-100), 0.5% sodium
Deoxycholate (DOC) (Carolina Biological 858740), 0.5% Triton X 100 (Alfa Aesar
A16046), and 0.2% Ethylene Diamine Tetra-Acetic acid (EDTA) (Sigma Aldrich E6511)
in 50 mM TRIS (tris (hydroxymethyl) amino-methane) (Bio-Rad 1610716) buffer (pH 7.4
± 0.05) for three days. Decellularization solution was replaced with fresh solution every
day.
Tissues after treatment with decellularization solution were rinsed thoroughly and
treated with 70% ethanol by shaking at room temperature and then incubated with DNase/
RNase solutions. DNase (Worthington, 3840 /mg dry weight) and RNase (Fisher, 97.1
Kunitz/mg) was used at a concentration of 360 U/mL (for both DNase and RNase) to
remove native nucleic acid components from the tissue. The DNase/ RNase treatment was
done for four days at 37°C, and the solution was replaced with fresh DNase/RNase every
24 hours. The decellularized scaffolds were sterilized by shaking with sterile 0.1%
Peracetic acid (pH 7.4 ± 0.05) at room temperature for 24 hours. After sterilization,
scaffolds were stored in sterile PBS with 1% penicillin/ streptomycin antibiotics. The
decellularization procedure has been schematically represented in Figure 27.

DNA Quantification:
Native and decellularized tissues were lyophilized by freezing tissues at -80°C, and
then placing them in a Freeze Dryer (Labconco, Kansas City, MO) for at least 24 hours.
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All tissues were washed thoroughly in Deionized (DI) water before freezing to remove any
salt contributing to false dry weight readings. DNA was extracted from lyophilized native
and decellularized tissues using Qiagen Dneasy Blood and Tissue Kit (Cat. No. 69504).
Briefly, 5-10 mg of the native and decellularized lyophilized tissues were cut into small
pieces and placed in Buffer ATL and Proteinase K at 56°C until all of the tissue was
digested. Ethanol was added to the digested samples to precipitate the nucleic acids, and
the DNA was isolated in a microcentrifuge spin-column by washing with appropriate
buffers and eluting bound DNA with equal volumes of buffer AE. The concentration of
DNA obtained from each sample was quantified with ultrasensitive fluorescent nucleic
acid stain Quant-It Pico green dsDNA Reagent kit. The fluorescence value for each sample
was measured at 502/523 nm and compared to a set of standards of known concentrations
of DNA to obtain the DNA concentration in the particular sample. Wherever required, the
samples were diluted at the appropriate levels for the fluorescence reading to be within the
range of the standards used. The DNA concentration for each sample was multiplied by
the volume of buffer AE used for elution, and the total amount of DNA obtained was
normalized to the dry weight of the tissue initially digested to determine the nanograms
(ng) of DNA/ mg of the tissue sample.

Histological Analysis:
Tissue samples were fixed in formalin for 48 hours, dehydrated by a series of
changes through ethanol concentrations, and embedded in paraffin. Paraffin blocks of
tissues were sectioned at 5 μm thickness, mounted on glass slides, and heated for 30
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minutes on a slide warmer to adhere the tissue sections to the slides. Slides were baked
overnight at 56°C in an oven. Subsequently, the slides were deparaffinized and stained with
hematoxylin and eosin to determine cellular components within the tissue matrix.

Polyphenol treatment of decellularized scaffolds:
Decellularized tissues were treated with polyphenols PGG, All-trans retinoic acid,
Hesperidin, D-Salicin, and Quercetin for 20 ± 2 hours by shaking at room temperature,
protected from light. For the PGG treatment, 0.15% PGG (SA Ajinimoto Omnichem N.V.,
Belgium) was dissolved in 20% isopropanol in HEPES (4-(2-hydroxyethyl)-1piperazineethanesulfonic acid) solution (pH 5.5). For treatment with All-Trans retinoic
acid, 0.07% ATRA (Sigma Aldrich, US) was dissolved in 20% isopropanol in HEPES at
pH 9. 0.28% Hesperidin (Sigma Aldrich, US) was dissolved in 10% DMSO in HEPES at
pH 11.4. 0.2% D-Salicin (Sigma Aldrich, US) was dissolved in HEPES buffer at pH 7.4.
Finally, for the Quercetin treatment, 0.16% Quercetin (Sigma Aldrich, US) was dissolved
in 20% isopropanol in HEPES (pH 9.5). After the polyphenol treatments, the tissues were
washed and stored in sterile PBS at 4°C. The polyphenol concentrations and buffers used
have been summarized in Table 3.

Polyphenol
All-trans
Retinoic
Acid
(ATRA)

Structure

Maximum
Dissolved

Buffer
(pH)

Final
Concentration

3.5 mg/ml
in
Isopropanol

HEPES
(9.0)

0.07%
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PentaGalloyl
Glucose
(PGG)

11.6 mg/ml
in
Isopropanol

HEPES
(5.5)

0.15%

Quercetin

8 mg/ml in
Isopropanol

HEPES
(9.5)

0.16%

Hesperidin

28 mg/ml in
DMSO

HEPES
(11.4)

0.28%

D-Salicin

43 mg/ml in
Water

HEPES
(7.4)

0.2%

Table 3: Polyphenol Concentrations used for Treatment of Decellularized Tissues

Enzyme (Elastase and Collagenase) Challenge:
Native, Decellularized, and Polyphenol treated decellularized tissues were rinsed
thoroughly in water and lyophilized to obtain the dry weight of the tissues. The scaffolds
were then subjected to treatment by elastase and collagenase to determine the ability of the
polyphenol-treated scaffolds to resist rapid degradation by elastase and collagenase
enzymes. 10-15 mg sections of lyophilized tissue were obtained for each sample. For the
elastase challenge, the sections were placed in 1.2 mL of 5 U/mL Elastase enzyme with 1
mM Calcium Chloride (CaCl2) and 0.02% Sodium Azide (NaN3) in 100 mM TRIS buffer
(pH 7.8 ± 0.05) for 24 hours. For the collagenase treatment, 1.2 mL of 75 U/mL type VII
Collagenase was used with 10 mM CaCl2 and 0.02% NaN3 in 50 mM TRIS buffer (pH 8 ±
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0.05) for 48 hours. The samples were placed in a warm room (37°C) with shaking at 650
RPM (revolutions per minute). The digested samples were rinsed in water and lyophilized
at the end of the 24-hour or 48-hour time points. The dry weights of the digested samples
were recorded and used to analyze the percent weight loss (% weight loss) after the
collagenase/ elastase enzyme challenge. Digested tissue samples were also fixed in 10%
NBF, tissue processed, embedded in paraffin, and sectioned using a microtome to
determine the Extracellular Matrix structure after enzyme digestion.

Cell culture and Polyphenol treatment of cells:
Primary Human Aortic Smooth Muscle Cells (HAoSMCs) isolated from the human
aorta were obtained from a commercial supplier (PromoCell, Heidelberg, Germany). Cells
were cultured in T-75 flasks in low serum (5% v/v) smooth muscle cell growth media
(PromoCell, Heidelberg, Germany). Growth media was prepared by adding the
Supplement Mix consisting of Fetal Calf Serum, Epidermal Growth Factor (recombinant
human), Basic Fibroblast Growth Factor (recombinant human), and Insulin (recombinant
human) to the basal medium to final supplement concentrations of 0.05 mL/mL, 0.5 ng/mL,
2 ng/mL, and 5 μg/mL respectively. Cells were maintained in a humidified incubator at
37°C and 5% CO2 and culture media were changed every three days.
Primary HAoSMCs were treated with polyphenol PGG, Quercetin, Hesperidin, DSalicin and ATRA (10 μg/ml) for 14 days. Stock solutions of the polyphenols (5 mg/ml)
in DMSO were filter sterilized through 0.2 μm filters before addition. Control groups were
used with the addition of only DMSO. The cell culture media was changed every 3 days.
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After 14-days of culture, soluble proteins and cell layers were collected and analyzed.
Passage numbers 3-7 were used for all cell culture studies.

Protein quantification:
After 14-days of cell culture with polyphenols, the cell layers were washed with
sterile DPBS and protein was extracted using Solulyze-M mammalian extraction buffer
(Genlantis, San Diego, CA). Prior to extraction, one tablet of protease inhibitor cocktail
(Sigma, St. Louis, MO), was added to 10 ml of the buffer to prevent protein degradation.
After ~15 minutes of buffer incubation at room temperature, cell layers were scraped from
the cell culture plate, collected, homogenized, and centrifuged at 12,000 x g for 15 minutes.
Cell pelettes were washed, frozen and lyophilized, while the supernatant was used to
determine the total soluble protein with Pierce BCA protein assay (Thermo Scientific,
Rockford, IL).

Fastin Assay for Elastin quantification:
Insoluble elastin deposition within cell layers treated with polyphenols was quantified
using Fastin assay (Accurate Scientific and Chemical Corporation, Westbury, NY).
Lyophilized cell pelettes were digested using 0.5M Oxalic acid by boiling for 1 hour at
100°C in a water bath. Digested samples were quantified for the presence of α-elastin using
fastin assay. The amount of elastin obtained from each sample was normalized to the total
soluble protein content of each sample.
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Immunocytochemistry (ICC) for Elastin and Fibrillin I:
HAoSMCs were treated with polyphenols for 14-days in culture as described
before. At the end of 14-days, polyphenol treated SMC cultures were washed with sterile
PBS and fixed at room temperature with 4% NBF for 15-20 minutes. Fixed cultures were
blocked using 5% bovine serum albumin. The primary antibody, mouse anti-rat elastin or
Fibrillin I antibody, was applied overnight at 4°C at a dilution of 1:100. Secondary
fluorescent tagged antibody was used at 1:200 dilution for 1 hour at room temperature. Cell
monolayers were stained with DAPI for 10 minutes and washed with PBS. Subsequently,
the wells were filled with PBS, and samples were examined with a fluorescent microscope.
All the samples were imaged under similar exposure for impartial analyses.

Semi-quantitative image analysis was done using FIJI ImageJ software. The elastin/
fibrillin I single-channel images were converted to 8-bit images, threshold adjusted to
remove any background, and the Mean Grey area was obtained for each image. The cell
count was obtained by threshold adjustment, watershed, and particle analysis from the
DAPI channel images. Mean Grey area values were normalized to the cell counts obtained
from each image to obtain the semi-quantitative elastin/ fibrillin I estimation (382, 383).

Statistical Analysis:
All in-vitro experiments, including cell cultures, were done in triplicates or more.
The data was reported as the Mean ± Standard Deviation. Data from different groups were
analyzed by one-way analysis of variance (ANOVA) using Tukey’s HSD. All statistical
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analysis was done using JMP® Pro 15.2.0. Significance was reported at three different
significance levels:

***

p ≤ 0.01,

**

p ≤ 0.05, *p ≤ 0.1. Statistical significance has been

reported in each result.

4.3 Results
Decellularization of Native Tissues:
The Decellularization process involved multiple 24-hour periods of treatment with
DNase and RNase enzymes. The optimum number of the DNase/RNase treatment cycles
was determined by measuring the DNA content in Bovine Jugular Vein tissues after every
DNase/RNase treatment.
DNA quantification of BJV conduits after every DNase/RNase treatment cycle
revealed a minimum of 4 treatment cycles necessary for optimum removal of DNA from
the native tissues (Figure 28). Native BJV tissues had a DNA concentration of 980.89 ±
151.65 ng/mg dry weight of tissue. This concentration decreased to 257.9 ± 36.52 ng/mg
after one DNase/RNase treatment: 126.62 ± 34.56 ng/mg after two DNase/RNase
treatments, 64.4 ± 39.32 ng/mg after three treatments, and to 26.13 ± 9.91 ng/mg after four
treatment cycles.
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Figure 28: DNA quantification of Bovine Jugular Vein conduits to optimize the number of
DNase/RNase treatment cycles. An acceptable level of DNA was obtained after 4
treatments
The optimum level of DNA achieved after four treatments was < 50 ng DNA/mg
dry weight of the tissue. A significant decrease in the DNA content was observed after each
DNase/RNase treatment cycle. The same treatment process applied to Native bovine
pericardium, porcine fascia, bovine inferior vena cava, porcine aortic valves, and porcine
pulmonary valves achieved successful decellularization of the native tissues with < 50 ng
of DNA/ mg dry weight of tissue (384).
Native bovine pericardium tissues had average DNA concentrations of 2862.05 ±
2117.38 ng/mg, which decreased to 270.02 ± 28.93 ng/mg, demonstrating a 90.5%
decrease. For porcine fascia, the DNA concentration of 2573.11 ± 842.3 ng/mg in native
tissues decreased 99.2% to 19.79 ± 8.29 ng/mg. Bovine vena cava showed a reduction from
769.02 ± 140.84 ng/mg to 9.32 ± 0.17 ng/mg, demonstrating a 98.78% reduction. The
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difference in the DNA content between the native and decellularized tissues was
significantly different for all the tissue types (Figure 29).
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Figure 29: DNA Quantification in A. Bovine Pericardium; B. Porcine Fascia; C. Bovine
Inferior Vena Cava (***, **, *: Represents different levels of significance, N ≥ 3)

Histological analysis of the native and decellularized tissues revealed the removal
of all visible cellular components from the native tissue after decellularization (Figure 30).
Hematoxylin and Eosin staining of the native and decellularized scaffolds did not reveal
any difference in the extracellular matrix before and after the decellularization process.
Decellularized Tissue

Bovine Jugular Vein

Native Tissue
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Bovine Vena Cava
Porcine Fascia
Bovine Pericardium
Figure 30: Hematoxylin and Eosin Staining of Native and Decellularized tissues showing
absence of cells in decellularized tissues

Enzyme Resistance of Polyphenol Treated Scaffolds:
Polyphenol treated decellularized scaffolds prepared from bovine pericardium,
porcine fascia, bovine jugular vein, and bovine inferior vena cava were compared to the
respective decellularized tissues to determine the ability of the polyphenol treatment to
provide resistance to the tissues against degradation by elastase and collagenase enzymes.
For the elastase treatment, there was no significant difference between any of the
polyphenol treated groups and the decellularized pericardium and fascia tissues (Figure
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31). For Bovine pericardium tissues, the % weight loss for decellularized, ATRA treatment,
Hesperidin treatment, PGG treatment, Quercetin, and D-Salicin treatments were 16.92 ±
0.54%, 14.56 ± 3.84%, 4.35 ± 1.36%, 10.2 ± 2.78%, 9.67 ± 2.25%, and 2.96 ± 2.54%
respectively. In fascia tissues, the corresponding weight loss values were 11.36 ± 2.63%,
4.58 ± 2.52%, 8.72 ± 4.74%, 8.5 ± 4.04%, 6.02 ± 5.62 % respectively.
BJV demonstrated significant decrease in the PGG and D-Salicin treated scaffolds
compared to the native tissue (Figure 31). The average % weight loss for the decellularized
BJV was 45.34± 1.58%, while the PGG and D-Salicin treatments decreased this loss to
20.92 ± 4.93% and 19.51 ± 2.5% respectively. No significant difference was seen for the
ATRA, Hesperidin, and Quercetin treatments, where the average losses were 33.52 ±
2.77%, 64.6 ± 9.89%, and 44.7 ± 13.14%. Bovine inferior vena cava tissues, on the other
hand, did not have any significant decrease in dry weight loss for any of the polyphenol
treatments compared to the Decellularized tissues. % Weight loss of the decellularized vena
cava tissues after elastase treatment was 20.72 ± 5.13% of the dry weight. After ATRA,
Hesperidin, PGG, Quercetin, and D-Salicin treatments, the weight loss values were 23.5 ±
3.47%, 27.21 ± 0.77%, 21.02 ± 4.73%, 24.76 ± 14.71%, and 34.7 ± 7.27% respectively.
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Figure 31: Resistance to Elastase treatment for polyphenol treated decellularized tissues;
A: Bovine Pericardium; B: Porcine Fascia; C: Bovine Jugular Vein; D: Bovine Inferior
Vena Cava; N=6; (*** statistically significant difference compared to decellularized group
p<0.01)
Collagenase treatment of the decellularized and polyphenol treated tissues showed
a significantly high decrease in weight loss for some of the polyphenol treated groups
(Figure 32). For the pericardium scaffolds, PGG treatment decreased the % loss in dry
weight from 100% in decellularized tissues to 5.9 ± 5.56%. The other treatments in
pericardium resulted in 99.49 ± 0.72% loss for ATRA treatment, 99.1 ± 0.66% loss for
Hesperidin, 100% loss for quercetin, and 99.9% ± 0.13% loss for D-Salicin, none of which
were significantly different from the decellularized group. A similar observation was made
for the fascia scaffolds, where the PGG treatment decreased the weight loss from 97.88 ±
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1.42% in the decellularized tissues to 3.78 ± 1.97% weight loss. In addition to PGG, ATRA,
and Quercetin treatments also significantly reduced the weight loss from decellularized
group to 36.51 ±16.83% and 62.24 ± 31.98%, respectively. The change in dry weight was,
however, significantly less in the PGG treated tissues compared to both the ATRA and
Quercetin treated groups. Hesperidin treatment resulted in weight loss of 89.54 ± 14.11%,
and D-Salicin in 61.75 ± 8.22%, none of which was significantly different from the control
group. For the jugular vein, the PGG treated group demonstrated a dry w eight loss of 6.36
± 4.77%, which was significantly less than 68.62 ± 17.51% loss in the decellularized
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Figure 32 : Resistance to Collagenase treatment for polyphenol treated decellularized
tissues; A: Bovine Pericardium; B: Porcine Fascia; C: Bovine Jugular Vein; D: Bovine
Inferior Vena Cava; N=6; (* statistically significant difference compared to decellularized
group p<0.01)
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tissues. None of the other polyphenol-treated jugular veins showed any significant decrease
in weight loss. The average % weight losses for the other treatments were 70.11 ± 3.98%
for ATRA, 56.76 ± 6.84± for Hesperidin, 46.1 ± 9.24% for Quercetin, and 80.12 ± 1.45%
for the D-Salicin treatment. Similarly, for the inferior vena cava tissues, PGG treatment
significantly reduced the % decrease in dry weight after collagenase treatment from 68.62
± 17.51% to 3.16 ± 2.32%. The other groups had weight losses of 61.39 ± 14.24%, 72.97
± 2.46%, 44.97 ± 24.05%, and 83.54 ± 4.34% for ATRA, Hesperidin, Quercetin, and DSalicin treatments, respectively.

Fastin Analysis for Polyphenol Treated HAoSMC cultures:
The addition of 10 μg/ml of PGG, ATRA, Quercetin, Hesperidin, and D-Salicin
demonstrated an increase in the average μg insoluble elastin/ μg soluble proteins within the
HAoSMC cultures after 14 days (Figure 33). The average μg elastin/ μg soluble proteins
for the control DMSO group was 0.34 ± 0.03; for the PGG, ATRA, Quercetin, Hesperidin,
and D-Salicin treatments, the respective concentrations were 1.43 ± 0.64, 1.29 ± 0.95, 1.94
± 0.77, 0.69 ± 0.19, and 0.83 ± 0.47 μg elastin/ μg soluble proteins. Normalized to the
DMSO control group, there was a significant increase in the insoluble elastin production
for PGG, Quercetin, and Hesperidin treatments. The elastin concentration within the
quercetin group was significantly higher than that of the hesperidin treatment. No
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significant difference was, however, observed between quercetin and PGG treatment
groups.
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Figure 33: Insoluble elastin deposition within cell cultures treated with polyphenols; (μg
Elastin/ μg soluble proteins); N=4

Immunocytochemistry (ICC) analysis for Elastin and Fastin Deposition in cell
cultures:
ICC staining of elastin and fibrillin within the polyphenol treated HAoSMC cell
cultures demonstrated the presence of the proteins after 14-days of culture. 10 μg/ml of
PGG, Quercetin, hesperidin, ATRA, and D-Salicin treatments demonstrated an increase in
elastin deposition after 14-days of culture compared to DMSO control groups (Figure 34).
A significant increase in fibrillin deposition was also observed within the PGG, Quercetin,
ATRA, and Hesperidin treatment groups. The D-Salicin treatment did not show
significantly higher fibrillin production after 14-days of culture.
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Figure 34: Immunocytochemical analysis of HAoSMC cultures using Elastin and Fibrillin
antibodies
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Figure 35: Semi-Quantitative analysis of (A) elastin and (B) fibrillin I ICC staining in
polyphenol treated HAoSMC cultures; N=4
Semi-quantitative analysis of the elastin and fibrillin 1 staining showed significant
increase in elastin and fibrillin proteins in both PGG and quercetin treated groups
normalized to DMSO control groups (Figure 35). The other treatment groups did not show
any significant increase.

4.5 Discussions
Tissue-derived scaffolds from xenogeneic sources used for development of
biomaterials in-vitro are easily available, possess the inherent structure of native ECM,
appropriate mechanical properties for physiological functioning of the biomaterials, and
signals for cell binding, growth, and differentiation. The xeno-antigenicity of the scaffolds
however needs to be addressed prior to implantation (385). Decellularization of xenogeneic
materials is a commonly used procedure to remove native cellular and nuclear components
from scaffolds. Decellularization protocol should effectively remove all xenogeneic
materials from the scaffolds but preserve the native structure of the extracellular matrix
within the scaffolds (386).
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In this study, a detergent-based decellularization protocol was used for the removal
of native cells. Tissues were briefly treated with NaOH before treatment with detergents.
NaOH – PBS treatment of tissues has been shown to denature ds-DNA to a single strand
as well as inactivate transmissible spongiform encephalitis (387). Optimization of the
decellularization procedure using SDS, DOC, EDTA, TRIS, and DNase/ RNase solutions
to remove cellular components from native tissues revealed four DNase/RNase treatment
cycles necessary for the final concentration of dsDNA to be < 50 ng/ mg tissue dry weight.
The same procedure applied to pericardium, fascia, and vena cava tissues also showed
optimum removal of DNA. Although these tissues have the same basic component of ECM,
collagen, and elastin, the relative arrangement of structure is different within the tissues,
which might demand different decellularization approaches (388). The structure and
arrangement of the ECM components were unaltered after the decellularization procedure,
implying the process does not affect the ECM structure. This approach for decellularization
of fresh tissues might be a better approach compared to lyophilization or freezing since
tissue structure is altered by those approaches (366).
Polyphenol and ATRA treatment of decellularized tissues demonstrated that PGG
was the most effective in protecting the elastin and collagen within the scaffolds from
enzyme degradation. Some differences within tissues were observed for the same
polyphenol treatments, however. For elastase treatment, there was a significant reduction
in weight loss compared to the control decellularized group only in the BJV tissues. Almost
50% of the dry weight of BJV tissues is composed of elastin (389). However, in the
pericardium, fascia, and vena cava, < 20% of the dry weight of tissues is composed of
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elastin (390, 391). This might have been a contributing factor in the absence of significant
weight loss for the polyphenol-treated scaffolds. It should, however, be noted, PGG has
been reported to prevent elastin degradation better than glutaraldehyde treatment.
Collagenase treatment, on the other hand, showed high weight losses since most of the
tissue matrix is composed of collagen. PGG reduced collagen loss from all of the tissues
consistently after treatment with the collagenase enzyme. For the fascia tissue, in addition
to collagen, ATRA, and quercetin also demonstrated some protection against collagenase
enzyme. A higher concentration or a different buffer treatment for these polyphenols might
have been more effective in providing optimum collagen crosslinking.
Treatment of HAoSMC cultures with 10 μg/ml of polyphenols demonstrated an
increase in the deposition of insoluble elastin significantly higher than the control DMSO
group for PGG and quercetin treatments. The concentration of 10 μg/ml was obtained from
previous studies reporting PGG treatment at these concentrations demonstrated higher
deposition of insoluble elastin within rat aortic smooth muscle cell cultures, dermal
fibroblasts as well as in lung fibroblast cells

(392-394). Studies have reported the

interaction of hesperidin with collagen structure, specifically binding to proteolytic
cleavage sites, preventing its degradation by enzymes (395-398). ATRA has been reported
to increase elastin deposition in HAoSMC cultures when grown in ATRA-doped
polycaprolactone electrospun scaffolds (399). In addition, 0.1% ATRA has been shown to
increase fibrillin I deposition in the photoaged dermis (400). However, the direct addition
of ATRA in the used quantities did not produce any significant difference in insoluble
elastin production.
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PGG and quercetin treatments also increased the fibrillin I protein expression
within the cell cultures compared to DMSO treatment. Fibrillin I, as mentioned in previous
chapters, is a Calcium-binding protein that assembles to form microfibrils in elastic and
non-elastic extracellular matrix structures (401). The increase in fibrillin deposition would
corroborate with the increase in the production of elastin by the polyphenol treatments. It
should also be noted that in addition to PGG, quercetin has been reportedly used for
crosslinking of porcine dermal tissues. (402)
One limitation of the study is that the effect of polyphenols on elastogenesis was
studied in two-dimensional cell cultures. Moreover, the effect of the polyphenols on
essential elastogenic structures like fibulin 4,5, fibrillin-II, LOX proteins and MMPs were
not studied. A better representation of the overall effect of the polyphenol treatments might
also be obtained by looking at the effect of the polyphenols on deposition and remodeling
of scaffolds in vivo or in a bioreactor.

4.6 Conclusion
In this aim, the efficiency developed decellularization protocol was compared in
tissues with different ECM structures, proving the protocol was successful in
decellularizing all kinds of tissues. The decellularization protocol did not alter the ECM
structure within these tissues. Additionally, polyphenols PGG, Quercetin, Hesperidin, DSalicin, and All-Trans Retinoic Acid were compared to their ability to crosslink elastin and
collagen within the decellularized extracellular matrices. PGG was the most effective in
protecting the treated scaffolds from rapid degradation by elastase and collagenase
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enzymes. HAoSMC cultures treated with the polyphenols and ATRA for 14 days in culture
demonstrated increased deposition of insoluble elastin as well as fibrillin I after treatment
with PGG and quercetin for 14-days.
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CHAPTER FIVE
SPECIFIC AIM 2: DEVELOPMENT OF TISSUE ENGINEERED BOVINE JUGULAR
VEIN CONDUITS FOR PEDIATRIC PATIENTS

5.1 Introduction
Pulmonary conduit replacements are required in pediatric patients for the correction
of critical congenital conditions like pulmonary stenosis, tetralogy of fallot, pulmonary
atresia, truncus arteriosus, and transposition of the great arteries along with ventricular
septal defects (403-405). Currently available replacement strategies for conduits involve
the use of homograft or synthetically developed conduits. Homografts are not always easily
available, whereas synthetically developed scaffolds lack the potential to grow along with
the patients (406, 407).
Bioprosthetic conduits developed from glutaraldehyde fixed native tissues have
been widely used for pulmonary conduit replacement, but these scaffolds fail rapidly after
implantation due to calcification and stenosis in the implants leading to implant retrieval
(408, 409). A major risk factor identified in pediatric conduit replacement is the young age
of the patients leading to the narrow size of the conduits required (410). Studies have also
shown that implantation of a larger size conduit does not have any specific advantage over
narrower conduits (411). Moreover, while the currently available strategies might be a
suitable option in older patients, in pediatric patients, owing to the growth and development
of the patients throughout their lives, with currently available strategies, there arises a need
for reinterventions and multiple surgeries throughout the patient’s life (412).
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There is, therefore, a need to develop replacement conduits that can grow along
with pediatric patients. In addition to providing optimal mechanical strength on
implantation, the implanted scaffold should be able to degrade over time, allowing cellular
infiltration, thereby displaying a potential to grow and remodel along with the patient
(413). To develop such conduit replacement scaffolds, decellularized bovine jugular vein
conduits can be crosslinked with Penta galloyl glucose (PGG). Decellularization removes
the principal sites of calcification within the scaffolds, and crosslinking with PGG (414,
415), as determined in Chapter Four, has been shown to protect the elastase and
collagenase within the extracellular matrix of the scaffolds from rapid degradation by
elastase and collagenase enzymes.
Moreover, compared to stented valves within Dacron or Bovine pericardium
conduits, the continuity between the valve and the conduits in bovine jugular vein conduits
is advantageous. BJV conduits have been found to be suitable under low pressure
conditions; additionally, the distal and proximal ends of BJV allow for easy manipulation
of the valved conduit during surgery (416). To be able to use as off-the-shelf conduits, the
treated scaffolds should also be able to retain properties after storage for extended periods
of time. In this aim, the PGG concentration required for optimal scaffold crosslinking has
been optimized along with the in vitro characterization of the scaffolds, biocompatibility
in subcutaneous implantations, and their functionality in a circulatory environment (417).
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5.2 Materials and methods
Optimization of PGG treatment of Decellularized Bovine Jugular Vein
Decellularized Bovine Jugular Vein (BJV) conduits were treated with different
concentrations of PGG to determine the concentration at which tissue crosslinking is
maximized. The PGG concentrations used have been listed in Table 4. A stock solution of
PGG was prepared at a concentration of 167 mg/ml in Isopropanol. The concentrated PGG
solution was diluted to the desired concentrations using Isopropanol. PGG in Isopropanol
solutions were added to HEPES buffer (pH 5.5) at a ratio of 10 mL PGG solution to 40 mL
HEPES. The treatment procedure was used as described for the polyphenol treatment in
Chapter Four. Briefly, sterilized decellularized tissues were treated in the prepared PGG
solutions for 20 ± 2 hours by shaking at room temperature, protected from light.
Isopropanol Concentration of PGG in
(ml)
Isopropanol (mg/ml)
0.05%
40
0.15
9.85
2.5
0.15%
40
0.45
9.55
7.5
0.25%
40
0.75
9.25
12.5
0.55%
40
1.6
8.4
27.5
0.85%
40
2.5
7.5
42.5
1%
40
3
7
50
2%
40
6
4
100
3.33%
40
10
0
167
Table 4: PGG concentrations used for Bovine Jugular Vein treatment optimization
PGG %

HEPES (ml) Stock (ml)

After PGG treatment, the BJV scaffolds were washed with PBS to remove any
excess PGG. The washing protocol was used as described in Figure 36. Measured volumes
of PBS were used for washing at each step, and the PBS spent from washing was quantified
for their PGG concentration to determine how much un-used PGG was washed out in every
step. The washing was done to obtain a low final concentration of PGG in the PBS solution.
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Subsequently, PGG treated tissues were washed in DI water and lyophilized.
Lyophilized tissues were treated with 80% methanol, and PGG within the tissues was
quantified as described below. Enzyme challenge with Elastase and Collagenase was also
done to determine the resistance of the different PGG concentrations to enzymatic
digestion.

BJV Tissues
Overnight PGG Treatment
PGG Solution Decanted (Solution 1)
PBS wash 15 minutes (Solution 2)
PBS wash 15 minutes (Solution 3)
PBS wash 15 minutes (Solution 4)
PBS wash 2 hours (Solution 5)
PBS wash 15 minutes (Solution 6)
PBS wash 15 minutes (Solution 7)
PBS wash 15 minutes (Solution 8)
Overnight Storage in PBS (Solution 9)
Storage in fresh PBS solution
Figure 36: Washing Protocol for PGG treated Bovine Jugular Vein Conduits. PBS wash
solutions were quantified for their PGG concentrations to ensure most of the un-used PGG
was removed
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Storage analysis for PGG treated Bovine Jugular Vein conduits:
Decellularized BJV scaffolds treated with 0.15% PGG were stored for up to 24
months in sterile PBS with 1% Pen/Strep antibiotics. After the storage points, tissues were
washed with DI water and lyophilized. The lyophilized samples were analyzed for the
stability of the PGG crosslinking after extended storage periods. For the PGG concentration
analysis, PGG was extracted and quantified using F-C reagent, as mentioned below.
Lyophilized samples were also treated with Elastase and Collagenase enzymes separately,
and the PGG treated tissues' resistance to enzyme degradation was determined.

PGG extraction and quantification:
PGG was extracted using Methanol and quantified using F-C Regent (418, 419) .
Tissue samples were rinsed in water and lyophilized. 10-15 mg of lyophilized tissue was
obtained for each sample, minced into 1 mm segments, and incubated in 80% methanol at
room temperature for 15 minutes. The methanol extracts from each sample were quantified
for their PGG concentrations using Folin-Ciocalteu’s (F-C) reagent (Sigma-Aldrich,
Germany). Briefly, 800 µl of F-C reagent, diluted 1:10, was added to 200 µl of each sample,
vortexed, and incubated at 37°C for 5 minutes. Next, 600 µl of sodium bicarbonate was
added to the solutions, vortexed, and incubated at 37°C for 30 minutes. Finally, 250 µl of
the final solution was pipetted into 96-well plates, and the Absorption was read at 760 nm.
The PGG concentration for each sample was determined by comparing to a calibration
curve prepared with known concentrations of PGG. The total amount of PGG obtained for
each sample was normalized to the initial weight of the tissue used for methanol extraction.
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Enzyme (Elastase and Collagenase) Challenge:
The resistance of the scaffolds to resist enzymatic degradation was determined as a
method described previously in Chapter IV (420). Briefly, lyophilized Native,
Decellularized and PGG treated decellularized tissues were subjected to treatment by
elastase and collagenase enzymes in 1 mM Calcium Chloride (CaCl2) and 0.02% Sodium
Azide (NaN3) in 100 mM TRIS buffer (pH 7.8 ± 0.05) for 24 hours and 48 hours
respectively at 37°C. The percentage (%) dry weight loss of the scaffolds after enzyme
treatment was used as an indication of the resistance of the scaffold to enzyme degradation.

Histological Analysis:
Formalin fixed samples were tissue processed, embedded in paraffin, sectioned at
5 μm thickness, mounted on glass slides and heated for 30 minutes to adhere the tissue
sections to the slides. Slides were baked overnight at 56°C in an oven. Subsequently, the
slides were deparaffinized and stained with hematoxylin and eosin to determine cellular
components within the tissue matrix. Tissue sections were also stained with Masson’s
Trichrome, Verhoeff’s-Van Geisen (VVG), and Alcian Blue to visualize the ECM structure
of the native, decellularized, and PGG treated scaffolds.

Uniaxial mechanical testing of Bovine Jugular Vein:
Native, decellularized, and PGG treated Bovine jugular vein scaffolds were cut into
2 cm x 1 cm rectangular sections in both the circumferential and longitudinal directions.
Uniaxial testing was performed on each section using Instron uniaxial tester (Instron,
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Norwood, MA, USA). Samples were pre-loaded to 0.05 N and then stretched at a uniform
rate of 1 N/s until tissue failure. The thickness of each sample was assessed before the
uniaxial testing procedure. The stress-strain biomechanical characteristics of the scaffolds
were analyzed. Tensile stress was calculated by dividing the load sustained by the specimen
by the cross-sectional area. The tensile strain was determined by dividing the change in
sample length by the original length of the sample. The modulus of elasticity (Young’s
modulus) was calculated by taking the slope of the stress-strain curve (421).
𝐿𝑜𝑎𝑑 𝑠𝑢𝑠𝑡𝑎𝑖𝑛𝑒𝑑 𝑖𝑛 𝑠𝑎𝑚𝑝𝑙𝑒
𝐶𝑟𝑜𝑠𝑠 𝑠𝑒𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝑎𝑟𝑒𝑎

𝑇𝑒𝑛𝑠𝑖𝑙𝑒 𝑆𝑡𝑟𝑒𝑠𝑠 (𝑀𝑃𝑎) =

𝑇𝑒𝑛𝑠𝑖𝑙𝑒 𝑆𝑡𝑟𝑎𝑖𝑛 =

𝐶ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑠𝑎𝑚𝑝𝑙𝑒 𝑙𝑒𝑛𝑔𝑡ℎ
𝑂𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑠𝑎𝑚𝑝𝑙𝑒 𝑙𝑒𝑛𝑔𝑡ℎ

𝑀𝑜𝑑𝑢𝑙𝑢𝑠 𝑜𝑓 𝑒𝑙𝑎𝑠𝑡𝑖𝑐𝑖𝑡𝑦 (𝑀𝑃𝑎) =

𝑇𝑒𝑛𝑠𝑖𝑙𝑒 𝑆𝑡𝑟𝑒𝑠𝑠
𝑇𝑒𝑛𝑠𝑖𝑙𝑒 𝑆𝑡𝑟𝑎𝑖𝑛

Subcutaneous Implantation in rats
PGG treated decellularized and glutaraldehyde fixed native bovine jugular vein
leaflets and walls were implanted subcutaneously in 3-4-week-old Sprague Dawley (SD)
rats to determine the biocompatibility of the scaffolds. For the surgical procedure, rats were
anesthetized with inhalation of isoflurane. Each animal's eyes were instilled with artificial
tears to prevent corneal ulcers. Using aseptic technique, one small, 1 cm incision was made
on the rat’s back. Blunt scissors were inserted into each incision and subcutaneous pockets
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were created dorso-laterally by blunt dissection. Pre-prepared implants (PGG treated
decellularized/ glutaraldehyde treated native leaflets or walls) were placed into each pouch
to study the effects of in-vivo calcification. One glut leaflet/wall and one PGG leaflet/wall
were implanted in each rat. The wound was closed with surgical staples, and the animals
were allowed to recover and housed in animal quarters. At the designated time interval,
rats were euthanized, and implants were retrieved. A gross view of the explants was
observed for any capsule formation and implant degradation. The implant periods used
were 30 days and 90 days. Twenty animals received PGG/ Glut BJV walls, and 20 animals
received BJV leaflet implants. The surgical procedure has been schematically represented
in Figure 37.
PGG
Leaflet

Glut
Leaflet

Glut
Wall

PGG
Wall

N= 20

N= 20
30-Days

90-Days

explant harvest

explant harvest

Histology: Alizarin red, H&E, IHC
ICP: Mineral Calcium and Phosphorous analysis

Figure 37: Schematic representation of subcutaneous implantation of BJV walls and
leaflets in rats
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ICP Calcium and Phosphorous mineral analysis:
Capsules (if any) were removed from the explants harvested subcutaneously from
rats. Samples were frozen at -80°C, and lyophilized. Measured dry weights were
hydrolyzed in 2 mL 6 N HCl overnights at 37ºC. Acid hydrolyzed samples were dried
under nitrogen gas at 96ºC, and the residues were resuspended in DI water. Resuspended
samples were filtered to remove any solid particles. The elemental calcium and
phosphorous within the samples were analyzed with ICP Spectrometer (SPECTRO
Analytical Instruments, Kiev, Germany)

(422). Resuspended samples were diluted,

wherever required, and the Ca/P content was normalized to the dry weights.

Immunohistochemical (IHC) analysis:
Histological tissue sections were deparaffinized, followed by antigen retrieval
using a citrate heat-conducting method. Sections were permeabilized with 0.1% triton, and
non-specific binding was blocked using the Background buster (Innovex Biosciences
NB306). Peroxidase blocking was performed with 3% Hydrogen peroxide (H2O2) in the
case of DAB (diaminobenzidine) detection system, followed by endogenous biotin
blocking (Avidin/ Biotin blocking kit, Vector SP 2001). Sections were incubated with
primary antibodies overnight at a dilution of 1:100 (or according to manufacturer
recommendation) in 1% BSA (Bovine Serum Albumin) and 0.01% azide in PBS at 4ºC.
After overnight incubation and washing, sections were incubated with secondary
antibodies labeled with DAB or fluorescent tag for 1 hr at room temperature, followed by
appropriate nuclear staining, mounting, and imaging (Keyence BZ-X810). Inflammatory

104

responses in the explants were evaluated using immunohistochemistry for CD 3-T cells,
CD 11c dendritic cells, and macrophage marker CD 68. Sectioned were also stained for
Vimentin and α-Smooth Muscle Actin (αSMA) to determine infiltration of fibroblasts and
myofibroblasts

(423, 424). Collagen remodeling and new collagen formation were

determined using Heat Shock Protein 47 (HSP-47) staining (425).

Implantation of PGG treated Bovine Jugular Vein conduits as pulmonary
conduit replacement unit in sheep2
Three PGG-treated BJV tricuspid conduits were implanted in one sheep for one
month and two sheep for three months. A cardiopulmonary bypass procedure was
performed to resect the native pulmonary valve leaflets and main pulmonary artery. PGG
treated decellularized bovine jugular vein valved conduit was used to replace the resected
native tissues. Sheep were monitored for cardiopulmonary function throughout the implant
period. At the end of one-month or two-months, animals were heparinized to prevent postmortem thrombosis and then euthanized with pentobarbital sodium (80-100 mg/kg, IV).
The gross view of explants was analyzed, and subsequently explants were analyzed
histologically and using IHC to determine cellular infiltration. The conduits were also
measured pre- and post-implant to determine any change in size of the conduits.

2

Sheep Implant surgeries performed by Dr. John E. Mayer at Boston Children’s Hospital
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Figure 38: Schematic representation of PGG treated BJV conduit replacement in sheep

Statistical Analysis:
All in-vitro experiments were done in triplicates or more. The data was reported as
the Mean ± Standard Deviation. Data from different groups were analyzed by one-way
analysis of variance (ANOVA) followed by Tukey’s HSD. All statistical analysis was done
using JMP® Pro 15.2.0. Significance was reported at three different significance levels:
***

p ≤ 0.01, **p ≤ 0.05, *p ≤ 0.1. Statistical significance has been reported in each result.

5.3 Results
Optimization of PGG concentration:
PGG quantification of the PBS solutions used for washing showed decrease in the
un-used PGG with every wash until wash 9, indicated in Table 5. The final BJV conduits
stored in fresh PBS with Pen/Strep antibiotics had <25 µg PGG/ ml of PBS buffer which
should not interfere with the PGG quantification done for the treated tissues subsequently.
PGG

Wash

Wash

Wash

Wash

Wash

Wash

Wash

Wash

2

3

4

5

6

7

8

9

Wash 1

0.05%

1152.80

113.98

9.96

5.14

4.62

2.41

1.76

6.19

1.11

0.15%

1791.07

59.27

17.26

12.83

17.52

4.88

6.19

6.58

1.37

0.25%

2989.46

90.53

23.77

17.52

20.65

10.22

7.10

6.06

2.54
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0.55%

8759.98

8.47

44.09

34.32

35.23

18.43

14.26

11.66

4.36

0.85%

7783.03

120.49

31.72

27.68

54.25

28.20

20.38

7.23

6.32

1%

10231.92

282.01

152.08

49.43

71.58

35.89

23.25

19.08

11.66

2%

19245.91

278.10

83.69

41.75

69.10

36.28

30.41

21.43

14.78

3.33%

32493.36

632.41

85.25

37.97

90.99

67.93

41.36

36.02

24.68

Table 5: PGG Quantification in PBS wash solutions: µg PGG/ ml of PBS buffer (All values
rounded up to 2 decimal places)
Quantification of PGG within the lyophilized BJV treated with 0.05% - 3.33% PGG
demonstrated PGG concentrations ranging from 20-60 µg of PGG/ mg dry weight of tissue
(Figure 39). This value was significantly higher than the control decellularized and native
tissues. No significant difference was found in the PGG concentration for treatments 0.05%
PGG – 0.55% PGG. BJV treated with 0.55% PGG had the highest concentration of
extracted PGG with an average of 46.2 ± 18.9 µg PGG/ mg tissue. This value was
significantly higher than groups treated with 0.85% PGG, 1.0% PGG, and 2.0% PGG,
where the average values were 25.7 ± 3.4 µg/ mg, 21 ± 12.7 µg/ mg, and 24.2 ± 2.9 µg/ mg
tissue weight respectively (Figure 39).
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Figure 39: PGG quantification in Methanol extracts from BJV tissues treated with different
concentrations of PGG (***, **, *: Indicates different levels of significance between
groups and native/decellularized tissues, and among groups) N=5

0.05%

0.15%

0.25%

0.55%

0.85%
1.0%
2.0%
3.33%
Figure 40: VVG staining of BJV treated with different concentrations of PGG showing
preservation of elastin within scaffold matrix
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Histological analysis of decellularized BJV treated with PGG concentrations
ranging from 0.05% - 3.33% demonstrated the maintenance of the elastin structure within
the extracellular matrix of the scaffolds (Figure 40). The gross view of the scaffolds have
been demonstrated in Figure 41.

Figure 41: Gross view of PGG treated decellularized Bovine Jugular Vein Conduit

Elastase enzyme digestion of BJV scaffolds treated with 0.15% - 3.33% PGG
demonstrated a significant decrease in % loss of dry weight compared to the native and
decellularized tissues. The % weight loss of native and decellularized control groups
ranged from 25% - 45% decrease in dry weight of tissues. 0.05% PGG treated BJV had an
average of 25.7 ± 3.3% decrease in weight loss, which was not significantly different from
the control groups (Figure 42).This value was also significantly higher than those for the
other concentrations of PGG. BJV treated with 0.15% - 3.33% PGG demonstrated average
weight losses ranging from 9% - 20%. No significant difference was observed among any
of the PGG treatments within this range.
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Figure 42: Elastase treatment of BJV conduits treated with different concentrations of
PGG. (***: Indicates significance levels of difference in % weight loss) Significant
decrease in % weight loss compared to Native, Decellularized, and 0.05% PGG treated
group; N=5

Collagenase challenge on the PGG treated BJV also demonstrated a significant
decrease in % weight loss for the treated groups compared to native and decellularized
tissues. In this case, the 0.05% PGG treated BJV also had significantly lower weight losses
than the control groups. The weight loss for the decellularized and native tissues ranged
from 72% - 96%. The value for the 0.05% PGG was 41.4 ± 28.3%. Weight losses for PGG
treatments 0.15% - 3.33% ranged from 0.1% - 15%. These values were significantly lower
than the control groups as well as the 0.05% PGG treated BJV. No significant difference
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was observed within the range of 0.15% - 3.33% PGG treatments for collagenase treatment
(Figure 43).
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Figure 43: Collagenase treatment of BJV conduits treated with different concentrations of
PGG. (***: Indicates significance levels of difference in % weight loss) Significant
decrease in % weight loss compared to Native, Decellularized, and 0.05% PGG treated
group’ N=5

Histologically, 0.15% PGG treated decellularized BJV scaffolds demonstrated
presence of elastin, collagen, and GAGs within the scaffold extracellular matrix (Figure
44). The arrangement and structure of ECM components was similar to those observed in
native BJV tissues.
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Figure 44: Native and PGG treated decellularized Bovine Jugular Vein Histology

Storage potential of PGG treated Bovine Jugular Vein:
Methanol extraction and quantification of PGG from BJV tissues treated with
0.15% PGG and stored for up to 24-months demonstrated PGG content ranging from 25
µg PGG/ mg – 55 µg PGG/ mg dry weight of tissue. Decellularized BJV demonstrated
PGG concentrations of 0.08 ± 0.15 µg/ mg. 0.15% PGG treated BJV had PGG
concentrations of 29.3 ± 10 µg/ mg, 28.8 ± 9.7 µg/ mg, 41.2 ± 15.9 µg/ mg, 55.5 ± 25.8
µg/ mg, and 34.5 ± 16.1 µg/ mg for storage periods of 0 months, 6 months, 9 months, 13
months, 16 months, and 24 months respectively. The PGG concentrations obtained for the
treatment groups were significantly higher compared to the control decellularized tissues.
However, no significant difference was observed among PGG treated BJV tissues stored
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in PBS for 3 months, 9 months, 13 months, 16 months, 24 months, and freshly prepared
PGG treated BJV (Figure 45).
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Figure 45: µg PGG/ mg dry weight of tissue for Bovine Jugular Vein Conduits stored for
up-to 24-months; (*** Statistically significant difference in PGG concentration compared
to decellularized tissues. No significant difference among groups.); N=8

Elastase treatment of the PGG treated BJV tissues demonstrated a significant
decrease in weight loss after elastase treatment compared to the decellularized BJV. The
weight loss for the Decellularized tissues was 27.6 ± 6.3%, while for the PGG treated
tissues, the weight loss values were 15.8 ± 3.2%, 16.1 ± 4.3%, 12.8 ± 2%, 17.5 ± 1.2%, 15
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± 3.2%, and 17.4 ± 1.5% for freshly prepared BJV, BJV stored for 3 months, 9 months, 13
months, 16 months, and 24 months respectively (Figure 46). There was no significant
difference between the % dry weight losses among the freshly prepared PGG treated BJV,
and those stored for up to 24 months in sterile PBS with Pen/Strep at 4°C.
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Figure 46: Elastase Challenge with 0.15% PGG treated Bovine Jugular Vein tissues stored
for up-to 24-months (*** Statistically significant difference compared to decellularized
BJV); N=8
Uniaxial Testing of BJV scaffolds:
The maximum stress required for tissue failure was comparable in native,
decellularized, and PGG treated BJV scaffolds. In native BJV, the maximum stress was
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37.6 ± 21.2 x105 Pa in the circumferential direction and 21.6 ± 19.4 x105 Pa in the
longitudinal direction. In decellularized scaffolds, these stresses increased to 41.5 ± 8.9
x105 Pa and 27 ± 16.3 x105 Pa in the circumferential and longitudinal directions,
respectively. PGG treated scaffolds had maximum stresses of 47.4 ± 14.1 x105 Pa and 30.4
± 4 x105 Pa in the circumferential and longitudinal directions, respectively (Figure 47.A).
There was no significant difference, however, in the maximum stresses between the two
directions or among the different groups (native, decellularized, and PGG treated).
The maximum strain at failure was 18.4 ± 9.2 and 27 ± 2.9 for the native BJV in
the circumferential and radial directions. In decellularized scaffolds, the respective strains
were 24.5 ± 1.4 and 31.6 ± 7.5, and in PGG treated decellularized scaffolds, the
circumferential and longitudinal strains for failure were 20.3 ± 5.7 and 28.3 ± 2. There was
no significant difference in the maximum strain at failure between the circumferential or
longitudinal directions or between different treatments (Figure 47.B).
The peak tangent modulus, calculated from the maximum slope of the stress-strain
curve for each sample was consistently higher in the circumferential direction compared to
the longitudinal direction for native, decellularized, and PGG treated decellularized BJV.
The peak tangent modulus was 4.7 ± 1.45 MPa in the circumferential direction and 2.37 ±
2.39 MPa in the longitudinal direction for native BJV. In decellularized BJV, the peak
moduli were 3.19 ± 2.27 MPa in the circumferential direction and 1.78 ± 0.66 MPa in the
longitudinal direction. PGG treated decellularized BJV had peak tangent modulus values
of 4.66 ± 1.59 MPa and 1.36 ± 0.44 MPa in the circumferential and longitudinal directions

115

respectively. No significant difference was observed within the peak modulus in either
directions or between the native, decellularized, and PGG treated groups. (Figure 47.C)
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Figure 47: Maximum (A) stress, (B) strain and (C) Peak Tangent Modulus in native,
decellularized, and PGG treated decellularized BJV scaffolds for failure in uniaxial testing;
No significant difference observed among the groups; N=5

Subcutaneous Implantation in rats:
PGG treated BJV wall and leaflet subcutaneous implants in sheep demonstrated
degradation of the implanted scaffolds after 30-days, and 90-days of implant. There was
very less capsule formation around the PGG treated scaffolds. Glutaraldehyde treated
tissues, on the other hand, developed thick capsules around the implanted tissues, with
minimal degradation.
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Alizarin red staining of the PGG treated decellularized wall and leaflets portions
demonstrated no calcification within the implanted scaffolds, whereas all the
glutaraldehyde treated tissues had heavy calcification within both the leaflet and wall
regions (Figure 48).

Figure 48: Alizarin red staining of 1-month, and 3-month subcutaneously implanted PGG
treated and Glut BJV

ICP analysis of the PGG and glutaraldehyde implants also demonstrated elevated
levels of mineral calcium and phosphorous within the glutaraldehyde tissues compared to
pre-implant, whereas for the PGG scaffolds, the mineral concentrations did not alter
significantly post-implant (Figure 49).
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Figure 49: ICP analysis of elemental (A) Calcium and (B) Phosphorous in subcutaneous
implanted BJV PGG and Glut walls and leaflets; N=5

H&E staining of glutaraldehyde and PGG treated BJV demonstrated the presence
of thick capsules around the glutaraldehyde treated implants, while less or no capsules were
present around the PGG implants. Additionally, within the PGG implants, fibroblasts were
found within the implant interstice, with the interstice resembling fat or connective tissue,
with presence of microvescicles (Figure 50). Table 6 represents the Jansen grading of the
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glutaraldehyde and PGG treated implants, demonstrating the superior biocompatibility of
PGG scaffolds compared to glutaraldehyde treated tissues.
Glutaraldehyde treated

PGG treated

30-days

90-days

Figure 50: H&E staining of glutaraldehyde and PGG treated BJV subcutaneous explants
Glut Treated
PGG Treated
1
4
(Thick capsule)
(1-4 cell layer capsule)
2
4
(Capsule dense and
(Surrounding tissue not dense,
granulous with fibroblasts
resembling connective or fat
and inflammatory cells)
tissue)
Interference
1
4
qualitatively
(Multiple layers of
(Fibroblasts contact implant
macrophages and foreign
surface without foreign body
body cells)
giant cells)
Interstice
1
4
qualitatively
(Tissue in interstitium dense (Interstitium tissue fibrous, not
and exclusively
dense, resembling fat or
inflammatory)
connective tissue)
Total Score
5
16
Table 6: Jansen Scoring of Subcutaneously implanted Glutaraldehyde and PGG treated
Reaction-zone semiqualitatively
Reaction zone
qualitatively

BJV
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Hematoxylin and Eosin staining of PGG treated BJV wall implants also
demonstrated the infiltration of cells within the scaffolds 30-days and 90-days post implant
(Figure 51). Formation of microvescicles were also observed within the 90-day post
implant scaffolds.

Pre-implant

30-day post implant

90-day post implant

Figure 51: H&E staining of 30-day and 90-day post-implant showing cellular infiltration
in subcutaneously implanted BJV
IHC analysis was performed on the explanted BJV walls to determine the types of
cells infiltrated within the scaffolds. BJV sections showed the presence of CD68 panmacrophage antigens. The sections also showed the presence of CD163 anti-inflammatory
macrophages, while no CD80 pro-inflammatory macrophage staining was observed. 30day post-implant scaffolds showed some presence of CD3 T-cells, while the CD3 antigen
staining decreased at 90-day post implant. Additionally, no staining was observed for
CD11c dendritic cells.
Staining with Vimentin and Alpha-Smooth muscle actin (α-SMA) demonstrated
the presence of fibroblast and myofibroblast cells within the subcutaneously implanted
scaffolds. The staining was more pronounced at 90-day compared to 30-day post implant.
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Representative IHC images of 30-day and 90-day post implant PGG treated decellularized
BJV tissues subcutaneously implanted in rats has been shown in Figure 52.
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Figure 52: Immunohistological (IHC) staining of subcutaneously implanted BJV Walls
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Pulmonary conduit replacement in sheep
PGG treated BJV conduits implanted in sheep as pulmonary conduit replacement
units for 1-3 months demonstrated normal functioning of the conduit and valves for the
implant period. There was no animal morbidity within the period of the implant. The gross
view of the explant showed no thrombus or tissue overgrowth within the implanted
conduits. There was no thickening observed in the leaflets within the conduits (Figure 53).

Figure 53: BJV conduits after 3 months of implant showing (A) no tissue overgrowth or
thrombosis; (B) cellular infiltration (H&E); (C) Luminal endothelialization shown by VWF
staining; (D) No calcification shown by Von Kossa staining; (E) HSP-47 staining for
collagen; (F) SMA and (F) Vimentin staining showing infiltration of myofibroblast-like
cells in the walls; (G) Leaflet showing cellular infiltration and no thickening
Histological analysis of the explanted conduits demonstrated infiltration of cells
within the scaffolds. No calcification was observed by Von Kossa staining of the explants.
Immunohistochemistry analysis on the explants showed the presence of endothelial cells
along the conduit lumen, as well as fibroblast and myofibroblast-like cells (indicated by
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positive staining for Vimentin and α-SMA). The explants also stained positive for HSP-47,
indicating collagen remodeling within the tissues (Figure 51).
Additionally, size measurements on the PGG treated conduits done before and after
the 3-month implants showed an increase in the size of the outer diameter and length by
10%.

5.4 Discussions
Bioprosthetic pulmonary conduit replacements have been traditionally produced
out of native tissues like pericardium, sub intestinal mucosa (SIS), or jugular veins (426).
The main advantages of bovine jugular vein valved conduits are the continuity between the
valves and conduits and its off-the-shelf availability in pediatric sizes (427). The valved
conduits have a structure similar to typical vein tissues, making them adequate to function
in a low-pressure system (428). Moreover, the distal and proximal ends of the conduits
allow for extended reconstructive procedures (429).
It has been shown that incomplete graft decellularization might result in severe
foreign body reaction directed towards graft leaflets (430). Optimum decellularization
process of BJV tissues was developed in Chapter IV with final DNA concentrations of <50
ng/ mg tissue dry weight. The PGG concentration for optimum elastin and collagen
crosslinking was established in this study. PGG treatment with concentrations > 0.15%
demonstrated optimum crosslinking of the ECM components without any significant
increase in resistance to enzyme degradation with increasing PGG concentration. The
stability of the PGG treatment was also established by the ability of the treated scaffolds to
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resist enzyme degradation after extended storage. For the developed scaffolds to be used
as easily accessible, off-the-shelf biomaterials, it is important for them to maintain their
properties after extended periods of storage. The result from this study indicates even after
storage for up to 2 years, there was no significant loss of PGG from the scaffolds, as the
enzyme resistance for stored scaffolds was not significantly different from those of freshly
prepared scaffolds. Differences in the PGG concentration in methanol extracts obtained
from different batches of prepared tissues might be due to the batch-to-batch differences in
the tissue characteristics or some un-uniformity in the time used for the PGG crosslinking
treatment. The PGG treatment was done for 20 ± 2 hours for all batches, but minor
differences in treatment time might have been a contributing factor.
Uniaxial mechanical testing demonstrated no significant difference between the
maximum stress and strain at failure between native, decellularized, and PGG treated
decellularized tissues. While using a replacement graft, it is desired that the mechanical
property of the implanted graft is not different from the native tissue being replaced (426).
The tensile strength of the human pulmonary artery demonstrated values of 0.95 ± 0.37
MPa. The strain at failure is reported to be at 1.61 ± 0.52 mm/mm (431). The mechanical
characteristics of the PGG treated decellularized tissues satisfy this criterion. It is important
to note, however, the mechanical strength of the material is not the sole indicator of implant
stability after implantation. Mechanical characteristics of decellularized scaffolds were
comparable to the other groups as well. However, they are susceptible to elastase and
collagenase degradation (432, 433). Therefore, even though decellularized tissues might
have optimum mechanical properties at implantation, due to enzyme degradation, they
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might be more susceptible to degradation after implantation compared to PGG treated
scaffolds.
Calcification and stenosis in implanted pulmonary valved conduits constitute a
significant concern for pediatric patients. Glutaraldehyde fixed xenografts, and allograft
tissues have been shown to be prone to calcification upon implantation. Many studies have
looked at anti-calcification treatment of glutaraldehyde treated tissues to reduce
calcification after implantation (194, 434). However, the long-term results of these
treatments remain to be seen. Decellularization has been identified to reduce calcification
in both homograft and xenograft tissues (13). Subcutaneous implantation in rats is a
standard procedure for the determination of biocompatibility and calcification of
biomaterials (434-437). The formation of capsules around subcutaneously implanted
materials indicates the ability of the material to be incorporated within the body.
Glutaraldehyde-fixed native tissues in this study showed the development of thick capsules
around the implants; PGG treated scaffolds, however, did not show extensive capsule
formation and demonstrated degradation and re-integration within the surrounding tissues,
showing their superior biocompatibility.
Moreover, the PGG treated scaffolds at 30-days, and 90-days post-implant
demonstrated little presence of inflammatory cells. CD68 positive cells were present, but
most were also stained positive for CD163, indicating most of these macrophages were
anti-inflammatory. No dendritic cells or T-cells were observed within the implants.
Moreover, the implants showed the presence of fibroblasts and myofibroblasts within the
scaffolds. Additionally, no calcification was observed within the PGG treated implants. It
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has been established that the principal regions of calcification are the native cells present
within the implanted tissues. Glutaraldehyde fixed native tissues, therefore, demonstrated
extensive calcification, with an increase in the calcium and phosphorous levels from 30days to 90-days post-implant.
Sheep implant studies further demonstrated infiltration of cellular components
within the decellularized PGG treated scaffolds. More than 90% of the infiltrated cells were
determined to be fibroblast and myofibroblast-like cells with very little inflammatory cells.
Moreover, endothelial cells were observed along the luminal side of the implanted
conduits. This indicates hemocompatibility of the PGG treated decellularized tissues after
implantation. Additionally, the explanted tissues demonstrated the presence of HSP-47.
HSP-47 is an indicator of collagen remodeling within the implanted scaffolds. Their
presence indicates the production of new Type I and type II collagen within the implanted
tissues. This would indicate remodeling of the conduits after implantation. Cellular
infiltration along with remodeling of the implants are an essential feature of the capacity
of the scaffolds to grow along with the patients.

5.5 Conclusions
In this aim, PGG treated decellularized BJV conduits were successfully developed
from the native tissues. The concentration of PGG treatment required for imparting
resistance against elastase and collagenase enzymes was optimized at 0.15%. The
potential of the PGG treated BJV tissues to be stored for extended periods of time was
also established. In-vitro mechanical studies demonstrated the that the PGG treated
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scaffolds were not significantly different from that of the native tissues. Biocompatibility
analysis of the PGG treated scaffolds in subcutaneous implant models demonstrated the
ability of the scaffolds to resist calcification and allow cellular infiltration. Sheep implant
studies of PGG treated BJV conduits demonstrated the potential of these conduits to be
used as pulmonary conduit replacement units, allowing cellular infiltration from the host
and with a potential to grow along with the patients.
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CHAPTER SIX
SPECIFIC AIM 3: DEVELOPMENT OF TISSUE ENGINEERED VALVE LEAFLET
PATCH FOR PULMONARY VALVE REPAIR IN PEDIATRIC PATIENTS

6.1 Introduction
Congenital heart diseases (CHD) affect approximately 40,000 new-borns each year
in the US. The total number of patients now living with congenital disorders is estimated
to be approaching 2 million (1). When the pulmonary valve is affected by congenital
disease, specifically resulting in valve stenosis or valve regurgitation, surgery is required
to correct the impaired hemodynamics (438-442). Whenever possible, valve repair is
preferred over valve replacement for the pediatric population since the available valve
devices are far from optimal for young patients. Mechanical valves require the use of lifelong anticoagulation therapy while bioprosthetic valves degenerate very rapidly in young
patients and are recommended only in patients above 50 years of age (443). The benefits
of valve repair over replacement include reduced risk of infection, thrombosis, and lower
rate of future reoperations. However, all valves cannot be repaired, and heart valve repair
surgery is often more complicated than valve replacement. The benefits of ‘valve-sparing’
surgery, with the ability to preserve the patient’s own native valvular structure, with the
elimination of life-long blood thinning medications, outweigh the overall complication of
the surgical procedure.
Pulmonary and aortic valve repairs are required for pediatric patients diagnosed
with conditions of tetralogy of fallot, which includes malformed pulmonary valve,
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pulmonary stenosis, and pulmonary atresia There is an additional group of patients with
prior repair of tetralogy of fallot and pulmonary valve regurgitation (also called valve
insufficiency or leaky valves). This group, comprising the largest group, currently receive
bioprosthetic valves surgically or by catheterization. However, the longevity of these
pulmonary valve replacements is limited. All current replacement material has significant
limitations, resulting in multiple reoperations throughout the patient’s life potential (444).
Glutaraldehyde crosslinked pericardium tissue (as used in the Ozaki procedure) or
xenograft materials are challenging to prepare and need highly skilled surgeons (188).
Glutaraldehyde treated pericardium also lacks the native tri-layer structure of valves, and
do not have tissue growth or repair potential since it is not living tissue (acellular) (445,
446). Decellularized tissue material developed from porcine intestinal submucosa
(CorMatrix) has been tried as leaflet patch repair material but without much success (447)
.
To overcome valve calcification, stenosis, and thrombosis, porcine valve leaflet
replacement units were prepared from PGG treated porcine aortic or pulmonary valve
leaflet with attached wall (Figure 54). The rationale for this was that decellularization
would remove the principal sites of immunogenicity and calcification, and treatment with
PGG would protect collagen and elastin from rapid degradation. The developed valve
replacements also had the valve leaflet attached to the wall. The attached wall would allow
easy suturing of the valve unit to the aortic/pulmonary annulus. The functional valve
leaflets would not be manipulated since sutures would pass through the attached wall.
Furthermore, PGG treatment would provide adequate mechanical properties at the
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beginning of the implant, with slow degradation over time, allowing cellular infiltration
and from the host tissues and slow remodeling of the grafts.

Figure 54: PGG treated leaflet repair patch can be used to repair both defective pulmonary
(top) or aortic (bottom) valves

6.2 Materials and methods
Decellularization and PGG treatment of Porcine Aortic Valves and Porcine
Pulmonary Valves
Fresh porcine aortic valves and porcine pulmonary valves harvested from 3–9month-old pigs were obtained from a commercial supplier (Animal Technologies, Texas).
Blood was removed from the native tissues by washing with PBS, and any muscle within
the tissue was trimmed. The aortic and pulmonary valves were separated into single valve
units comprising of the leaflet with the attached wall. The valve leaflet units were
decellularized using the decellularization protocol described in previous chapters. Briefly,
tissues were treated with 0.05 M NaOH for 1 hour at room temperature, followed by
decellularizing solution composed of 0.25% sodium dodecyl sulfate (SDS), 0.5% sodium
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Deoxycholate (DOC), 0.5% Triton X 100, and 0.2% Ethylene Diamine Tetra-Acetic acid
(EDTA) in 50 mM TRIS (tris (hydroxymethyl) amino-methane) buffer (pH 7.4 ± 0.05) for
six days. DNase and RNase enzymes were used at a concentration of 360 U/mL in
Phosphate Buffered Saline (PBS) with 5mM Magnesium Chloride (MgCl2), and 0.02%
Sodium azide for four days at 37°C. The scaffolds were sterilized by shaking with sterile
0.1% Peracetic acid (pH 7.4 ± 0.05) for 24 hours at room temperature, treated with sterile
0.15% PGG in 20% Isopropanol in HEPES (pH 5.5) buffer and stored in sterile PBS with
1% Penicillin/ Streptomycin antibiotics.

DNA Quantification
DNA was quantified in native and decellularized valve leaflets and walls using a
procedure described in previous chapters. Briefly, tissues were lyophilized, dry weights
measured, digested, and DNA was extracted using Qiagen Dneasy Blood and Tissue Kit.
The concentration of dsDNA obtained from each sample was quantified with Quant-It Pico
green dsDNA Reagent kit. The DNA concentration for each sample was normalized to the
dry weight of the tissue initially digested to determine the nanograms (ng) of DNA/ mg of
dry weight of the sample.

Histological Analysis
Samples were fixed in formalin, tissue processed, and embedded in paraffin.
Paraffin blocks were sectioned at 5 μm thickness and baked overnight in an oven. For
staining, slides were deparaffinized and stained with hematoxylin and eosin to determine
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cellular and nuclear remains within the scaffolds. The structure of the scaffold ECM was
also visualized using Masson’s Trichrome, VVG, and Alcian Blue staining.

Enzyme (Elastase and Collagenase) Treatment of Valves
Native, decellularized and PGG treated decellularized leaflets and walls of valves
were challenged with elastase and collagenase to determine the resistance of the scaffolds
to enzymatic degradation. As described previously, elastase treatment was done in Calcium
Chloride (CaCl2) and Sodium Azide (NaN3) in TRIS buffer (pH 7.8 ± 0.05) for 24 hours.
For collagenase treatment, type VII Collagenase was used in CaCl2 and NaN3 in TRIS
buffer (pH 8 ± 0.05) for 48 hours. Samples were lyophilized after the treatment and the %
loss in dry weight calculated.

Biaxial mechanical testing of tissue-engineered valves
Biaxial testing was performed with the native, decellularized and PGG treated valve
leaflets to determine their mechanical strength. The biaxial testing procedure was used as
described in the literature for biaxial testing of bovine jugular vein valves (448). The central
belly regions of the valve leaflets were trimmed into 7 mm x 7 mm sections. The testing
was performed using the BioTester 5000 (CellScale, Waterloo, Ontario, Canada), equipped
with two load cells and real-time monitoring capabilities with a charged coupled device
(CCD) camera. The 7mm x 7mm leaflet sections were mounted and secured by gripping
with BioRake ‘tines’ on all four edges, preventing sample shear and deformation (449).
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After the initial set-up, samples were pre-loaded to 0.01N to generate repeatable
and reliable results. Equibiaxial stretching was applied at a rate of 1%/sec to a strain of
60% of initial dimensions and recovered back to 0% strain, for three cycles. The stretching
to 60% strain was calculated by initial testing, which did not result in tissue failure at that
strain rate. Displacement and force data was collected during the stretching-relaxation
cycles. Based on the measured dimensions of the sample and the output data, corresponding
nominal stress (i.e., first Piola–Kirchhoff stress) and true strain values were calculated,
using equations described below, and stress-strain curves were plotted. The peak tangent
modulus was calculated from the stress-strain curve of each sample between the relatively
linear region of 45% and 60% strain. The stress at 45% strain was subtracted from the
stress at 60% strain, and the value was divided by the difference in strain % (15%). Peak

4700 μm

7 mm

stress was defined as the stress values measured at 60% strain rate.

4700 μm
7 mm

Figure 55: Biaxial testing set-up for porcine aortic valve leaflets
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𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝑆𝑡𝑟𝑒𝑠𝑠 𝑎𝑡 60% 𝑠𝑡𝑟𝑎𝑖𝑛 (𝑀𝑃𝑎)
=

𝐿𝑜𝑎𝑑 𝑎𝑡 60% 𝑠𝑡𝑟𝑎𝑖𝑛 (𝑚𝑁)
𝑇𝑖𝑠𝑠𝑢𝑒 𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠 (𝑚𝑚)𝑥 𝑡𝑖𝑠𝑠𝑢𝑒 𝑤𝑖𝑑𝑡ℎ (𝑐𝑚)

𝑃𝑒𝑎𝑘 𝑡𝑎𝑛𝑔𝑒𝑛𝑡 𝑚𝑜𝑑𝑢𝑙𝑢𝑒𝑠 (𝑀𝑃𝑎)
=

(𝑆𝑡𝑟𝑒𝑠𝑠 𝑎𝑡 60% 𝑠𝑡𝑟𝑎𝑖𝑛 (𝑀𝑃𝑎)) − (𝑆𝑡𝑟𝑒𝑠𝑠 𝑎𝑡 45% 𝑠𝑡𝑟𝑎𝑖𝑛 (𝑀𝑃𝑎))
15%

Suture retention strength of tissue engineered valves
Wall portions of the PGG treated porcine aortic valves were compared to native
glutaraldehyde (glut) fixed aortic walls to determine the ability of the tissues to resist suture
failure.
Rectangular sections of 1 cm x 0.5 cm were excised from PGG treated and
glutaraldehyde treated walls in both the circumferential and longitudinal directions. The
bottom 0.5 cm section of each sample was secured in the lower clamp of a uniaxial tester
(Instron, Norwood, Massachusetts, USA). A 4-0 Prolene suture was inserted through the
center of the section 0.2 cm from the top. The top of the suture was secured and attached
to the upper clamp of the uniaxial tester. Samples were pre-loaded to 0.01 N and then
stretched at a rate of 1mm/sec. The maximum load for tissue failure was recorded, and the
maximum stress at failure was calculated by dividing the maximum load by the crosssectional area of the hole (Tissue thickness x suture diameter)
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Figure 56: Suture retention strength measurement sample preparation and experiment setup

𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝑆𝑡𝑟𝑒𝑠𝑠 𝑎𝑡 𝑓𝑎𝑖𝑙𝑢𝑟𝑒 (𝑀𝑃𝑎)
=

𝐿𝑜𝑎𝑑 𝑎𝑡 𝑓𝑎𝑖𝑙𝑢𝑟𝑒 (𝑁)
𝑇𝑖𝑠𝑠𝑢𝑒 𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠 (𝑚𝑚)𝑥 𝐷𝑖𝑎𝑚𝑡𝑒𝑟 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑢𝑡𝑢𝑟𝑒 (𝑚𝑚)

Subcutaneous implantation of PGG treated porcine aortic valves
PGG treated decellularized and glutaraldehyde fixed native porcine aortic valve
leaflets and walls were implanted subcutaneously in 3-4-week-old Sprague Dawley (SD)
rats to determine the biocompatibility of the scaffolds (450, 451). Subcutaneous
implantation was done as described previously in Chapter Five.
Pre-prepared implants (PGG treated decellularized/ glutaraldehyde treated native
leaflets or walls) were placed into pouches created surgically at the back of SD rats to study
the effects of in-vivo calcification. One valve and one wall were implanted in each rat. The
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wound was closed with surgical staples and the animals were allowed to recover and
housed in animal quarters. At the designated time interval, rats were euthanized, and
implants were retrieved.
Gross view of the explants was observed for any capsule formation, and implant
degradation. The implant periods used were 30 days, 60 days, and 90 days. 10 animals
were used for PGG tissue implant at each time point, and 5 animals at each time point had
glutaraldehyde treated aortic valve and wall implants. The subcutaneous implantation
procedure has been demonstrated schematically in Figure 57.
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Figure 57: Schematic representation of subcutaneous study in rats

Micro-Computed Tomography (Micro-CT) analysis of subcutaneous explants
Subcutaneous valve leaflets and walls explanted from rats were scanned using
Micro-CT (Bruker Micro CT 1176) to identify any calcification within the explants. A
voltage of 65 kV was used with the current of 296 µA, for 60 ms, and 0.2 Al filter. 3-D
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models of the scanned images were reconstructed using NRecon (Micro Photonics Inc.)
and visualized with CTvox (Bruker MicroCT) Software.

Histological analysis of subcutaneous implants
Harvested explants were fixed in formalin, tissue processed, embedded in paraffin,
sectioned to 5 μm sections, and were mounted on glass slides and heated for 30 mins to
adhere the sections to the slides. Slides were deparaffinized and stained with hematoxylin
and eosin for cellular infiltration. Explant sections were also stained with Alizarin red to
determine any calcification within the explants.

ICP (Inductively Coupled Plasma) analysis of subcutaneous explants
The subcutaneously explanted samples, after removal of capsules, were
lyophilized, acid hydrolyzed, and dried under nitrogen gas. The residue was resuspended
in DI water and filtered to remove any solid particles. Calcium and phosphorous content
within the samples were analyzed using the Spectro Acros ICP Spectrometer (SPECTRO
Analytical Instruments, Kleve, Germany). Element concentration values were normalized
to the dry sample weights. (452)

Immuno-histochemical (IHC) Analysis
Histological tissue sections were deparaffinized, boiled in Citrate buffer, blocked,
and incubated with primary antibodies at 1:100 dilution overnight. Secondary florescent
antibody incubation was done for 1 hour, followed by DAPI nuclear staining, mounting,
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and imaging (Keyence BZ-X810). Inflammatory responses in the explants were evaluated
using immunohistochemistry for CD 3-T cells, CD 11c dendritic cells, and macrophage
marker CD 68. Sectioned were also stained for Vimentin and α-Smooth Muscle Actin
(αSMA) to determine infiltration of fibroblasts and myofibroblasts. Collagen remodeling
and new collagen formation was determined using Heat Shock Protein 47 (HSP-47)
staining.

Flow Cytometry analysis of subcutaneous explants
Freshly explanted valve leaflets and walls from the 90-day explants were used for
flow cytometry analysis. For the PGG treated scaffolds, the leaflets/ walls along with the
surrounding tissue were digested. Since no cellular infiltration was expected within the
glutaraldehyde treated explants, the capsules formed around the glutaraldehyde tissues
were separated from the implants and used for the analysis.
Samples were digested using a cell dispersion procedure for subcutaneous tissues
(453, 454). Briefly, freshly explanted samples were placed in PBS containing Dispase I,
3% FBS (Fetal Bovine Serum), and 1% Pen/Strep at 4ºC overnight with shaking. The next
day, remaining samples were removed, minced, and incubated in RPMI (Roswell Park
Memorial Institute media 1640, Lonza) media with 1 mg/ml collagenase, 1 mg/ml
hyaluronidase, 150 U/ml DNase, and 1% Pen/Strep at 37ºC for 2 hours with shaking. After
digestion, both solutions were passed through 40µm nylon mesh sterile cell strainers
(Fisher scientific), and any remaining tissue was mashed and washed with PBS. The cell
suspension obtained after filtering was centrifuged, resuspended in Cell staining Buffer,
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washed, blocked with Fc block, and incubated with 1:100 diluted fluorescent labeled
primary antibody cocktail for extracellular antigens (CD45 and CD31) for 30 minutes at
4ºC. After primary antibody incubation, cells were treated with fixation buffer,
permeabilized using permeabilization buffer, and incubated with 1:50 diluted fluorescent
labeled primary antibody cocktail for intracellular staining (Vimentin and αSMA) for 1
hour at room temperature. Subsequently, the cell suspension was washed to remove any
unbound antibodies, resuspended in cell staining buffer, and analyzed using Attune NxT
flow cytometer (Thermofisher Scientific).

Implantation of tissue-engineered valves as pulmonary valve repair unit in
sheep2
PGG treated porcine aortic valves and porcine pulmonary valves were implanted in
sheep as pulmonary valve repair units for up to three months. For the surgery, the main
pulmonary artery was partially transected at 1 cm above the level of the sino-tubular
junction, and one pulmonary valve leaflet was excised. An appropriately sized PGG treated
valve repair patch with the attached wall was trimmed to an appropriate geometry and
sutured to repair the excised leaflet. After pulmonary arteriotomy closure, the animals were
weaned from cardiopulmonary bypass and when hemodynamically stable, the function of
the implanted valve leaflet was assessed with epicardial 2-D and 3-D echocardiography.
At three months after the implant procedure, the left thoracotomy incision was reopened
under general anesthesia, and 2-D and 3-D echocardiography images were acquired. The
2

Sheep Implant surgeries done by Dr. John E. Mayer at Boston Children’s Hospital
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animals were heparinized to prevent post-mortem thrombosis, and then euthanized with
pentobarbital sodium (80-100 mg/kg, IV). Pulmonary valve explanted were obtained and
analyzed by their gross view, histologically, and immunohistochemically.

Statistical analysis
The data was reported as the Mean ± Standard Deviation. Data from different
groups were analyzed by one-way analysis of variance (ANOVA) followed by Tukey’s
HSD. All statistical analysis was done using JMP® Pro 15.2.0. Significance was reported
at three different significance levels: ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05.

6.3 Results
DNA Quantification:
Native porcine aortic valve leaflets and walls had average DNA concentrations of
2986.2 ± 1017 ng DNA/ mg tissue weight and 4057.4 ± 1583 ng DNA/ mg dry weight of
tissue, respectively. After decellularization, this value decreased to 38.2 ± 33 ng DNA/ mg
tissue and 34.7 ± 18.9 ng DNA/ mg tissue (Figure 58). This represented a 98.7% decrease
in DNA content in the leaflets and 99.1% decrease in the walls. The difference in DNA
content between the native and decellularized scaffolds was statistically significant.
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Figure 58: DNA quantification in porcine aortic valve leaflets and walls before and after
decellularization; N=6; *** p≤ 0.001
Native porcine pulmonary valve leaflets had average DNA concentrations of
11317.9 ± 864 ng/ mg tissue weight and 4697.6 ± 1076 ng DNA/ mg tissue weight for the
leaflets and walls, respectively. In decellularized leaflets and valves, the DNA
concentration decreased to averages of 87.82 ± 11.8 ng/ mg dry weight and 63.9 ± 24.4 ng
DNA/ mg dry weight (Figure 59). This represented a 99.2% and 98.6% decrease in DNA
content in the pulmonary leaflets and walls, respectively.
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Figure 59: DNA quantification in porcine pulmonary valve leaflets and walls before and
after decellularization; N=6; *** p≤ 0.001
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Figure 60: Gross View of native, decellularized and PGG treated valve leaflets
Histologically, H&E staining of the decellularized and PGG treated aortic and
pulmonary valves did not show the presence of any cellular or nuclear material. Masson’s
trichrome and VVG staining of the native, decellularized, and PGG treated scaffolds
showed the presence of collagen and elastin within the extracellular matrix of the scaffolds.
There was no difference observed histologically between the arrangement of these fibers
within the ECM. Alcian blue staining also confirmed the presence of glycose-amino
glycans (GAGs) within the scaffolds after decellularization and PGG treatment (Figures
61 and 62).
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Figure 61: Porcine Aortic Valves Histology

144

100 µm

Native

Decellularized

PGG Treated

H&E

Valve
Wall
Wall

Masson’ s Trichrome

Valve

VVG

Valve
Wall

145

Alcian Blue

Valve
Wall

Figure 62: Porcine pulmonary valves histology
Resistance to elastase and collagenase enzymes
PGG treated decellularized porcine aortic valve and wall tissues treated separately
with elastase and collagenase enzymes demonstrated a decrease in weight loss after the
enzyme treatments compared to decellularized valves and walls. The % loss in dry weight
for the decellularized valve leaflets and walls were 41.3 ± 13.2 % and 77.2 ± 7.9 %,
respectively, after elastase treatment. PGG treatment of the decellularized tissues decreased
this weight loss to 19.7 ± 2 % and 54.7 ± 2.1 % for the valves and walls, respectively
(Figure 63.A). Collagenase treatment of decellularized valves and walls resulted in weight
losses of 95.1 ± 7.8 % and 46.2 ± 11.6 % respectively, while PGG crosslinking of the
tissues decreased the weight loss to 10.9 ± 5 % and 9.7 ± 4.1 %, respectively (Figure 63.B).
All the reductions in weight loss from enzyme treatments were statistically significant, as
indicated below.
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Figure 63: A. Elastase and B. Collagenase Enzyme treatment of Native, Decellularized,
and PGG treated decellularized Porcine Aortic Valves and Walls; N=8 (**, ***:
Statistically significant difference in % weight loss after enzyme treatment)
Native pulmonary valve leaflets and walls demonstrated weight losses of 40 ± 2.5%
and 63.7 ± 14.8% when treated with elastase enzyme. For decellularized scaffolds, the
values were 30.6 ± 2.5% 63.3 ± 18.3% respectively. In PGG treated scaffolds, the % weight
loss from elastase treatment decreased to 2.7 ± 0.7% and 9.2 ± 3.4% in the leaflets and
walls, respectively. For collagenase treatment, native pulmonary valve leaflets and walls
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demonstrated loss in dry weight of 90.7 ± 4.8% and 38.8 ± 13.6%, respectively. In
decellularized valves, the weight loss was 79.6 ± 11.7% for leaflets and 33.5 ± 20.4% for
walls. PGG treated scaffolds had weight losses of 7.9 ± 0.6% and 2.9 ± 0.9% respectively
in the leaflets and walls. The difference in weight loss was statistically significant between
the PGG scaffolds and the native and decellularized valves (Figure 64).
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Figure 64: (A) Elastase and (B) Collagenase Enzyme treatment of Native, Decellularized,
and PGG treated decellularized Porcine Pulmonary Valves and Walls; N=8 (**,

***

Statistically significant difference in % weight loss after enzyme treatment)
Biaxial testing
Equibiaxial stretching and relaxing of native, decellularized, and PGG treated
porcine aortic valve leaflets demonstrated the ability of the leaflets to withstand cyclical
stretching and relaxation cycles without tissue deformation (Figure 65).
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Figure 65: Stress-strain biaxial curves for native, decellularized, and PGG treated porcine
aortic valve leaflets
The maximum peak stress at 60% strain for native, decellularized, and PGG treated
aortic valve leaflets revealed higher average maximum peak stress in the circumferential
direction compared to the radial direction for all three kinds of tissues. The maximum peak
stress for native PAV was 0.23 ± 0.08 MPa in the circumferential direction, compared to
0.05 ± 0.03 MPa in the radial direction. In decellularized leaflets, the peak stress in the
circumferential direction was 0.27 ± 0.16 MPa compared to 0.15 ± 0.11 MPa in the radial
direction. PGG treated PAV leaflets had 0.32 ± 0.17 MPa peak stress in the circumferential
direction compared to 0.26 ± 0.16 MPa in the radial direction (Figure 66).
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Figure 66: Average maximum peak stress at 60% strain from biaxial testing in porcine
aortic valve leaflets; N=6
The peak tangent modulus for the native PAV leaflets was 0.15 ± 0.09 in the
circumferential direction and 0.04 ± 0.03 in the radial direction. For the decellularized
leaflets, the tangent modulus was 0.15 ± 0.11 in the circumferential direction and 0.09 ±
0.05 in the radial direction. In PGG treated leaflets, the values were 0.19 ± 0.12 and 0.16
± 0.11 in the circumferential and radial directions, respectively (Figure 67).
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Figure 67: Peak tangent modulus for biaxial testing in porcine aortic valve leaflets; N=6
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The thickness of the native, decellularized, and PGG treated porcine pulmonary
valves was measured prior to biaxial testing. The average thickness of the tissues was 0.26
± 0.03 mm, 0.24 ± 0.02 mm, and 0.29 ± 0.04 mm, for the native, decellularized, PGG
treated, and glutaraldehyde fixed valve leaflets, respectively (Figure 68). No significant
difference was observed within the tissue thickness of the different groups.
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Figure 68: Average thickness of native, decellularized, and treated porcine pulmonary
valves; N=5
Biaxial testing of the native, decellularized, and PGG treated decellularized porcine
pulmonary valve leaflets demonstrated the ability of the leaflets to stretch and recoil with
cyclical applied forces in both the circumferential and radial directions (Figure 69).
The maximum stress at 60% strain for native PPV was 0.81 ± 0.4 MPa in the
circumferential direction and 0.59 ± 0.55 MPa in the radial direction. For the decellularized
PPV, circumferential and radial stresses were 0.98 ± 0.09 MPa and 0.72 ± 0.24 MPa,
respectively. PGG treated decellularized PPV leaflets demonstrated maximum stress
values at 60% strain at 0.99 ± 0.19 MPa and 0.57 ± 0.49 MPa in the circumferential and
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radial directions, respectively (Figure 70.A). There was no statistical difference observed
between the maximum stresses among the three groups. The anisotropic trend in maximum
stresses was preserved after decellularization and PGG treatment of the PPV leaflets.
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Figure 69: Stress-Strain biaxial analysis of porcine pulmonary valve leaflets; Cir:
Circumferential direction; Rad: Radial direction; NPPV: Native pulmonary valves; DPPV:
Decellularized pulmonary valves; PPPV: PGG treated pulmonary valves
Peak tangent modulus, calculated from the relatively linear region of 45% to 60%
strain was similar in the three groups of PPV. The average peak tangent modulus for the
native tissues were 3.53 ± 1.91 MPa in the circumferential direction, and 2.5 ± 1.59 MPa
in the radial direction. For decellularized scaffolds, the tangent modulus values were 4.39
± 0.62 MPa in the circumferential direction, and 3.09 ± 1.78 MPa in the radial direction.
PGG treated decellularized leaflet scaffolds demonstrated maximum peak tangent modulus
values of 4.04 ± 0.55 MPa in the circumferential direction and 2.3 ± 4.13 in the radial
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direction (Figure 70.B). No significant differences were observed in the tangent modulus
values between the groups.
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Figure 70: (A) Maximum stress at 60% strain (MPa) for native (NPPV), decellularized
(DPPV), and PGG treated (PPPV) porcine pulmonary valve leaflets; (B) Peak Tangent
Modulus (MPa) for native, decellularized, and PGG treated porcine pulmonary valve
leaflets; Cir: Circumferential direction, Rad: Radial direction; N=5

Suture retention testing
PGG and glut treated aortic valve walls, with inserted suture, were stretched in a
uniaxial tester until tissue failure. The average maximum force required for tissue failure
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in PGG treated scaffolds was 73.59 ± 15.34 MPa in the circumferential direction, and 17.21
± 4.29 MPa in the longitudinal direction. The corresponding values for the glutaraldehyde
treated walls were 7.97 ± 2.03 MPa in the circumferential direction and 14.96 ± 9.17 MPa
in the longitudinal direction. The maximum force required for suture failure was
significantly higher in PGG treated walls compared to glutaraldehyde fixed walls in the
circumferential direction, whereas the difference in the required force was not significantly
different between the two treatments in the longitudinal direction (Figure 71).
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Figure 71: Maximum stress required for failure in suture pull-through test for PGG and
glut aortic walls; N=8

Glutaraldehyde and PGG treated pulmonary walls stretched at a constant rate with
suture insertion did not result in a significant difference in the maximum force and stress
at failure. Glutaraldehyde treated walls had a maximum stress at tissue failure of 36.1 ±
8.75 MPa in the circumferential direction and 27.36 ± 3.76 MPa in the radial direction. The
stresses calculated at failure for the glutaraldehyde treated group were 14.99 ± 7.9 MPa
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and 16.9 ± 8.2 MPa in the circumferential and radial directions, respectively. Although the
average values for the force and stress were higher for the PGG tissues, no significant

Maximum stress
at failure (MPa)

difference was observed between glutaraldehyde and PGG treated groups (Figure 72).
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Figure 72: Suture pull-through testing of native, decellularized, and PGG treated porcine
pulmonary valves; Cir: circumferential direction; Rad: Radial direction; No significant
difference between groups; N=5

Subcutaneous implantation
All rats with subcutaneous implants, both glut valves and PGG treated valves,
healed after the implantation procedure without any infection or morbidity. The gross view
of the subcutaneously implanted glut treated native porcine aortic valves demonstrated
thick capsule formation around all the leaflet and wall implants for all time points. There
was no degradation of any of the glut implants. PGG treated decellularized aortic valve
implants, on the other hand, did not show any extensive capsule formation. The PGG
treated implants also demonstrated degradation of the tissues after implantation; the
degradation rate increased with the time of implantation. At the end of the 90-day implant
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period, the PGG treated decellularized leaflets implants had been mostly absorbed into the

Glut

PGG

surrounding tissue, without any visible signs of inflammation (Figure 73).

30-day

90-day

Figure 73: Gross view of 30-day and 90-day glut and PGG subcutaneous implants

Micro CT imaging of glut and PGG implants demonstrated the presence of heavy
calcification within the glut leaflets and walls. All glut implants at 30, 60, and 90-days
showed calcification within the tissues. None of the PGG implants showed the presence of
any calcification by micro-CT imaging. Calcification within the tissues or scaffolds were
identified as mineralized densities with an attenuation coefficient higher than surrounding
soft tissues (Figure 74).
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Figure 74: Micro CT imaging of subcutaneous porcine aortic valve explants after 30, 60,
and 90 days of implantation
Alizarin red staining of the glut and PGG explants confirmed calcification within
the glut valves. Dark red staining by alizarin red indicates presence of calcium within the
tissues. All the glut explant sections demonstrated staining with alizarin red, while none of
the PGG explant sections demonstrated any calcification (Figure 75).
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Figure 75: Alizarin red staining of porcine aortic valve subcutaneous explants after 30, 60,
and 90 days of implant
ICP calcium (Ca) and phosphorous (P) mineral analysis within the subcutaneously
explanted porcine aortic valves demonstrated increase in average Ca and P content in glut
leaflets and walls. Pre-implant glut leaflets had Ca and P concentrations of 2.3 ± 1.4 μg/
mg tissue weight and 1.7 ± 0.21 μg/ mg tissue, which increased to 124.7 ± 66.8 μg/ mg and
60.6 ± 30.5 μg/ mg respectively at 30 days, 129.8 ± 50.4 μg/ mg and 64.1 ± 24.4 μg/ mg at
60 days, and 460.9 ± 608.9 μg/ mg and 214.7 ± 290.4 μg/ mg at 90 days respectively. In
the glut walls, the Ca and P concentrations increased from 0.86 ± 0.3 μg/ mg and 1.2 ± 0.1
μg/ mg pre implant to 76.5 ± 7.9 μg/ mg and 37.7 ± 4.4 μg/ mg at 30 days, 100 ± 19.5 μg/
mg and 47.4 ± 9.2 μg/ mg at 60 days, and 149.2 ± 32 μg/ mg and 66.7 ± 13.6 μg/ mg
respectively at 90 days. PGG treated valve leaflets and implants, on the other hand, had Ca
and P concentrations ranging from 0.76 ± 0.32 μg/ mg to 8.57 ± 4.1 μg/ mg of tissue for
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the pre-implant and post implant tissues. No significant increase in Ca or P concentrations
were seen (Figure 76).
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Figure 76: Calcium and phosphorous mineral analysis in explanted aortic valves; N=5
H&E staining of the PGG treated aortic valve and leaflets showed cellular
infiltration post-implant. Moreover, no significant capsule formation was seen around the
PGG implants. Most of the tissues were surrounded by subcutaneous tissue. At 90-days,
most of the explanted valves had been absorbed into the surrounding tissue (Figure 77).
Jansen grading of the subcutaneous implants (Table 7) demonstrated superior
biocompatibility of PGG treated scaffolds compared to glutaraldehyde treated tissues.
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Figure 77: Hematoxylin and eosin staining of 30-, 60-, and 90-day aortic valve
subcutaneous explants
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Table 7: Jansen grading of glutaraldehyde and PGG treated aortic valve subcutaneous
Reaction-zone semiqualitatively
Reaction zone
qualitatively

implants

Immunohistochemical staining of PGG treated decellularized aortic leaflet
subcutaneous implants demonstrated the presence of CD68 macrophages at 30 days and 60
days, but at 90 days, there was no significant staining of CD68. Leaflets also demonstrated
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some CD3 T cell staining at 30 days, but at 60 and 90 days, no CD3 staining was observed.
No CD11c dendritic cell staining was observed in any of the PGG treated leaflets. In
comparison to inflammatory cells, vimentin, α Smooth muscle actin, and HSP-47 positive
staining was observed in all PGG implants, with more prominent HSP-47 staining at 90
days post implant (Figure 78).
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Figure 78: IHC staining of subcutaneously explanted 30-, 60-, and 90-day aortic valve
leaflet implants
Flow Cytometry
Flow cytometry analysis of the PGG treated decellularized valves and walls
subcutaneously explanted from rats demonstrated <27% and <36% of the cells were
inflammatory within the leaflets and walls, respectively. More than 60% of the infiltrated
cells were fibroblasts and myofibroblasts as well, as some infiltration of endothelial CD31
cells were also observed (Table 8).
A

B

Figure 79: Representative dot plots from flow cytometry (A) PGG valve leaflets (B) PGG
valve walls subcutaneous explants from rats
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α-SMA

4.04
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Antig
en
Mean
(%)
SD

CD45
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1.22
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EndoFibrothelial
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CD31

Vimentin

α-SMA

35.44

10.87

16.85

44.47

5.9

4.01

2.07

14.15

Table 8: Statistics of cells stained positive for different antigens; Mean and Standard
deviation of the % of cells; N=3

Implantation of PGG treated porcine aortic valves in sheep
PGG treated decellularized porcine aortic and pulmonary valves implanted in
juvenile sheep as pulmonary valve replacement units for up to 6 weeks demonstrated
thickening of the valve replacements after explanting 4-weeks and 6-weeks post
implantation. Figure 80 represents thickening observed within PGG treated aortic valve
explant after 4 weeks in the pulmonary position.

Figure 80: PGG treated decellularized porcine aortic valves explanted from sheep as
pulmonary valve implants
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6.4 Discussions
The current gold standard for valve replacement in pediatric patients is the use of
cryopreserved allograft valves (455). There is, however, a shortage of available allografts
as well as patient-valve size mismatch (456). Mechanical and synthetic valves, as discussed
before, have their own limitations. Moreover, none of the currently available valve
replacement strategies allow the somatic growth of cells within the valves. Therefore,
multiple reoperations are required for pediatric patients.
Tissue-engineered heart valves are a promising approach to overcoming the
limitations of current heart valves. Tissue-engineered valves are composed of a porous
scaffold, cell population, and signaling factors (11, 457, 458). Ideally, tissue engineered
valves should provide sufficient hemodynamics, thereby eliminating the need for
reoperations; active tissue remodeling prevents degeneration and growth characteristics,
preventing the need for multiple reoperations. To achieve these characteristics, the
scaffolds of tissue-engineered valves are composed either from natural scaffolds or from
degradable polymers (5). Recreation of the macro- and micro- valve anatomy and
mechanical anisotropy might be challenging to achieve with degradable polymers (459).
Decellularized valves, on the other hand, are composed of biological materials that can
positively impact cellular differentiation and remodeling (460, 461). Moreover, complete
degradation is not necessary with decellularized valves, and the mechanical anisotropic
characteristics are maintained (462-466). Although some polymer valves have recently
been used for valve replacement strategies, the long term performance of these remain to
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be evaluated (467-471). Decellularized valve replacements have therefore been more
widely used in clinical applications (472-478).
The detergent-based decellularization procedure utilized in this study was
successful in removing most of the nuclear material from the scaffolds. The presence of
nuclear and cellular material within the implanted scaffolds has been identified as the foci
for the development of calcification within the tissues (374). Moreover, the absence of
xenogeneic cellular material removes the possibility of the inflammatory response to the
implanted tissue (369). The final DNA concentration within the porcine leaflets and walls
was less than 50 ng/ mg tissue dry weight, which has been identified as an optimum level
of remaining DNA (479).
Crosslinking of decellularized aortic and pulmonary valves with PGG was
demonstrated to have significantly lower weight loss compared to decellularized and native
tissues. This indicates the PGG treated scaffolds would be less susceptible to enzymatic
degradation upon implantation, potentially prolonging the degradation time of the
scaffolds. Early degradation of implanted valves is a major issue in bioprosthetic heart
valves. Commercially, glutaraldehyde is the most widely used crosslinker to prevent rapid
degradation of implanted valves. Glutaraldehyde crosslinking, however, does not
effectively protect elastin from enzymatic degradation (14, 15).
Biaxial mechanical testing on the native, decellularized, and PGG treated aortic and
pulmonary valve leaflets demonstrated the leaflets had comparable mechanical strength
even after decellularization and PGG treatment procedures. Moreover, cyclical stretching
and relaxation of the PGG treated tissues demonstrated they were capable of withstanding
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cyclical forces. Suture pull-through testing performed on the aortic and pulmonary walls
also demonstrated that the suture retention strength of the wall portions was comparable or
higher than those of the glutaraldehyde treated tissues. This indicates the PGG treated
tissues are comparable or more resistant to suture tearing compared to glutaraldehyde
tissues.
Subcutaneous implantation of PGG decellularized treated porcine aortic valves
demonstrated no calcification within both the leaflet and wall portions. The glutaraldehyde
treated implants, on the other hand, demonstrated extensive calcification. Additionally,
unlike glutaraldehyde implants, PGG treated implants did not have extensive capsule
formation around the tissues. The thickness and nature of the surrounding capsule are an
indication of the biocompatibility of the material. The PGG implants also demonstrated
degradation of the scaffolds after 90-days of subcutaneous implantation indicating the
potential of the scaffolds to integrate with the surrounding tissue. Flow cytometry and IHC
analysis of the 90-day implants showed the presence of endothelial cells, fibroblasts, and
myofibroblasts, with very few inflammatory cells. The glutaraldehyde treated implants, on
the other hand, had more inflammatory cells within the surrounding capsules.
Sheep implants of the porcine aortic and pulmonary valves demonstrated some
thickening of the valves after 4-weeks. Analysis of the explanted valves indicates this
might have been due to the mismatch of the aortic tissue implanted at the pulmonary
position. Aortic valves are more robust than pulmonary valves and are equipped to handle
more shear stress. The absence of this might have led to the deposition of cellular material
within the valves. Additionally, porcine tissues contain alpha-galactose epitopes and their
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insufficient removal by the decellularization procedure might have been a cause for the
thickening of the implanted valves. Alpha galactose, or Galactose-alpha-1,3-galactose is a
carbohydrate found in most mammalian cell membranes. It is not found in humans and
most primates. Presence of xenogeneic alpha-gal might illicit immune responses leading
to graft failure. The alpha-galactose content within the tissues were not measured in this
experiment. Further investigations need to be conducted regarding the failure of the PGG
treated aortic and pulmonary valves in sheep. Moreover, for a more effective analysis of
the failure of the valve replacements as a pulmonary valve, in vitro bioreactor studies can
be performed. Evaluation of the functioning of the valves in a controlled hemodynamic
environment might be able to effectively point out the reason for leaflet thickening.
Additionally, alternate tissue sources, not containing alpha-galactose can be
investigated for pulmonary valve replacements. Since the decellularization and PGG
treatment process was shown to produce optimal in vitro results in both porcine aortic and
pulmonary valves, the same treatment might be beneficial in the production of functional
valves from a more suitable donor source.

6.5 Conclusions
In this aim, tissue-engineered valve replacements were developed from porcine
aortic valves and porcine pulmonary valves. The valve units demonstrated sufficient
mechanical strength and resistance against enzyme degradation. Subcutaneous
implantation of porcine aortic valves demonstrated the ability of the PGG treated
decellularized valve leaflets and walls to resist calcification upon implantation. Cellular
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analysis of infiltrated cells within the subcutaneous PGG implants demonstrated most of
the cells were endothelial and myofibroblast-like cells, with very few inflammatory cells.
Implantation of PGG treated decellularized porcine aortic and pulmonary valves in sheep
as pulmonary valve repair units demonstrated some tissue thickening, probably due to
tissue mismatch and presence of alpha galactose epitopes within the porcine tissue.
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CHAPTER SEVEN
SPECIFIC AIM 4: EVALUATION OF PGG TREATED BOVINE PERICARDIUM
SCAFFOLDS AS INTRA-MUSCULAR IMPLANTS IN DIABETIC CONDITIONS

7.1 Introduction
Biomaterials are increasingly being used for the repair of tissue defects. Muscular
defects such as that of the abdominal wall result from surgery or tissue loss from traumatic
injuries (480, 481). The use of synthetic materials for such tissue construction involves
polypropylene or polytetrafluorethylene meshes, which are prone to infections and
adhesions leading to severe bowel obstruction and herniation (482). Tissue substitutes such
as acellular dermal matrices or small intestine submucosa are considered to be more
favorable to promote tissue regeneration.
Decellularized pericardium tissues are rich in collagen, which is able to provide
mechanical stability as well as structural guidance to cells, along with providing a matrix
for cellular attachment (483). PGG treatment of decellularized pericardium scaffolds would
further enhance the mechanical stability of the biomaterial and provide protection against
enzymatic degradation, thus allowing more time for cellular infiltration and remodeling.
Decellularized bovine pericardium and PGG treated bovine pericardium scaffolds were
used as intra-muscular implants to repair abdominal wall defects.
Moreover, the repair and regeneration potential of abdominal defects is reduced
with the incidence of diabetes due to an increase in pro-inflammatory cell response and

169

reduced anti-inflammatory cytokines (484). This impairs the healing of chronic wounds
and might lead to herniation in abdominal defects. Diabetic rats with abdominal wall
defects will also be implanted with intra-muscular decellularized and PGG treated
pericardium to determine the adhesion of the tissues, the ability of the biomaterials to repair
the wound and prevent herniation, as well as cellular infiltration within the decellularized
and PGG treated implants.
PGG as a therapeutic reagent has been reported to have antimicrobial properties
(18). The Minimum Inhibitory Concentration (MIC) of PGG with anti-microbial properties
against Staphylococcus aureus is 0.13 ± 0.00 mg/ml (485). PGG added to cultures at
concentrations of 12.5 µM, PGG has also been reported to prevent biofilm formation by S
aureus on polycarbonate membranes (486). In this study, it was determined if the PGG
bound within the tissue ECM still possesses this antimicrobial property and if it renders
resistance to the bacterial attachment to the PGG treated tissues.

7.2 Materials and Methods
Development of PGG treated decellularized scaffolds from bovine pericardium
Native Bovine Pericardium was obtained from Animal Technologies, Inc. The
tissues after washing and removal of fat were decellularized as described in previous
chapters. The tissues were treated with a decellularizing solution composed of 0.25%
sodium dodecyl sulfate (SDS), 0.5% sodium Deoxycholate (DOC), 0.5% Triton X 100,
and 0.2% Ethylene Diamine Tetra-Acetic acid (EDTA) in 50 mM TRIS buffer (pH 7.4 ±
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0.05) for three days. Decellularization solution was replaced with fresh solution every day.
The pericardium sheets were cut into 10 cm x 10 cm patches prior to the decellularization
process to ensure the effective removal of nuclear material. DNase and RNase solutions
were used at a concentration of 360 U/mL (for both DNase and RNase) to remove bovine
nucleic acid components from the pericardium tissue. The DNase/ RNase treatment was
done for four days at 37°C, and the solution was replaced with fresh DNase/RNase every
24 hours. The decellularized scaffolds were sterilized by shaking with sterile 0.1%
Peracetic acid (pH 7.4 ± 0.05) at room temperature for 24 hours. Sterilized Decellularized
Pericardium was crosslinked by treatment with sterile 0.15% PGG solution in 50 mM
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) solution (pH 5.5) for 20 ± 2
hours. After PGG crosslinking, pericardium scaffolds were washed with PBS, and stored
in sterile PBS with 1% Penicillin/Streptomycin Antibiotics.

DNA Extraction and Quantification
DNA was extracted from lyophilized native and decellularized pericardium tissues
using Qiagen Dneasy Blood and Tissue Kit (Cat. No. 69504). The amount of DNA obtained
from each sample was quantified with Quant-It Pico green dsDNA Reagent kit. DNA
concentrations were normalized to the dry weight of tissue used for extraction.

Histology:
Native, Decellularized, and PGG treated decellularized scaffolds were fixed in 10%
Neutral Buffered Formalin (NBF) Solution and processed by a series of changes through
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formalin, ethanol, and paraffin to prepare the samples for histological analyses. Paraffin
embedded samples were cut into 5 Micrometer sections using a microtome and stained to
determine the presence of cellular material in the scaffolds as well as to determine the
composition of the extracellular matrix of the scaffolds after each step.

Enzyme Treatment (Elastase and Collagenase):
Enzyme treatment was done on the native, decellularized, and PGG treated bovine
pericardium scaffolds as described previously. Briefly, lyophilized tissues were treated
with elastase and collagenase enzymes in TRIS buffer with CaCl2 and NaN3 for 24 hours
and 48 hours respectively. The digested samples were lyophilized, and the percent (%)
weight loss calculated for each sample.

Antimicrobial properties of PGG:
PGG as a therapeutic reagent has been reported to have antimicrobial properties.
The antimicrobial property of PGG was analyzed by using free PGG in the bacterial culture
media as well as after being integrated within the tissue as a crosslinking reagent.

An overnight culture in Lysogeny Broth (LB) media of Staphylococcus aureus was
diluted to a concentration of 64x105 Colony Forming Units (CFU)/mL. Lyophilized
decellularized and PGG treated decellularized scaffolds were soaked in 5 mL of LB media
overnight. Free PGG control samples were prepared by adding PGG to LB media at
concentrations of 2 mM/mL and 0.4 mM/mL. Antibiotic controls were prepared by adding
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0.2 mM/mL of Penicillin/ Streptomycin and 1.7 mM/mL of Cefalexin. Positive control was
used with no addition of scaffolds, PGG or antibiotics. Each of the 5 mL media samples
were inoculated with 20 µL of the diluted S aureus culture. A negative control was also
used with no addition of bacterial culture. All of the samples were put on a shaker in an
incubator at 37°C The bacterial growth in each sample was measured at time points of 3hour, 6-hour, 12-hour, and 24-hour from the time of incubation. The CFU/mL of each
sample was analyzed at each of the time points by plating on LB-Agar. At the end of 24
hours, the decellularized and PGG treated decellularized samples were removed from the
bacterial culture and washed in sterile PBS to remove any bacteria that might not have
adhered to the scaffolds. Each of the sample scaffolds were divided into two equal halves.
The first half of the scaffolds were placed in fresh 5mL of LB Media after washing with
sterile media. These samples in fresh media were placed in a shaker at 37°C for 24 hours.
Bacterial growth after 24-hour from the time of incubation was measured by plating the
samples after 24-hours on LB-agar plates.
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Figure 81: Experimental design for the study of antimicrobial properties of PGG treated
decellularized pericardium
The second halves of the scaffolds were fixed with glutaraldehyde; the scaffolds
were

treated

with

0.6%

glutaraldehyde

in

50

mM

4-(2-hydroxyethyl)-1-

piperazineethanesulfonic acid (HEPES) buffered saline (pH 7.4) at room temperature with
gentle shaking for 24 hours, solution decanted, and replaced with 0.2% glutaraldehyde in
50 mM HEPES buffered saline (pH 7.4) for another 24 hours (452). The Glutaraldehyde
treated samples were lyophilized and sputter-coated with Platinum to be analyzed under a
Scanning Electron Microscope (SEM). An electron beam with a voltage of 3 kV was used
with an SE Lower Detector to visualize the surface of the scaffolds and determine bacterial
attachment to the scaffolds.
Bacterial culture was also done with the extracts from the enzyme (Elastase and
Collagenase) treatment. The enzyme challenge extracts were added to LB media at
concentrations of 20%, 2%, and 0.2% of the total media volume. The solutions were
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incubated with an incubation culture of 24x105 CFU/ml, and incubated overnight at 37°C.
The bacterial growth within the samples were observed the next day by plating the samples
and determining the CFU/ml counts.

Development of Type 2 Diabetes Model in Sprague Dawley Rats:
Type II diabetes was developed in 6-week-old SD rats using a High Fat
Diet/Streptozotocin (HFD/STZ) model (487-489). The animals were allowed a week of
acclimatization after obtaining from a commercial vendor. They were fed a high-fat diet
consisting of 10% lard, 20% sucrose, 2.5% cholesterol and 1.0% cholate for two weeks.
After two weeks, the animals were subjected to overnight fast, and injected with
Streptozotocin (55 mg/kg body weight in 0.1 M citrate buffer, pH 4.5) by tail vein injection.
Animals had free access to food and water after STZ injection. A small amount of blood
(~0.3 ml) was collected after three days from the tail vein, and blood glucose level was
assayed using Alpha TRAK (Gen II) test strips on the Alpha TRAK Blood Glucose
Monitoring System, designed specifically for animals. A blood glucose level >200 mg
glucose/dL blood was considered as an establishment of Diabetes in the animals. Levels of
blood glucose were monitored 3-4 times per week. Diabetic rats were given subcutaneous
injections of long-lasting insulin (2-4 U Isophane) every other day to maintain blood
glucose levels in a desirable range (300-500 mg glucose/dL blood) and to prevent the
development of ketonuria and weight loss. Glucose levels, individual weights, hydration
status, and food and water consumption were monitored closely. Animals were provided
with food and water ad libitum.

175

The healthy animal group consisted of SD rats fed on a normal diet without any
STZ injection.

Intra-muscular implantation surgery:
Decellularized and PGG treated decellularized pericardium patches were implanted
in healthy and diabetic Sprague Dawley (SD) rats as an abdominal intra-muscular implant.
Before the full-thickness wound surgery, 1.1 -1.2 mg/kg of buprenorphine SR was
administered subcutaneously to the rats at the time of surgery for analgesia. Anesthesia
was induced using isoflurane in a chamber. Each animal was administered ophthalmic
ointment to prevent corneal desiccation. Once the animal had reached an acceptable level
of anesthesia sufficient for surgery, the ventral abdomen was shaved using clippers from
the pubis to the sternum and from the lateral margins on the ventrum. The shaved area was
prepared for surgery by scrubbing with an iodophor antiseptic and 70% ethanol wipe. A
vertical incision, approximately 3-4 cm, was made along the ventral midline to the
abdominal musculature. The abdominal wall was gently lifted, and a small opening was
made through the linea alba. Incision was made into the muscle to create an approximately
2 cm x 2 cm full-thickness defect, cutting approximately 1 cm lateral from each side of the
midline on both sides of the linea alba incision. A pre-cut section of mechanical bridging
material (implant) was laid over the defect, the four corners of which were sutured to the
abdominal wall muscle using non-absorbable suture in a simple interrupted suture pattern.
Each edge of the material was secured using three additional sutures spaced equally. If
significant gaps existed, which might allow passage of viscera through the abdominal wall,
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they were secured using additional sutures. The subcutaneous tissue was closed using 4-0
absorbable sutures in a simple interrupted pattern (490, 491). Additionally, if the linea
alba's surgical incision extended beyond the defect's margins, the remaining linea alba was
closed with 4-0 absorbable sutures, also in an interrupted pattern. The skin was closed using
surgical staples. Animals were allowed to recover and closely monitored until complete
recovery. The skin staples were removed 7-10 days following surgery.
Animals from each group were euthanized at time points of 2 weeks, four weeks
and six weeks after implantation and the implanted material was harvested. After
euthanizing the animals, the skin and abdominal wall were opened to expose the area of
the implant. The adhesion of the implanted material to the underlying viscera, if any, was
observed. Gross pathology observations were made, and the implant was removed by
cutting a wide section of the tissue, including the implant. In vitro analysis of the implant
along with the surrounding tissue was done to determine the comparative ability and
effectiveness of the implants incorporated into the host tissues. (Figure 82)

Figure 82: Intra-muscular abdominal implant surgery
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In vitro analysis of explants:
The explants were analyzed in vitro to determine the cellular infiltration within the
implants as well as the nature of the cellular infiltrates. Each implant was analyzed at two
areas- the center of the implant and the intersection area between the implant and the
abdominal muscle of the rat. Histological staining, including Hematoxylin and Eosin
(H&E), Verhoeff’s Elastic Stain (VVG), Alcian Blue and Masson’s trichrome staining was
done to determine the cellular infiltration of cells, as well as the composition of the
extracellular matrix (relative distribution and structure of elastin and collagen) of the
scaffolds after the implant period. Alizarin red staining was also done to determine any
development of calcification within the implants.
The center and intersection areas of the implants were also analyzed immunohistochemically (IHC) to determine the relative infiltration of polarized macrophages as
well as fibroblasts within the scaffolds. CD68, iNOS, and CD163 antibodies were used to
look at the relative distribution of pro-inflammatory and anti-inflammatory macrophages.
Vimentin and alpha-Smooth Muscle Cell staining was performed to identify the fibroblast
distribution, and the implants were also stained for TNF-α to determine the presence of the
inflammatory cytokine within the implant tissue. Sections were additionally stained with
MMP-9 to determine the presence of this matrix metalloprotease within the decellularized
and PGG treated explants. IHC images were semi-quantitatively analyzed using ImageJ
software, the amount of DAB staining in each section was normalized to the cell count in
the particular sample for the analysis (492).
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7.3 Results
DNA Analysis:
The nanograms of DNA obtained from each sample were normalized to the initial
dry weight of the sample to obtain the ng DNA/ mg dry weight of tissue. The DNA
concentration obtained from the Native tissue averaged 2862.05 ± 2117.28 ng DNA/mg
Dry tissue weight, and the decellularized tissues had an average DNA content of 270.03 ±
28.94 ng DNA/ mg dry weight of tissue. The DNA quantification indicated a 90.5%
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decrease in the DNA content of the tissues after decellularization (Figure 83).
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Figure 83: Pico-green dsDNA quantification in native and decellularized bovine
pericardium; N=6
Histology:
Hematoxylin and Eosin (H&E) staining of the Native tissue sections indicated the
presence of cell nuclei within the scaffolds (indicated by blue staining). The scaffolds after
decellularization did not show the presence of any nuclear material indicating the
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successful removal of Bovine nuclear material from within the scaffolds. Since the PGG
crosslinking of the scaffolds was done after the decellularization step, no nuclear material
was observed in the PGG treated Decellularized Pericardium scaffolds (Figure 84).

NATIVE

PGG TREATED

DECELLULARIZED

Figure 84: Hematoxylin and eosin staining of native, decellularized, and PGG treated
decellularized bovine pericardium

PGG treated decellularized bovine pericardium tissues showed the presence of
elastic fibers within the extracellular matrix was confirmed by the presence of dark brown
staining in VVG. Masson’s Trichrome staining showed the presence of collagen fibers
(blue staining) within the ECM. The relative distribution and arrangement of the elastin
and collagen fibers remained constant throughout the decellularization and PGG treatment
processes, indicating that the processing of the native tissues to produce PGG crosslinked
decellularized tissues do not affect the structure and distribution of elastin and collagen in
the ECM.

Antimicrobial properties of PGG:
Incubation of decellularized and PGG treated decellularized bovine pericardium
scaffolds in staphylococcus aureus cultures overnight did not affect bacterial growth in the
cultures compared to control (media without any scaffolds) over a period of 24 hours. The
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addition of PGG to bacterial culture media, at concentrations of 2 mg/ml and 0.4 mg/ml,
however, did not show any bacterial growth, indicating PGG as a free compound was
capable of inhibiting the growth of bacteria in cultures (Figure 85).
The scaffolds from the above bacterial cultures washed with PBS to remove any
unattached bacterial cells when put into fresh media for 24 hours and incubated at 37°C
showed growths of bacterial cells within both the decellularized and PGG treated
decellularized scaffolds. There was no difference observed between the CFU/ml
concentrations between the decellularized and PGG treated groups (Figure 86).
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Figure 85: Decellularized and PGG treated decellularized bovine pericardium scaffolds in
S aureus cultures (Samples in media Day-1); Decell BJV: Decellularized bovine jugular
vein; PGG BJV: PGG treated Bovine jugular vein; Decell BP: Decellularized Bovine
Pericardium; PGG BP: PGG treated bovine pericardium; N=4
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Figure 86: Growth of bacteria in S aureus cultures with the addition of scaffolds incubated
in culture from day1; Decell BJV: Decellularized bovine jugular vein; PGG BJV: PGG
treated Bovine jugular vein; Decell BP: Decellularized Bovine Pericardium; PGG BP: PGG
treated bovine pericardium; N=4

Decellularized and PGG treated decellularized scaffolds after the first day in
bacterial cultures were washed to remove any unattached bacterial cells and fixed in
glutaraldehyde to be subsequently visualized under Scanning electron microscopy. SEM
imaging of the scaffolds did not show any resistance to bacterial attachment by the PGG
treated scaffolds. Figures 87, 88 and 89 represent the surface structures of decellularized
and PGG treated pericardium scaffolds before and after incubation in bacterial cultures.
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Figure 87: SEM imaging of (A,B) Decellularized and (C-E) PGG treated decellularized
bovine pericardium scaffolds without bacterial incubation

Figure 88: SEM images of decellularized bovine pericardium incubated with
Staphylococcus aureus cultures
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Figure 89: SEM images of PGG treated decellularized bovine pericardium incubated with
Staphylococcus aureus cultures
Additionally, extracts from elastase and collagenase enzyme challenge of
decellularized and PGG treated decellularized bovine pericardium scaffolds incubated with
bacterial culture media at 20%, 2%, and 0.2% of the total media volume demonstrated a
reduction in bacterial growth within the PGG group compared to decellularized extracts at
a concentration of 20% for elastase treatment, and 2% for collagenase treatment. Free PGG
added to bacterial cultures were capable of reducing bacterial growth at concentrations up
to 50 micro-grams/ml (Figure 90).
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Figure 90: Bacterial growth in cultures after addition of elastase and collagenase enzyme
digestion extracts from decellularized and PGG treated decellularized bovine pericardium
scaffolds. PGG dissolved in DMSO was used as control; DBP: Decellularized Bovine
pericardium PBP: PGG treated Bovine pericardium; N=4

High Fat Diet-Streptozotocin induced Type 2 Diabetes model in SD rats:
Diabetes was successfully induced in SD rats using the 14-day High Fat Diet
followed by a single injection of STZ. The blood glucose levels of the rats were consistently
maintained above 200 mg glucose/ dL blood over the time period of the implants. The
weights of the individual rats were maintained at a constant level throughout the implant
period. The average weights of the female diabetic rats were significantly lower than the
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average weights of the male diabetic rats. The weights and blood glucose levels of the
diabetic rats over the time period of the implants have been depicted in Figure 91 below.
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Figure 91: Weight and Blood Glucose Levels of HFD/STZ induced diabetic rats (Day 1 to
Day 35); Rat 1-Rat 6: Males; Rat 7-Rat 12: Females
Gross view analysis of explants
The gross view of the implants was analysis after euthanizing the animals. One out
of 10 of the non-diabetic SD rats implanted with decellularized pericardium, showed the
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presence of herniation and attachment of the intestines to the implant after 4 weeks. None
of the animals with PGG treated implants displayed any herniation or implant adhesion to
the underlying intestines (Figure 92).
PGG Implant
Explant

6 weeks

4 weeks

2 weeks

Decellularized Pericardium
Explant

Figure 92: Gross view analysis of decellularized and PGG treated pericardium as intramuscular implants in healthy rats
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Induction of diabetes in the SD rats reduced their rate of wound healing compared
to the normal rats. After two weeks of pericardium implantation, all of the diabetic rats
developed herniation. To counteract the lower rate of healing, the number of sutures used
to secure the implant was increased in the diabetic rats for the 4-week and 6-week time
points. The addition of extra sutures prevented any further incidence of herniation, and
after 4/6 weeks of implant, no adhesion was observed in any of the implants (Figure 93)

PGG Pericardium

6 weeks

4 weeks

2 weeks

Decellularized Pericardium

Figure 93: Gross view analysis of decellularized and PGG treated decellularized
pericardium intra-muscular implants in diabetic rats

Histological analysis of intra-muscular implants
Hematoxylin and eosin staining of decellularized and PGG treated explants from
intra-muscular implants in healthy and diabetic rats demonstrated infiltration of cells within
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the implants after 2-, 4-, and 6- weeks of implantation. Higher number of cells were seen
at the intersection of the implant and muscle compared to the center of the implants for
both decellularized and PGG treated pericardium. There was no extensive inflammation
observed within the explants with H&E staining.
Masson’s trichrome, VVG, and Alcian blue staining of the explants demonstrated
the presence of collagen, elastin, and some GAGs within the explants. No calcification was
seen, as demonstrated by Alizarin red staining. The histology images of explants from
healthy and diabetic rats have been demonstrated in the Figures 94-98 below.
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Figure 94: Histology of decellularized and PGG treated decellularized pericardium intramuscular implants in healthy rats for 2 weeks

Figure 95: Histology of decellularized and PGG treated decellularized pericardium
intramuscular implants in healthy rats for 4 weeks
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Figure 96: Histology of decellularized and PGG treated decellularized pericardium intramuscular implants in diabetic rats for 4 weeks

Figure 97:Histology of decellularized and PGG treated decellularized pericardium intramuscular implants in healthy rats
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Figure 98: Histology of decellularized and PGG treated decellularized pericardium intramuscular implants in diabetic rats
IHC Analysis of explants
To determine the infiltration of inflammatory cells within the decellularized and
PGG treated bovine pericardium intra-muscular implants, explants were stained with CD68
and CD3 primary cells. M1 and M2 macrophage infiltration were also observed using
iNOS and CD163 markers. TNF-alpha staining within the tissues was done to determine
the presence of this pro-inflammatory cytokine in the tissues. Additionally, vimentin
staining was also performed to determine the infiltration of fibroblast cells within the intramuscular explants.
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CD68 staining
Higher CD68 staining was observed in the 2-week diabetic explants compared to
the healthy explants. This increase in macrophage concentration might be because of the
herniation within the 2-week diabetic rats. At 4 and 6 weeks, no difference was observed
between the healthy and diabetic rats for the decellularized and PGG treated groups.
Furthermore, within non-diabetic animals, CD68 showed an increase in staining from 2week to 6-week (Figure 99)
PGG treated (NonDiabetic)

Decellularized
(Diabetic)

PGG treated
(Diabetic)

Negative

6-weeks

4-weeks

2-weeks

Decellularized
(Non-Diabetic)

Figure 99: Representative IHC images for CD68 staining for decellularized and PGG
treated decellularized bovine pericardium intra-muscular implants
Decellularized
PGG treated
Decellularized
PGG treated
(Non-Diabetic)
(Non-Diabetic)
(Diabetic)
(Diabetic)
2-weeks
0.70
0.72
1.65
2.12
4-weeks
4.61
1.68
5.75
2.81
6-weeks
1.10
2.85
1.71
1.13
Table 9: IHC semi-quantification for CD68 DAB staining: DAB staining: number of nuclei
x 1000
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CD80- Pro-inflammatory macrophages
For CD80 pro-inflammatory macrophage staining, higher CD80 positive cells were
observed at 2-weeks in diabetic rats. Subsequently, at 4-week and 6-week lower CD80
staining was observed in both healthy and diabetic rats, indicating no severe inflammatory
response to the implanted scaffolds. No significant difference was observed between
decellularized and PGG treated implants. Moreover, diabetic implants showed an increased
inflammatory response at 4- and 6- weeks compared to healthy implants (Figure 100).
PGG treated (NonDiabetic)

Decellularized
(Diabetic)

PGG treated
(Diabetic)

6-weeks

4-weeks

2-weeks

Decellularized
(Non-Diabetic)

Figure 100: Representative IHC images for CD80 staining for decellularized and PGG
treated decellularized bovine pericardium intra-muscular implants
Decellularized
PGG treated
Decellularized
PGG treated
(Non-Diabetic)
(Non-Diabetic)
(Diabetic)
(Diabetic)
2-weeks
1.58
0.72
1.74
2.53
4-weeks
0.79
2.74
2.7
1.52
6-weeks
2.34
1.27
1.30
2.11
Table 10:IHC semi-quantification for CD80 DAB staining: DAB staining: number of
nuclei x 1000
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CD163 – anti-inflammatory Macrophages
Significant infiltration of anti-inflammatory macrophages was observed within the
implanted decellularized and PGG treated implants. The staining of M2 macrophages
increased from 2-week to 6-weeks. No significant difference was observed between the
decellularized and PGG groups. Moreover, significant CD163 staining was observed
within the diabetic implants at 4 and week time points (Figure 101).
PGG treated (NonDiabetic)

Decellularized
(Diabetic)

PGG treated
(Diabetic)

6-weeks

4-weeks

2-weeks

Decellularized (NonDiabetic)

Figure 101:Representative IHC images for CD163 staining for decellularized and PGG
treated decellularized bovine pericardium intra-muscular implants
Decellularized
PGG treated
Decellularized
PGG treated
(Non-Diabetic) (Non-Diabetic)
(Diabetic)
(Diabetic)
2-weeks
5.23
7.44
9.61
7.72
4-weeks
16.21
9.91
2.32
6.36
6-weeks
9.77
11.56
5.51
6.47
Table 11: IHC semi-quantification for CD163 DAB staining: DAB staining: number of
nuclei x 1000
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CD3 – T cells
CD3 T-cell infiltration was less compared to macrophages seen previously. For
healthy rats, some CD3 was observed at 2-weeks for decellularized implants. However,
PGG treatment demonstrated less CD3 cell infiltration. At 4-week and 6-weeks, the CD3
staining was less for both decellularized and PGG implants, with no significant difference.
It is important to note that for the diabetic implants, no elevated CD3 presence was
observed at 2- , 4-, or 6- week time points (Figure 102).
PGG treated (NonDiabetic)

Decellularized
(Diabetic)

PGG treated
(Diabetic)

6-weeks

4-weeks

2-weeks

Decellularized
(Non-Diabetic)

Figure 102: Representative IHC images for CD3 staining for decellularized and PGG
treated decellularized bovine pericardium intra-muscular implants
Decellularized
PGG treated
Decellularized
PGG treated
(Non-Diabetic) (Non-Diabetic)
(Diabetic)
(Diabetic)
2-weeks
0.15
0.01
0.02
0.006
4-weeks
0.009
0.01
0.04
0.04
6-weeks
0.01
0.01
0.02
0.01
Table 12: IHC semi-quantification for CD3 DAB staining: DAB staining: number of nuclei
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TNF-alpha pro-inflammatory cytokine
Less TNF-alpha attaining was observed within all explants. This might be because
most of the pro-inflammatory cytokine is found within the blood, and very less within
tissues. Moreover, staining was less pronounced in healthy rats at 4-, and 6- weeks for
both decellularized and PGG implants. Diabetic rats demonstrated an increased level of
the cytokine as is observed in diabetic conditions. There was, however, no difference
observed between decellularized and PGG implants in diabetic conditions (Figure 103).
PGG treated
(Non-Diabetic)

Decellularized
(Diabetic)

PGG treated
(Diabetic)

2-weeks

Decellularized
(Non-Diabetic)

6-weeks

4-weeks

Negative

Figure 103: Representative IHC images for TNF - Alpha staining for decellularized and
PGG treated decellularized bovine pericardium intra-muscular implants
Decellularized
PGG treated
Decellularized
PGG treated
(Non-Diabetic) (Non-Diabetic)
(Diabetic)
(Diabetic)
2-weeks
2.73
2.14
6.78
1.30
4-weeks
3.79
5.75
5.92
4.10
6-weeks
1.64
8.52
1.65
2.62
Table 13: IHC semi-quantification for TNF-alpha DAB staining: DAB staining: number of
nuclei x1000
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iNOS- Nitric Oxide Synthase
i-NOS (inducible Nitric Oxide Synthase) staining of the intra-muscular explants
demonstrated significantly less presence of nitric oxide species within the PGG treated
implants. Presence of iNOS might be an indication of the production of inflammatory
macrophages and cytokines. Moreover, PGG implants demonstrated less iNOS expression
compared to decellularized explants in both healthy and diabetic conditions (Figure 104).
PGG treated (NonDiabetic)

Decellularized
(Diabetic)

2-weeks

Decellularized
(Non-Diabetic)

PGG treated
(Diabetic)

6-weeks

4-weeks

Negative

Figure 104: Representative IHC images for i-NOS staining for decellularized and PGG
treated decellularized bovine pericardium intra-muscular implants
Decellularized
PGG treated
Decellularized
PGG treated
(Non-Diabetic)
(Non-Diabetic)
(Diabetic)
(Diabetic)
2-weeks
0.9
0.35
1.11
0.68
4-weeks
0.67
0.41
0.81
0.40
6-weeks
0.41
0.47
0.93
0.58
Table 14: IHC semi-quantification for i-NOS staining: Immunofluorescence staining: area
of nuclei
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MMP-9
MMP-9 is a matrix metalloproteinase that regulates pathological remodeling of
tissues associated with inflammation and fibrosis in cardiovascular diseases. While the
presence of some MMPs like MMP-1 is normal in wound healing sites, excessive MMP-9
indicates chronic inflammation. The PGG treated explants demonstrated lesser expression
of MMP for 4- and 6- weeks in both healthy and diabetic conditions indicating lower
incidence of chronic inflammation (Figure 105).
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Decellularized
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2-weeks
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(Non-Diabetic)

PGG treated
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Neg ativ e

Figure 105: Representative IHC images for MMP-9 staining for decellularized and PGG
treated decellularized bovine pericardium intra-muscular implants
Decellularized
PGG treated
Decellularized
PGG treated
(Non-Diabetic)
(Non-Diabetic)
(Diabetic)
(Diabetic)
2-weeks
1.72
1.02
0.77
0.25
4-weeks
1.04
0.51
0.63
0.57
6-weeks
1.14
0.68
1.74
0.81
Table 15: IHC semi-quantification for MMP-9 staining: Immunofluorescence staining:
area of nuclei
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Vimentin - Fibroblasts
Infiltration of vimentin-positive fibroblasts within healthy implants increased with
an increase in time of implant. At 2-weeks, significantly less cells were observed, which
increased at 4-, and 6- weeks. No difference was observed between decellularized and PGG
implants. More spindle-shaped fibroblasts were observed in PGG implants. Diabetic
implants showed more fibroblast infiltration. Additionally, more vimentin staining was
seen in PGG implants in diabetic rats compared to decellularized implants (Figure 106).
PGG treated (NonDiabetic)

Decellularized
(Diabetic)

PGG treated
(Diabetic)

6-weeks

4-weeks

2-weeks

Decellularized
(Non-Diabetic)

Figure 106: Representative IHC images for Vimentin staining for decellularized and PGG
treated decellularized bovine pericardium intra-muscular implants
Decellularized
PGG treated
Decellularized
PGG treated
(Non-Diabetic) (Non-Diabetic)
(Diabetic)
(Diabetic)
2-weeks
0.20
2.27
5.16
4.04
4-weeks
3.57
2.19
2.69
5.58
6-weeks
2.79
1.78
5.04
3.32
Table 16: IHC semi-quantification for Vimentin DAB staining: DAB staining: number of
nuclei
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Alpha-Smooth Muscle Actin (SMA)
Both decellularized and PGG treated decellularized explants demonstrated the
expression of Smooth Muscle actin in lower concentrations, indicating some infiltration of
myofibroblast cells. The infiltration of SMA increased with increase in implantation time.
No significant difference was observed between the decellularized and PGG implants with
respect to myofibroblast infiltration (Figure 107).
PGG treated (NonDiabetic)

Decellularized
(Diabetic)

2-weeks

Decellularized
(Non-Diabetic)

PGG treated
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Neg ativ e

Figure 107: Representative IHC images for Alpha-Smooth muscle cell staining for
decellularized and PGG treated decellularized bovine pericardium intra-muscular implants
Decellularized
PGG treated
Decellularized
PGG treated
(Non-Diabetic) (Non-Diabetic)
(Diabetic)
(Diabetic)
2-weeks
0.95
1.19
0.68
1.89
4-weeks
0.59
1.21
0.73
1.27
6-weeks
2.79
1.48
0.46
1.06
Table 17: IHC semi-quantification for Alpha-SMC staining: Immunofluorescence staining:
area of nuclei
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7.4 Discussions
Wound healing in diabetic conditions is a major issue resulting from a prolonged
inflammatory phase and delayed regeneration of tissues. It results in various complications,
including the susceptibility of the wound to infection. Moreover, delayed abdominal wound
healing in diabetic conditions leads to herniation and bowel obstruction in patients.
In this study, PGG and decellularized pericardium scaffolds were initially analyzed
for their antibacterial properties. PGG has been observed to inhibit the growth of bacterial
cells in cultures, as well as the adhesion of bacterial cells to surfaces. The addition of free
PGG to media resulted in inhibition of growth of Staphylococcus aureus in cultures for up
to concentrations of 50 ug/ ml. However, when PGG was used to crosslink decellularized
scaffolds, there was no inhibition to bacterial growth observed. The PGG treated
decellularized scaffolds further failed to prevent attachment by bacterial cells as observed
with Scanning electron microscopy. Extracts obtained from enzyme degradation of PGG
treated decellularized scaffolds were able to inhibit bacterial growth at higher
concentrations, however at lower concentrations, owing to the very less concentration of
PGG present in the extracts, no significant inhibition to bacterial growth was observed. It
would therefore be more beneficial to treat PGG treated decellularized scaffolds with
antibiotics to render them anti-microbial properties.
The type II diabetic model developed in this study using a high-fat diet and STZ
injection was capable of developing and maintaining elevated blood glucose levels within
the rats. The elevated glucose levels were maintained for at least 7-weeks after the STZ
injections, covering the whole time of the intra-muscular implant experiments.
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Decellularized and PGG treated decellularized pericardium scaffolds implanted in
rats as intra-muscular implants demonstrated effective closure of the wound in healthy and
diabetic rats. In diabetic conditions, however, owing to the delayed wound healing in the
rats, with the same number of sutures for patch securing, herniation of the intestines was
observed after the surgery. Corrective measures using a higher number of the noncontinuous suture securing were successful in counteracting the adverse reactions. No
herniation was observed in the diabetic rats with an increased number of sutures.
Additionally, decellularized implants, due to their higher susceptibility to enzymes
degrading the ECM components, demonstrated a higher degree of absorption into the
surrounding tissues. While the integration of implants is desired, a speedy rate of
degradation might lead to implant failure and herniation or intestinal adhesion in the case
of intra-muscular implants. Adhesion to underlying organs was observed in two of the
decellularized implants in healthy rats. The PGG treated decellularized pericardium
scaffolds did not show any adhesion to the underlying organs for any of the rats. This
property of PGG treated implants should be further studied and utilized for abdominal
wound healing patch developments.
Histologically, no increased inflammatory response was observed to the PGG
treated implants compared to the decellularized implants. Even under diabetic conditions,
the PGG treated implants did not induce any higher inflammatory response. There was,
however, no reduction in infiltration of inflammatory cells observed with PGG treated
implants. Moreover, a higher number of fibroblasts were seen in PGG treated diabetic
implants compared to decellularized scaffolds. It has been observed in studies, however,
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that fibroblast morphology in diabetic conditions is altered. Additionally, lesser expression
of i-NOS and MMP-9 was observed in the PGG treated implants for both healthy and
diabetic rats. Lower nitric oxide synthase as well as MMP-9 within the PGG treated
implants might be an indication of the ability of these scaffolds to prevent chronic
inflammation. More investigation is required in understanding the effect of altered
fibroblast morphology, number, and wound healing potential in diabetic conditions.

7.8 Conclusions
PGG treated decellularized bovine pericardium scaffolds did not demonstrate
antibacterial properties, although free PGG is capable of inhibiting bacterial growth at
concentrations up to 50 ug/ml. PGG treated decellularized implants in healthy and diabetic
rats as intra-muscular implants did not show any extensive inflammatory response in
diabetic conditions. Both decellularized and PGG treated bovine pericardium implants
showed optimum performance as intra-muscular patches. PGG treated implants degraded
and reintegrated slower to decellularized scaffolds. Moreover, PGG treatment of implants
encouraged more fibroblast infiltration in diabetic conditions, as well as reduced i-NOS
and MMP-9 expression within the scaffolds. PGG treated decellularized pericardium
implants can therefore be a suitable patch material for diabetic conditions.
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CHAPTER EIGHT
CONCLUSIONS AND FUTURE RECOMMENDATIONS

8.1 Conclusions
Treatment of congenital heart diseases requiring replacement conduit and valves
has always been challenging owing to the failure of these grafts in the long run. Use of
synthetically derived or bioprosthetic scaffolds that do not grow along with pediatric
patients lead to multiple surgeries throughout their lifetime leading to increased risk of
infection, thrombosis, calcification, and implant failure. This research aimed at developing
conduit and valve replacements for pediatric patients that allow cellular infiltration and
have a growth potential.
The first part of this research aimed at developing a decellularization protocol and
optimizing its efficiency in different tissue types. The Ethanol- NaOH- detergent based
decellularization protocol developed was successful in decellularizing most of the cellular
and nuclear components from bovine jugular veins, bovine pericardium, and porcine fascia
tissues. The process maintained the structure of the extracellular matrix within the native
tissues while successfully reducing the ng DNA/mg dry weight of tissue concentrations.
Decellularized scaffolds were then crosslinked to prevent rapid degradation of elastin and
collagen within the extracellular matrix of the tissues. Different polyphenols were
compared for their efficiency in the crosslinking procedure. Among polyphenols,
Quercetin, Hesperidin, PGG, D-Salicin, and ATRA; Quercetin, PGG and ATRA showed
crosslinking capabilities to various degrees in different tissues. PGG however was
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determined as the most effective in protecting elastin and collagen from enzymatic
degradation. Additionally, addition of 10 ug/ml of each of the polyphenols to HAoSMC
cultures demonstrated that quercetin and PGG substantially increased the deposition of
insoluble elastin as well as Fibrillin I within the cell culture matrix. PGG, therefore was
the most effective in protecting extracellular components from enzyme degradation and
was used for studies in the next aims.
The second part of the research aimed at developing pediatric conduit and valve
replacements from decellularized scaffolds crosslinked with PGG. The concentration of
PGG required for optimal crosslinking was determined, and PGG crosslinked BJV
demonstrated superior resistance to enzyme degradation compared to decellularized
scaffolds. PGG treated scaffolds also demonstrated mechanical properties comparable to
that of native tissues, and when implanted subcutaneously in rats showed resistance to
calcification as well as cellular infiltration. PGG treated decellularized BJV conduits
implanted in juvenile sheep as pulmonary conduit replacements also demonstrated no
calcification, stenosis, no leaflet thickening, as well as significant cellular infiltration of
fibroblasts, myo-fibroblasts, endothelial luminization, collagen remodeling, and an
increase in size explanted after 3 months. Valve replacements developed from porcine
aortic valves and porcine aortic valves also demonstrated resistance to enzyme degradation
and had mechanical characteristics not significantly different from native tissues. PGG
treated porcine aortic valves also resisted calcification in subcutaneous implantations,
unlike glutaraldehyde tissues, and showed infiltration of >60% non-inflammatory cells.
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However, pulmonary valve repairs in sheep using porcine aortic and pulmonary valves
showed some thickening within the leaflet walls due to tissue mismatch
Finally, in the last section of this research, PGG treated decellularized bovine
pericardium scaffolds were evaluated as intra-muscular implants in healthy and diabetic
rats to look at the inflammatory responses induced by the implants. The infiltration of
inflammatory cells in PGG treated scaffolds was not different from decellularized
scaffolds. PGG treated decellularized scaffolds demonstrated lesser expression of nitric
oxide synthase and MMP-9. Additionally, PGG treated tissues in-vitro showed reduced
degradation compared to decellularized scaffolds and prevented herniation within the
animals.

8.2 Recommendations for future work
•

In aim 1, the ability of different polyphenols to crosslink components of the
extracellular matrix was studied. All the polyphenol treatments were done
at the same concentrations. At the used concentrations and buffering
solutions, PGG was identified as the most effective crosslinker. However,
ATRA, Hesperidin and Quercetin also demonstrated some degree of
collagen and crosslinking in some of the tissues. It would be useful to study
the individual polyphenols at different concentrations and under optimal
buffering solutions. Even though these polyphenols did not show optimal
crosslinking at the used concentrations, a different buffering solution or
concentration would be more suitable for them.
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•

The effect of polyphenols PGG, quercetin, hesperidin, D-salicin, and ATRA
on elastin synthesis was studied in human aortic smooth muscle cell
cultures. However, only the amount of insoluble elastin deposited and the
effect of treatment on Fibrillin I protein were analyzed. To better understand
the effect of the specific polyphenol on cell cultures, proteins affecting the
elastin synthesis process, like LOX, can also be studied. Additionally, it
would also be interesting to look at the effect of polyphenol treatments on
the production of tropoelastin within the cell culture.

•

The decellularization procedure using Ethanol-NaOH and detergents could
be optimized for the different tissue types used. In this study, the efficiency
of the decellularization treatment was optimized in bovine jugular vein
tissues, and subsequently, the same treatment was used for all the other
tissue types. Although no destruction of the extracellular matrix was seen
within any of the tissue types decellularized, optimization of the procedure
for each tissue might result in a reduction of the decellularization steps and
optimize time as well as the use of reagents.

•

Determination of the efficiency of the decellularization procedure in this
research was done by quantifying the amount of dsDNA within the native
and decellularized tissues. For a more effective evaluation, lengths of the
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remaining DNA base pairs must also be analyzed (<200 bp), as well as the
effective removal of alpha-galactose within the scaffolds should also be
analyzed.
•

Additionally, the decellularization process was carried out in a laboratory
setup for this research. To standardize the procedure and use the
decellularization process for commercial applications, it is necessary to
develop a bioreactor set-up for the process. The set-up should ensure the
uniform time of treatments for different batches, as well as optimum
hemodynamics during the decellularization process. Sub-standard
decellularization or insufficient shaking during the process might leave out
patches of native cellular and DNA material in regions less accessible. A
bioreactor setup would help in ensuring uniform decellularization of the
complete tissue.

•

In this research, the development of PGG treated conduits and valves were
discussed for congenital disease disorders. However, in addition to valved
conduits and patches, repair of congenital abnormalities also requires
replacement patches. Developed decellularized PGG treated bovine jugular
veins could also be evaluated as patch replacements. Since the scaffolds
showed optimal biocompatibility, cellular infiltration, and remodeling as in
vivo implants, the same advantages might also be helpful when used as
patch repairs.
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•

In vivo sheep implant studies with PGG treated bovine jugular vein conduits
were conducted for a maximum of three months. Although the conduits
showed excellent biocompatibility, functionality, cellular infiltration, and
hemodynamics within this period, longer animal studies are required before
these conduits can be used for clinical applications.

•

PGG treated decellularized porcine aortic valve leaflets used as pulmonary
valve repair units in this study demonstrated leaflet thickenings after 4weeks of the implant. To effectively understand the reason for the failure of
these valves, as well as to get a deeper understanding of the biomechanics
and hemodynamic characteristics in a circulatory environment leading to
graft or valve failures, in-vitro bioreactor studies can be more helpful.

•

Additionally, it is hypothesized that the failure of the PGG treated
decellularized porcine aortic valve leaflets in the pulmonary position might
have been because of the difference in the thickness of the leaflet materials,
which might have led to altered hemodynamics leading to thickening. Since
the decellularization and PGG treatment process showed optimal in vitro
properties of the scaffolds, alternate tissue material could be investigated
with the same treatment procedure for development of more suitable valve
repair units.
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•

Furthermore, the cause of leaflet thickening within the porcine aortic and
pulmonary valve implants might be the presence of alpha-galactose within
the porcine tissues. The quantification of this epitope was not done in this
study. Further investigations need to be made into whether alpha galactose
was the cause of leaflet thickening and valve failure.

•

A lot of the strategies developed in this study aims at the reduction or
elimination of calcification within vascular grafts and valve implants. The
complexities of the development of calcification within vascular implants
is still unclear; however, since the PGG treated decellularized scaffolds
were able to resist calcification, it would be helpful to study the effects of
these scaffolds in cell cultures and compared to glutaraldehyde treated
tissues to get a better understanding of the mechanism of formation of
calcification within the commercially available glutaraldehyde treated
tissues.

•

Furthermore, although the replacement strategies developed in this research
were aimed at pediatric patients, the same strategies can be applied to adult
patients as well. Valved conduit and valve replacements in children pose
more significant risk factors owing to the smaller size of the required
implants and the change in their sizes with growth in patients. Although
there should not be many alterations in implanted graft sizes in adults, the
use of the replacements developed with these strategies might be more
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effective in reducing valve and conduit stenosis as well as calcification
within adult patients.
•

Flow cytometry studies performed in this research for the subcutaneously
implanted decellularized PGG treated porcine aortic valves analyzed
inflammatory and non-inflammatory cells. The pan-inflammatory marker
CD45 was used for inflammatory cells. To study the concentrations of
different inflammatory cell infiltrations within the explants, studies can be
performed with a wider range of inflammatory cell markers (M1 and M2
macrophages, Cytotoxic and Helper T-cells, dendritic cells).

•

Anti-microbial studies were done on decellularized and PGG treated bovine
pericardium tissues in this research failed to show the resistance of the
scaffolds to bacterial attachment. For conduit and valve replacements, as
well as in wound healing applications, infection of the implants is a major
concern. Although PGG possesses anti-bacterial properties in its free form,
when crosslinked to extracellular matrix components, the anti-microbial
properties of PGG were not preserved. It would therefore be helpful to treat
these prepared scaffolds with antibiotics to impart antibacterial properties
to the scaffolds. Moreover, treatment with a higher concentration of PGG
(>0.15%) might be helpful in utilizing the properties of PGG. Cell culture
studies done with spent solutions from elastase and collagenase enzymes
did not show any bacterial resistance due to the low concentrations of PGG
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within the solutions. Concentration optimization done in Chapter V
demonstrated 0.55% PGG treated bovine jugular vein conduits
demonstrated the highest average concentration of extracted PGG. Perhaps
treatment of scaffolds with this concentration might be able to produce
significant amounts of PGG after degradation to be effective anti-microbial
agents (Appendix).

•

In aim 4, the PGG treated decellularized pericardium tissues were analyzed
histochemically for their responses in healthy and diabetic intra-muscular
implants. The PGG treated scaffolds did not show significantly different
tissue response compared to decellularized tissues immunohistochemically.
To obtain a more quantitative estimation of cellular responses to PGG
treated scaffolds in intra-muscular implants, it might be helpful to perform
flow-cytometric analysis within the implants. Moreover, the systemic
response of these implants can be studied by analyzing spleen samples from
the implanted animals.
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APPENDIX

Enzyme treatment solutions BJV quantification
PGG was quantified within the extracts obtained from elastase and collagenase
treatments of decellularized BJV scaffolds treated with different concentrations of PGG.
PGG concentrations of 0.55% and higher demonstrated a higher concentration of PGG
compared to 0.15% within the extracts after enzyme treatment (Figure 108).

Native Collagenase

Decell Elastase

Decell Collagenase

0.05% Elastase

0.05% Collagenase

0.15% Elastase

0.15% Collagenase

0.25% Elastase

0.25% Collagenase

0.55% Elastase

0.55% Collagenase

0.85% Elastase

0.85% Collagenase

1% Elastase

1% Collagenase

2% Elastase

2% Collagenase

3.33% Elastase

3.33% Collagenase

Micrograms PGG/ mg dry weight
loss of tissue

3000
2500
2000
1500
1000
500
0
-500

Figure 108: PGG quantification in enzyme treatment extracts of BJV treated with different
PGG concentration; N=4
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A higher PGG concentration within extracts could potentially inhibit the growth of
bacteria within cultures after incubation. Within experiments in this study, bacterial culture
studies were performed with 0.15% PGG treated scaffolds, with an average PGG
concentration ~100 micrograms/mg dry weight of tissue, which demonstrated no
significant decrease in bacterial growth. However, with PGG treatments of 0.55% or
higher, since the PGG concentration within the extracts increase, it might be sufficient to
demonstrate significant reduction of bacterial growth.
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